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ABSTRACT 
Quality by Design (QbD) is a systematic approach that has been recommended as suitable for 
the development of quality pharmaceutical products. The QbD approach commences with the 
definition of a quality target drug profile and predetermined objectives that are then used to 
direct the formulation development process with an emphasis on understanding the 
pharmaceutical science and manufacturing principles that apply to a product. The design 
space is directly linked to the use of QbD for formulation development and is a 
multidimensional combination and interaction of input variables and process parameters that 
have been demonstrated to provide an assurance of quality. The objective of these studies 
was to apply the principles of QbD as a framework for the optimisation of a sustained release 
(SR) formulation of salbutamol sulphate (SBS), and for the establishment of a design space 
using Response Surface Methodology (RSM) and Artificial Neural Networks (ANN). 
SBS is a short-acting {32 agonist that is used for the management of asthma and chronic 
obstructive pulmonary disease (COPD). The use of a SR formulation of SBS may provide 
clinical benefits in the management of these respiratory disorders. Ashtalin®8 ER (Cipla Ltd., 
Mumbai, Maharashtra, India) was selected as a reference formulation for use in these studies. 
An Ishikawa or Cause and Effect diagram was used to determine the impact of formulation 
and process factors that have the potential to affect product quality. Key areas of concern that 
must be monitored include the raw materials, the manufacturing equipment and processes, 
and the analytical and assessment methods employed. The conditions in the laboratory and 
manufacturing processes were carefully monitored and recorded for any deviation from 
protocol, and equipment for assessment of dosage form performance, including dissolution 
equipment, balances and hardness testers, underwent regular maintenance. 
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Preliminary studies to assess the potential utility of Methocel® Kl OOM, alone and in 
combination with other matrix forming polymers, revealed that the combination of this 
polymer with xanthan gum and Carbopol® has the potential to modulate the release of SBS at 
a specific rate, for a period of 12 hr. 
A central composite design using MethocelQ\- KlOOM, xanthan gum, Carbopol® 974P and 
Surelease® as the granulating fluid was constructed to fully evaluate the impact of these 
formulation variables on the rate and extent of SBS release from manufactured formulations. 
The results revealed that although Methocel® KlOOM and xanthan gum had the greatest 
retardant effect on drug release, interactions between the polymers used in the study were 
also important determinants of the measureable responses. 
An ANN model was trained for optimisation usmg the data generated from a central 
composite study. The efficiency of the network was optimised by assessing the impact of the 
number of nodes in the hidden layer using a three layer Multi Layer Perceptron (MLP). The 
results revealed that a network with nine nodes in the hidden layer had the best predictive 
ability, suitable for application to formulation optimisation studies. 
Pharmaceutical optimisation was conducted usmg both the RSM and the trained ANN 
models. The results from the two optimisation procedures yielded two different formulation 
compositions that were subjected to in vitro dissolution testing using USP Apparatus 3. The 
results revealed that, although the formulation compositions that were derived from the 
optimisation procedures were different, both solutions gave reproducible results for which the 
dissolution profiles were indeed similar to that of the reference formulation. 
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RSM and ANN were further investigated as possible means of establishing a design space for 
formulation compositions that would result in dosage forms that have similar in vitro release 
test profiles comparable to the reference product. Constraint plots were used to determine the 
bounds of the formulation variables that would result in the manufacture of dosage forms 
with the desired release profile. ANN simulations with hypothetical formulations that were 
generated within a small region of the experimental domain were investigated as a means of 
understanding the impact of varying the composition of the formulation on resultant 
dissolution profiles. 
Although both methods were suitable for the establishment of a design space, the use of ANN 
may be better suited for this purpose because of the manner in which ANN handles data. As 
more information about the behaviour of a formulation and its processes is generated during 
the product Iifecycle, ANN may be used to evaluate the impact of formulation and process 
variables on measureable responses. 
It is recommended that ANN may be suitable for the optimisation of pharmaceutical 
formulations and establishment of a design space in line with ICH Pharmaceutical 
Development [1], Quality Risk Management [2] and Pharmaceutical Quality Systems [3] 
guidelines. 
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STUDY OBJECTIVES 
The International Conference on Harmonization (ICH) Pharmaceutical Development 
guideline (ICH Q8) [I] was originally published by the Food and Drug Administration (FDA) 
of the United States Department of Health [4] and the European Medicines Agency (EMEA) 
[5] in May 2006. The guideline provides direction for the pharmaceutical industry to facilitate 
the registration of new chemical entities in the original application and subsequently during 
the product lifecycle, placing emphasis on the application of pharmaceutical and 
manufacturing sciences to form a basis for flexible regulatory approaches [ 4,5]. Subsequently 
the guideline has been amended to include an annexure to clarify concepts discussed in the 
Pharmaceutical Development guideline and how to implement the principles outlined in the 
documentation [ 1]. 
The document recognises that a pharmaceutical product must be of appropriate quality, 
suitable for its intended purpose and include characteristics such as identity, strength and 
purity [ 4,5]. Pharmaceutical quality may also be considered as representing a low risk of 
failure in achieving the desired clinical outcomes [ 6]. Therefore all pharmaceutical products 
must satisfy both physicochemical quality control aspects and be able to elicit a desired 
biological response, in vivo. 
The objectives of this study were therefore: 
1. To discuss the impact of the newly recommended Pharmaceutical Development 
guideline on the development of pharmaceutical products, 
n. To develop and validate a suitable and sensitive High Performance Liquid 
Chromatographic method to accurately and precisely quantitate salbutamol 
sulphate (SBS) in pharmaceutical dosage forms and SBS release from dosage 
forms during in vitro release testing, 
111. To conduct preliminary formulation studies and risk assessment analysis for 
development of high quality sustained release (SR) formulations, 
IV. To optimise a sustained release formulation of salbutamol sulphate usmg 
Response Surface Methodology (RSM), 
v. To optimise a SR formulation of SBS using Artificial Neural Networks (ANN), 
v1. To establish a design space using both RSM and ANN. 
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CHAPTER! 
QUALITY BY DESIGN 
1.1 QUALITY BY DESIGN 
1.1.1 Introduction 
Quality by Design (QbD) is a systematic approach that may be used for the development of 
pharmaceutical products and commences with predefined dosage form performance 
objectives. The procedure places an emphasis on understanding all aspects of product and 
process performance, based on sound scientific principles and quality risk management 
[ 1 ,6, 7]. Quality products are products that ensure consistent dosage form performance and 
that are designed to achieve specific therapeutic outcomes with a low risk of failure in 
patients [ 6]. The principles of QbD are to ensure the production of quality pharmaceutical 
products and to allow for continuous product improvement throughout the lifecycle of a 
product. A schematic depiction of the various components of QbD and the interrelationship of 
related components is illustrated in Figure 1.1. 
Figure 1.1 QbD graphic, adapted and redrawn from [8] 
The ideal QbD approach involves a mechanistic understanding of how formulation input 
attributes and process variables affect the ultimate quality of a drug product [7]. Dosage form 
specifications and attributes that determine product performance are important considerations 
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in product design and an understanding of these factors is paramount to success in product 
development. In addition, manufacturing processes and controls must be specifically 
optimised to ensure that quality products are consistently manufactured. 
-
Product performance characteristics are often referred to as critical quality attributes (CQA) 
and are typically those physical, chemical, biological or specific characteristics of a dosage 
form that should be within an appropriate or specified range or limit to ensure that a product 
of the desired quality and efficacy is produced [ 1]. CQA are used to guide product quality 
during pharmaceutical development and should be identified and discussed during the 
product development stages of research and development [ 6]. It is also important to 
understand and monitor critical process parameters (CPP), which are typically those 
manufacturing conditions that, if varied, have the potential to affect product quality [1]. 
A mechanistic understanding of how formulation and processing variables impact CQA will 
provide information for the development of a robust process that assures the production of 
pharmaceutical products with desired quality characteristics on every occasion [7]. 
Multivariate experiments may be conducted to enhance the understanding of interactions 
between product and process variables on dosage form performance. Information gained from 
these studies supports the development of an appropriate design space, which is a 
multidimensional combination and interaction of material attributes and process conditions 
that have been demonstrated to ensure a quality product is produced consistently [1]. In 
addition, the establishment of a design space facilitates the development of control and 
monitoring strategies that assure product quality and enables the management of information 
throughout the product lifecycle [7]. 
The objective of these studies was to apply the principles of QbD as a framework for the 
development of a design space for a sustained release (SR) formulation of salbutamol 
sulphate (SBS). 
1.1.2 Traditional Formulation Approach versus Quality by Design 
The view of the Food and Drug Administration (FDA) on the differences between QbD and 
traditional approaches to formulation development are summarised in Table 1.1. 
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Table 1.1 Comparison of traditional and QbD approaches to formulation development [9- 11] 
Aspects Traditional approach QbD approach 
Pharmaceutical 
development 
• Empirical • Systematic multivariate experiments 
• Optimisation of formulations using a conducted 
univariate approach • Optimisation of formulations using 
statistical methods 
Manufacturing • Fixed manufacturing conditions • Manufacturing is adjustable within the 
process • Validation on three initial full scale batches · design space 
• Focus is on reproducibility 
Process control • In process testing for decision making 
• Offline analysis with slow response 
Product • Primary means of quality control 
specification • Based on batch data 
• Continuous verification within the design 
space 
• Focus is on control strategy and robustness 
• Process analytical technology (PAT) is 
used for feed-back, feed-forward and real-
time testing of products 
• Part of overall quality control strategy 
• Based on desired product performance, i.e. 
quality 
Control strategy • Mainly by intennediate and end product • Risk based control strategy 
testing • Controls shifted upstream 
Lifecycle 
management 
• Reactive to problems 
• Post-approval changes needed 
1.1.3 Advantages of Quality by Design 
• Real-time release 
• Continual improvement enabled within the 
design space 
• Does not require post-approval changes if 
operating within design space 
The application of QbD has advantages over the traditional approach to formulation 
development, in particular for manufacturing processes, expediting regulatory applications 
and saving money. 
The pharmaceutical industry is set to benefit from QbD since the implementation of sound 
pharmaceutical and manufacturing sciences to product development ensures the design of 
products based on an increased understanding of the interactions between an active 
pharmaceutical ingredient (API), excipients, manufacturing .variables and conditions. QbD 
has the potential to reduce the incidence of manufacturing difficulties that are often 
encountered during normal and routine manufacturing processes. The number of 
manufacturing supplements required for post-marketing dossier changes, which are usually 
necessary during the product lifecycle in order to maintain and/or improve quality, are also 
• 
likely to decrease when QbD principles are applied. Furthermore the application of QbD has 
the potential to eliminate the production of "atypical" batches thereby saving pharmaceutical 
companies money in inventory costs [12]. QbD permits real-time quality control which 
potentially reduces end-product testing thereby saving the pham1aceutical industry substantial 
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funds [13]. QbD will therefore result in reduced overall product development and production 
costs for the pharmaceutical industry. It is likely that the application of QbD by 
pharmaceutical companies will result in a shorter time-to-market and will significantly 
increase success rates for new products [12,14], which in tum provides a better business 
model for the pharmaceutical industry as a result of improved efficiency [11]. 
The information presented to regulatory bodies according to QbD principles enhances the 
scientific foundation for the review of regulatory applications for registration of medicinal 
products. This allows better coordination of the review of an application, compliance and 
inspection, and often results in quicker approvals. Furthermore QbD may improve the 
consistency and transparency of regulatory applications. Regulatory considerations for post-
marketing changes in manufacturing conditions and implementation of new technology are 
also expedited for a well defined design space when QbD is applied in development and 
manufacture ofpharmaceutical products [10,11]. 
1.1.4 Application of Quality by Design 
The application of QbD principles for the production of pharmaceutical products has resulted 
in the successful registration of products on the market including Januvia® (sitagliptin), 
(Merck and Co., Inc., Whitehouse Station, N.J., U.S.A.) for the treatment of Type II diabetes 
[12,15] and Chantix™ (varenicline tartrate) (Pfizer, New York, N.Y., U.S.A) for the 
promotion of smoking cessation [ 16]. 
1.1.5 The Challenges of Quality by Design 
Although QbD presents a novel approach for the development of quality products, one of the 
biggest challenges in the implementation of QbD has been the limited understanding of the 
terminology and interrelationships that are described in the International Conference on 
Harmonization (ICH) Q8 (R2) guideline and related documents, Q9 and Q 10 [ 17]. 
Communication and training are therefore essential to ensure the successful implementation 
of these guidelines. The potential influence of these three guidelines on older ICH quality 
guidelines must also be discussed [ 11, 1 7]. 
The implementation of QbD for pharmaceutical formulation development has also been 
challenging since there is a need to allocate company resources to fulfil the requirements of 
QbD. For instance, there is a need to manage large amounts of data that are generated during 
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multivariate studies, in addition to managing the design space and control strategies that 
assure product quality [9]. Moreover, quality systems for managing process inputs must be 
adapted to ensure their suitability when implementing QbD [9]. 
1.2 PHARMACEUTICAL DEVELOPMENT GUIDELINES 
1.2.1 Introduction 
The core ICH Q8 (R2) [1] guideline describes the recommended contents for the 
pharmaceutical development section of a regulatory submission for the original marketing 
application of a pharmaceutical product. Core areas that are emphasised in the ICH Q8 
guideline that have the potential to impact product quality include the physicochemical 
properties of an API and the proposed excipients, formulation development of a drug product 
and the impact of manufacturing processes on product quality and dosage form performance. 
In addition, information on the container and closure system, microbiological attributes and 
compatibility of a formulation with reconstitution diluents must also be included. The 
severity of risk on product quality when formulation variables and processing conditions are 
changed must be determined through risk assessment which is an important part of the 
formulation development process [1]. 
Multivariate studies, formal experimental design, process analytical technology (PAT) and 
prior knowledge facilitate the establishment of an appropriate design space for a 
pharmaceutical product. Changes to a product or a process whilst operating within a design 
space is not considered a change that necessitates regulatory approval, but movement out of 
that design space will initiate a post-approval regulatory change process [1] . 
1.2.2 Components of a Drug Product 
The physicochemical and biological properties of an API that influence performance and 
manufacturability must be discussed in the application for registration or marketing 
authorisation of a product. These properties include, but are not limited to, the solubility, 
moisture content, particle size, biological activity and permeability of a molecule [1]. The 
choice of pharmaceutical excipients, their concentration and characteristics that influence 
CQA, manufacturability and dosage form performance must also be discussed. The 
compatibility of excipients with an API must be evaluated using suitable experimental 
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techniques, although prior knowledge acquired using sound scientific principles may also be 
applied [1). 
1.2.3 Drug Product 
Information that is provided relating to a drug product should encompass the evolution of 
formulation design in a study, starting from preliminary stages to the final optimised 
formulation. Pharmaceutical development studies that focus on CQA that may impact 
pharmacokinetic profiles and biological activity must be summarised in the application for 
registration. Formal experimental design may be used to identify critical formulation 
variables and interactions between fonnulation components, all of which may need to be 
monitored to ensure product quality [18). 
Information from in vitro and in vivo comparative studies that demonstrate links between 
dosage form characteristics and clinical performance must also be included in the application, 
and where possible in vitro/in vivo correlations must be shown [1). The physicochemical and 
biological characteristics of dosage forms that impact safety, dosage form performance or 
manufacturability of a dosage form must also be evaluated and discussed in detail [1). 
1.2.4 Manufacturing Process Development 
The manufacturing and process conditions that have the potential to impact CQA of 
pharmaceutical products must be explained, and therefore the selection and control of 
manufacturing and processing conditions should be justified in the application for market 
authorisation. Process development studies should also provide the basis for process 
improvement and validation, continuous process verification and any process control 
requirements that provide assurance of the quality of the product [1) . Measurement systems 
for monitoring CPP and process endpoints must be justified; they are often useful for 
enhancing the understanding of a process and to facilitate the establishment of an appropriate 
design space. 
1.2.5 Container Closure System 
The choice and rationale for the container closure system selected for a commercial product, 
including a justification for the intended use, suitability of the container closure system to 
assure product stability and quality, must be included in the application. Other considerations 
which are vitally important in ensuring long term product quality include the suitability of the 
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system for storage and transportation of a pharmaceutical product [1]. The selection of 
materials for primary packaging and how they impact product stability with respect to 
protection from light and moisture must also be considered. The appropriate nature of dosing 
devices such as droppers and pipettes for intended use must also be reported in the 
application [1]. 
1.2.6 Microbiological Attributes 
The microbiological attributes of pharmaceutical products must be described in the 
application documents for product registration and must include details that relate to the use 
of preservatives in formulations and the effectiveness of container closure systems to prevent 
microbial contamination [ 1]. 
1.2. 7 Compatibility 
Where applicable, the compatibility of a formulation with diluents used for reconstitution 
must be addressed in the regulatory application. The application must include information 
relating to the recommended in-use shelf-life following reconstitution and appropriate storage 
conditions for which in-use product quality, safety and efficacy can be assured [1]. 
1.3 THE IMPLEMENTATION OF QbD 
1.3.1 Introduction 
The implementation of QbD has been recommended in the annexure to ICH Q8 (R2) [1], 
which provides direction of how the principles of QbD can be put into practice. The 
minimum requirements for a pharmaceutical development process include the defmition of a 
quality target drug profile, the identification of potential CQA and the development of a link 
between material attributes and process parameters with potential CQA. A risk assessment of 
the impact of material attributes and CPP on product quality, the establishment of a design 
space using multivariate methods and selection of an appropriate manufacturing process are 
also important. In addition, the definition of a control strategy for which product quality can 
be assured is also a vital aspect of the formulation development process [ 1 ,6, 19]. The steps 
for the development of a pharmaceutical product using QbD have been summarised in Figure 
1.2 [6]. 
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Figure 1.2 Steps in the implementation ofQbD adapted and redrawn from [6,18] 
These principles were used in conjunction with the ICH Q8 (R2) guideline [1] for the 
development of a framework for the development of a SR formulation of SBS in these 
studies. 
1.3.2 Quality Target Product Profile 
The primary focus of any pharmaceutical development process is the production of a safe and 
effective drug product of appropriate quality that poses a minimal risk to patients and that 
will achieve the desired therapeutic outcome. Appropriate dosage forms and strength, route of 
administration and the intended use of the product in the clinical setting must be considered 
during the development stages of a pharmaceutical product. An understanding of the disease 
state, desired drug release characteristics and resultant pharmacokinetic profile to optimise 
the safety and therapeutic efficacy of a product must be aligned with the product development 
process [ 1 ,6]. 
The physicochemical and biological properties of a drug molecule that may affect product 
quality and dosage form performance must be addressed and discussed during the 
development process [1,4,5]. In Chapter 2 aspects of the physicochemical properties of SBS 
that may affect the manufacturability and assessment of a SR dosage form are discussed. In 
addition, the biological activity and pharmacokinetics of SBS are used to highlight the 
potential benefits of using SR formulations for the administration of SBS in the clinic. 
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1.3.3 Critical Quality Attributes 
CQA of solid oral dosage forms are typically those aspects of a formulation that affect 
product purity, strength, drug release characteristics and stability [1]. The primary indicator 
of dosage form performance for the SR formulation of SBS was considered to be the in vitro 
drug release profile over a 12 hr period. Drug release profiles of formulations that were 
manufactured in these studies were compared with the in vitro release profile of SBS from a 
commercially available formulation, Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, 
India) and this profile was used as the reference formulation for the optimisation procedures 
conducted in development studies. 
Information on the development of tests that are designed to assess product quality and 
performance, including analytical and dissolution tests, may also be included in the 
application for regulatory approval [ 4,5]. An analytical method for the assay of dosage units 
that were manufactured, and for the assessment of the extent of drug release from SR dosage 
forms, was developed and validated and is reported in Chapter 3 of this dissertation. 
1.3.4 Linkage of Material Attributes and Process Parameters to Critical Quality 
Attributes 
Understanding the principles of formulation and manufacturing science and the control of 
pharmaceutical processes is crucial in mitigating the risk of producing a poor quality product 
[20]. Risk assessment is particularly useful for determining the impact of changing 
formulation variables and processing conditions on key CQA of a product [1]. The principles 
of risk management according to ICH Q9 [2] were used to evaluate the potential impact of 
formulation and manufacturing process on key CQA and is described in Chapter 5 of this 
dissertation. 
1.3.5 Establishing the Design Space 
The design space defines the relationship between process inputs and CQA that are 
determined during studies that are conducted during the pharmaceutical product development 
process [ 1]. A central composite design was used to determine the impact of chosen 
formulation variables on in vitro release profiles and to determine whether the interactions 
between input variables do exist and these are described in Chapter 6. In addition the 
application of Response Surface Methodology (RSM) as a tool for statistical optimisation of 
SR formulations of SBS is described in that chapter. The use of Artificial Neural Networks 
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(ANN) was also assessed as a tool for pharmaceutical formulation optimisation and these 
findings are summarised in Chapter 7. 
A comparison of RSM and ANN was undertaken to assess their suitability as tools for the 
development of a design space and the relative merits and limitations of RSM and ANN for 
the development of the design space are evaluated and discussed in Chapter 7. 
1.3.6 Establishing the Control Strategy 
The control strategy should describe and justify how in-process controls and the control of 
input materials contribute to ultimate product quality and ensures that products of the desired 
quality are consistently produced [6]. Sources of variability that can impact product quality 
must be identified, appropriately understood and controlled during the manufacturing 
process. In-process control strategies were established in the study and were used to monitor 
product quality during the tablet manufacturing procedure. 
1.3. 7 Product Lifecycle 
The establishment of a design space allows manufacturers to add more information to the 
body of knowledge about a product and its manufacturing processes and therefore continually 
improve on product quality [3]. QbD facilitates continual product improvement through an 
increased understanding of the pharmaceutical and manufacturing sciences as they pertain to 
the product and recommendations in this respect are made in the final chapter of this thesis. 
1.4 CONCLUSIONS 
QbD is a systematic approach for the development of pharmaceutical dosage forms that 
begins with predefined objectives, i.e., as a result of quality control and manufacturing 
procedures, quality is built and not tested into products. The main emphasis is on 
understanding the factors that influence CQA, focusing on pharmaceutical and manufacturing 
sciences to ensure the consistent production of a safe and efficacious pharmaceutical dosage 
form. 
The basic principles of QbD recommend the use of systematic multivariate experiments to 
understand the impact of formulation and process variables on product quality and for the 
optimisation of formulations using statistical methods. This allows for the establishment of a 
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design space within which product quality and dosage form specifications or criteria can be 
inferred and assured. The combination of the Pharmaceutical Development guideline with 
risk-based control strategies ensures the development of a quality product throughout the 
lifecycle of that product. 
The Pharmaceutical Development guideline, ICH Q8 (R2), is focused on the development of 
quality products, specifically emphasising those key areas of the manufacturing process that 
must be considered when developing a pharmaceutical product. Understanding the 
components of a drug product, the manufacturing process and other aspects including the 
container closure system, compatibility issues and microbiological aspects are important 
considerations. 
The implementation process of the principles of QbD has been recommended and was used in 
these studies for the establishment of a design space for a model SR formulation. The quality 
target product profile, CQA and a risk assessment are described and discussed in subsequent 
chapters. RSM and statistical methods were employed to link formulation variables with the 
in vitro release profile and for optimisation of a formulation with the desirable dissolution 
characteristics. In addition ANN was used for product optimisation and was compared with 
RSM to assess its utility in developing and presenting a design space for a SR formulation of 
SBS. Therefore the principles of QbD were applied to the development of a design space and 
for the successful development of a SR formulation of SBS. 
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CHAPTER2 
MONOGRAPH FOR SALBUTAMOL SULPHATE (SBS) 
2.1 SALBUTAMOL SULPHATE (SBS) 
2.1.1 Introduction 
SBS is a water-soluble salt of salbutamol (SB), a short-acting {32 agonist, that is used for the 
alleviation of bronchoconstriction and bronchospasm in patients with reversible obstructive 
airway disease and chronic obstructive pulmonary disease (COPD) [21,22]. 
2.1.2 Chemical Formula 
The empirical formula of SB is C13H21N03 and is known as 2-tert-butylamino-1-(4-hydroxy-
3-hydroxymethylphenyl) ethanol. SB is also known as albuterol and has a molecular weight 
of 239.3 g/mol. The empirical formula for SBS is (C13Hz1N03) 2.H2S04 and has a molecular 
weight of 576.7 g/mol. Approximately 1.2 mg of SBS is equivalent to 1 mg of SB [21,23]. 
The chemical structure of SB is depicted in Figure 2.1 [21 ,23- 25]. 
* Chiral centre 
on H 
I 
11( ~ 
Figure 2.1 Chemical structure ofSB 
SB has a single asymmetric carbon atom as shown in Figure 2.1 and therefore SB exists as a 
pair of enantiomers. The (-)R-enantiomer (levo-SB) possesses biological activity (eutomer) 
and the (+)S-enantiomer (dextro-SB) has limited {32 adrenergic activity (distomer). Despite 
these differences in pharmacological activity, SB is administered as a racemic mixture in 
most dosage forms [26]. 
2.1.3 Salbutamol Dosage Forms 
SB is marketed commercially as Ventolin®, Vari-Salbutamol(l\) and Venteze(l\) in South Africa 
[27]. SB may be used as the free base or as the sulphate salt in aerosol products but the salt 
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form is used in the manufacture of solid oral dosage forms, parenteral formulations, powders 
for inhalation and nebuliser solutions. 
2.2 PHYSICOCHEMICAL PROPERTIES 
2.2.1 Appearance 
SB is a white or almost white crystalline powder that is odourless and almost tasteless 
[21,23,25]. SBS is also a white or almost white crystalline powder that is odourless [21,23). 
2.2.2 Solubility 
SB is soluble 1 g in 70 ml of water, 1 g in 25 ml of ethanol and is soluble in most organic 
solvents [23,25]. SBS is freely soluble in water, slightly soluble in alcohol but has limited 
solubility in organic solvents such as dichloroform, ether and dichloromethane [21]. 
2.2.3 pKa 
SB is a weakly basic drug with a pKa of 9.3 [28] and has been shown to undergo reversible 
protonation. SB undergoes an association-dissociation reaction when placed in an aqueous 
medium to produce a cation. 
2.2.4 UV Absorption 
SBS shows an absorption maximum at a wavelength of 276 nm when examined using UV 
spectroscopy [23,25] thereby indicating that UV detection may be used in analytical methods 
to monitor SBS. 
2.3 AETIOLOGY OF ASTHMA 
Asthma is a chronic inflammatory disease, in which a patient exhibits episodes of reversible 
obstruction in the airways due to bronchial hyperresponsiveness and which results in 
wheezing, dyspnoea, tightness of chest and coughing. Tachycardia and rapid respiratory rates 
are also common clinical symptoms observed during an acute asthma attack [29,30). 
The interaction of genetic and environmental factors contributes to the development and 
progression of asthma in patients [29,30]. Genes that regulate the production of sensitive cell 
lines and mediators that result in bronchoconstriction are likely to be present in individuals 
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susceptible to asthma. These include genes for T-helper 1 and 2 cells, Immunoglobulin E, 
cytokines (lnterleukin (IL)-3, -4, -5 , -9 and -13), granulocyte-monocyte colony-stimulating 
factor (GM-CSF), tumour necrosis factor-a. (TNF-o.) and the ADAM33 gene. The presence of 
these genetic and other factors results in stimulation of the smooth muscle of the airways, the 
proliferation of fibroblasts or the regulation of cytokinc production that ultimately results in 
bronchoconstriction [29]. 
Genetic factors may present as abnormalities in the airways of asthma patients and include 
increased contractility of the airway smooth muscle tissue, excessive secretions within the 
airway lumen and inflammatory cell infiltration which promote resistance to airflow in 
asthma. Furthermore, inflammation in chronic asthma causes remodelling of the airway 
epithelium, hypertrophy and hyperplasia of smooth muscle, which may result in the 
irreversible narrowing of airways over time in these patients [30]. 
Environmental factors that exacerbate asthma include exposure to allergens, diet and 
perinatal factors. Allergens including house dust mites, pets, cockroaches and diets that are 
low in vitamins C and E have also been linked to asthma. Perinatal factors that result in 
asthma include young maternal age, poor maternal nutrition, premature birth, low birth 
weight and lack ofbreastfeeding [29]. 
Common triggers for asthmatic attacks include exposure to allergens, infections, exercise, 
inhaled irritants, emotional stress and associated response, aspirin and gastroesophageal 
reflux [29]. Exposure to these triggers results in a reversible narrowing of the airways and 
uneven lung ventilation which subsequently manifests as a decrease in alveolar oxygen and 
an increase in alveolar carbon dioxide concentrations. Most patients respond by 
hyperventilating and in severe cases bronchoconstriction, this causes severe gas trapping in 
the lungs and results in the respiratory muscles overworking. Overworking of the muscle 
tissue causes hypoxemia and a consequent increase in carbon dioxide concentration in the 
lungs, resulting in respiratory and metabolic acidosis, which can ultimately cause respiratory 
and cardiac arrest ifleft untreated [29]. 
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2.4 CLINICAL USE OF SALBUTAMOL SULPHATE IN ASTHMA 
2.4.1 Use and Administration 
The inhalation of SBS is a preferred method of administration for the management of asthma, 
although solid oral dosage forms, nebulisers and parenteral preparations have also been used 
[21). The relief of acute bronchospasm is achieved by administration of one to two 
inhalations of 100 )lg SB from a metered-dose aerosol up to four times daily. Prior to 
physical exertion two inhalations may be administered as a prophylactic measure against 
bronchoconstriction [21). SBS may also be administered using inhalation capsules or discs in 
doses of 200 )lg, which is therapeutically equivalent to the delivery of 100 ~Lg of SB from an 
aerosol inhaler [21]. 
Oral SB may be given in doses of 2-4 mg, three to four times daily when inhalation is 
ineffective. However some patients may require doses of up to 8 mg at the same frequency to 
ensure relief of symptoms. Such high doses are generally not well tolerated nor do they 
provide additional clinical benefits. Alternatively, administration of 4 or 8 mg of SB 
delivered from SR dosage forms may be better for the management of asthma symptoms 
[21). 
The administration of intermittent doses of 2.5- 5 mg SBS up to four times daily with the aid 
of a nebuliser may be used to treat unresponsive bronchospasm in adults and children. The 
continuous use of SB at a rate of 1- 2 mg/h is also possible and in severe cases where a 
nebuliser is not available, 4-6 inhalations of I 00 )lg may be given every 10-20 min using a 
large spacer [21). 
Intravenous (IV) injections containing 250 )lg of SBS may be administered for the 
management of severe bronchospasm, or alternatively an IV infusion of 10 )lg/ml SBS may 
be administered at a rate of 3-20 )lg/min depending on the needs of the patient [21). 
Subcutaneous or intramuscular injections of 500 )lg SBS may also be administered every 4 hr 
as required [21). 
2.4.2 Mechanism of Action 
SB is a {32 receptor agonist that exhibits dose dependent effects on smooth and skeletal 
muscle tissue. It has been postulated that binding of SB to {32 receptors in bronchial smooth 
Page 115 
Chapter 2. Salbutamol Literature Review 
muscle results in the conversion of adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP) by adenyl cyclase which in turn activates protein kinase, an enzyme 
that catalyses protein phosphorylation, with a consequent increase in the concentration of 
bound calcium ions. The binding of calcium reduces the availability of ionised calcium in 
tissues which inhibits the actin-myosin linkage causing relaxation of smooth muscle tissue 
[31,32]. 
It has also been proposed that the binding of agonists to {32 receptors increases the 
conductance of large calcium-sensitive potassium channels in airway smooth muscle and 
results in membrane hyperpolarisation and relaxation. This process is independent of the 
presence of adenyl cyclase and cAMP and may involve the regulation of capacitative calcium 
entry into muscle cells by small G-proteins [31,33,34]. 
{32 agonists also bind to {32 receptors in numerous inflammatory cell types in the airways 
including mast cells, basophils, eosinophils, neutrophils and lymphocytes. {32 agonists inhibit 
the release of bronchoconstrictor mediators such as histamine, neutrophil chemotactive factor 
and prostaglandin D2 from these cell types and therefore have an anti-allergic effect that is 
usually beneficial in the treatment of asthma [31 ,35]. 
2.4.3 The Clinical Benefits of Salbutamol Sulphate 
The therapeutic effects ofbronchodilators and anti-asthmatic medicines may be evaluated by 
physiological and clinical assessment criteria that are related to lung function. These criteria 
include peak expiratory flow rate (PEFR), forced expiratory volume in 1 second (FEV1) , 
forced vital capacity (FVC), presence or absence of wheezing and assessment of the need for 
emergency or rescue bronchodilator therapy. 
The administration of SBS results in an increase in FEV1 and FVC, reduced resting and 
dynamic hyperinflation, increased self-paced walking distance and improved respiratory 
muscle function [22]. Clinically, bronchodilators cause a reduction in dyspnoea at rest and 
during exercise, an increased capacity to exercise and a reduction in the frequency of night-
time symptoms with an ultimate improvement in the health status of the patient [22]. 
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2.4.4 Tolerance 
Regular inhalation of short-acting {32 agonists has been reported to increase airway 
hyperresponsiveness which reduces the protective effects of such compounds against allergen 
and mediator induced bronchoconstriction [36,37]. Studies have shown that 
hyperresponsiveness is likely due to the presence of the S-enantiomer, which does not have 
any bronchodilatory effects [38). It has also been proposed that the change in effect may also 
be due to genetic polymorphism of {32 receptors in some individuals [39,40]. 
2.4.5 Adverse Effects 
The non-selective binding of SB to {31 receptors causes most of the side effects associated 
with the administration of SB. Commonly reported side effects include fine tremor of skeletal 
muscle, palpitations, tachycardia, headaches and peripheral vasodilation [21]. The oral 
administration of SBS is associated with a greater incidence of side effects compared with 
inhalation therapy since higher doses equivalent to 2-4 mg of SB are administered orally, 
whereas 100-200 jlg doses of SB are administered by inhalation. The administration of SBS 
also results in a greater incidence of side effects compared with more selective {32 agonists 
such as salmeterol and formoterol that have limited activity on {31 receptors [21]. 
Rare side effects observed following the administration of high doses of SBS include 
hypokalaemia, although this is more common following use of the parenteral and nebuliser 
routes of delivery. Myocardial ischaemia and hypersensitivity reactions including paradoxical 
bronchospasm, urticaria, hypotension and collapse have also been reported [21 ]. 
The effects of administration of an overdose of SBS are related to {31 receptor stimulation and 
include tachycardia, tremor, hypokalaemia and hyperglycaemia. Overdose situations have 
been managed successfully by the symptomatic treatment of adverse events, although 
activated charcoal may be considered for treating an overdose if patients are treated within an 
hour of ingestion of SBS [21]. 
The S-enantiomer of SB (distomer) exhibits poor binding to the {32 receptor site and is 
associated with bronchial hyperresponsiveness that is associated with SBS therapy [41,42]. In 
vitro and animal studies have revealed that this effect may be due to the activation of 
muscarinic receptors and a phospholipase-C dependent mechanism which results in increased 
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levels of free intracellular calcium [ 43]. S-SB is also reported to increase the 
hyperresponsiveness of tissues to allergens resulting in bronchoconstriction and asthma-like 
symptoms [38]. 
2.4.6 Drug Interactions 
The concomitant use of SB with corticosteroid, cardiac glycoside, diuretic and xanthene type 
compounds increases the risk of hypokalaemia. The monitoring of potassium concentrations 
in patients with severe asthma who are on combination therapy is therefore recommended 
[21]. 
Corticosteroids have been shown to modify the activity of {3 receptors in severe asthma, and 
the combination of corticosteroids with {32 agonists may result in increased bronchodiJatory 
effects. This effect results in a reversal of receptor desensitisation and down-regulation that is 
caused by {32 agonists thereby enhancing the bronchodilator response to these compounds 
[44]. However, there has been little evidence to support this theory, although combination use 
of {32 agonists and corticosteroids has been shown to exhibit clinical benefits in patients who 
suffer from severe asthma [21]. 
Non-cardiac selective {3 blockers oppose the bronchodilatory effects of {32 agonists and are 
contraindicated m asthma patients smce the combination may cause severe 
bronchoconstriction. Although this phenomenon has been reported in some patients [21], the 
concurrent administration of cardio-selective {3 blockers and {32 agonists does not cause 
deleterious effects in many patients. 
2.4.7 Contraindications 
SB and other {32 agonists should be given with caution m patients that present with 
hyperthyroidism, myocardial insufficiency, hypertension, diabetes mellitus, and who are 
susceptible to QT-interval prolongation [21]. 
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2.5 CLINICAL BENEFITS OF SUSTAINED RELEASE SALBUT AMOL 
SULPHATE 
The administration of SR dosage forms of SBS results in a significant improvement in the 
morning FEV of asthma patients when compared with those who received a placebo, but their 
use in COPD patients does not appear to have the same effect [ 45]. 
The clinical efficacy of 8 mg SBS SR tablets administered twice daily has been compared 
with immediate release or conventional 4 mg tablets taken four times a day for two weeks in 
a double-blind cross-over study [ 46]. It was observed that morning PEFR was significantly 
higher in patients who were given SBS in SR tablets compared with those on conventional 
tablets, although there was no significant difference in the evening PEFR. A comparison of 
plasma levels following administration of the SR and conventional tablets revealed that 
although the minimum and average plasma levels were similar in the two study groups, the 
maximum plasma concentration was significantly lower in patients on SR medication. It was 
also observed that there was less fluctuation in plasma concentrations in patients using SR 
therapy, and that this was associated with better management of asthma symptoms with fewer 
side effects [ 46]. 
SR SBS tablets may also be considered as an alternate therapy to theophylline [47,48] and 
aminophylline [ 49] for the management of reversible airways obstruction. There were no 
statistically significant differences in the results of lung function tests and PEFR, although the 
non-asthma symptom score was higher with SR theophylline [47,48]. However, patients 
reported a preference for SR SBS formulations compared with theophylline due to a lower 
incidence of side effects and better tolerance of SBS [47]. Higenbottam et al [49] reported 
similar findings when comparing the clinical effects of SR SBS and aminophylline where 
68% of clinical trial participants preferred SR SBS due to a lower incidence of side effects. 
However no statistically significant differences in terms of lung function tests, PEFR, 
frequency of asthma symptoms or the need of relief medication were observed for the patient 
groups taking aminophylline or SR SBS [ 49]. 
SR SBS formulations are useful for the treatment of nocturnal asthma with an increase in 
waking PEFR being reported, which is beneficial for therapy [50]. SR tablets were also found 
to be effective against histamine induced bronchoconstriction, and the protection was found 
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to last for at least twice as long for SR formulations compared with conventional 
formulations [51] . Morning PEFR was higher when SR SBS formulations were administered 
compared with conventional formulations and there was a significant reduction in wheezing 
and the need for "rescue" inhalation of bronchodilators [ 46,52]. However, the administration 
of SR formulations of {32 agonists may not necessarily reduce the side effects in all patients 
but may improve the quality of life of patients by improving adherence and therefore provide 
for better management of asthma [53]. 
2.6 PHARMACOKINETICS FOLLOWING ORAL ADMINISTRATION 
2.6.1 Absorption 
SBS is readily absorbed from the gastrointestinal tract (GIT); clinical effects occur within 15 
min and may last for up to 14 hr [25,54]. The oral bioavailability of SBS is fairly low and has 
been reported to be 0.44 [55]. Similar values for bioavailability of0.50 ± 0.04 [56] and 0.53 ± 
0.08 [26] have also been reported. 
2.6.2 Distribution 
The peak plasma concentration of SBS observed following administration of a single 4 mg 
oral dose ranges between 5.1 and 11.7 ng/ml with a time to peak of approximately 2.5- 3 hr 
[25]. However, when SBS is administered as a solution, peak plasma concentrations are 
reached much earlier, i.e. 1- 2 hr following administration [54]. Similar values for peak 
concentration and time to peak for SBS ranging between 10.0 and 16.9 ng/ml observed 1-4 
hr [56] and between 10 and 20 ng/ml after 1-3 hr after oral administration [55] have been 
reported. 
The binding of SBS is negligible and approximately 7 ± 1% of circulating SB is bound to 
plasma proteins [56]. The apparent volume of distribution for SB following IV administration 
has been reported to be 156 ± 38 L [56]. SB does not cross the blood-brain barrier, although it 
crosses the placenta by a flow-dependent diffusion process [57]. 
2.6.3 Metabolism 
SB undergoes first-pass metabolism in the gut wall and liver, but does not appear to be 
metabolised to any great extent in the lungs [21]. The rate of SBS metabolism in the gut wall 
is higher than that observed in the liver [58]. SB is metabolised by sulphotransferase (SULT 
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1A3) [59] in the gut wall to form SB 4'-0-sulphate, an inactive metabolite as shown in 
Figure 2.2 [60]. SULT1A3 has inter-patient phenotypic variability which results in variable 
drug plasma levels in patients [61,62]. 
0:. H 
I 
SULT 1A3 
I I 
'Y Sulphotransferase 
Figure 2.2 Metabolism of SB in the gut wall 
2.6.4 Elimination 
The half-life ofSBS has been estimated to range between 4 and 6 hr [21 ], 4.8 and 5.5 hr [63], 
as 3.9 ± 0.8 hr [56], and as 3.8 hr [55]. Following oral administration approximately 50% of a 
dose of SB is excreted within 4 hr, and the remainder is excreted within 24 hr [25,54]. The 
total plasma clearance of SB following the administration of an IV dose is 480 ± 123 rnVmin. 
The renal clearance of SBS following IV and oral administration has been reported to be 291 
± 70 ml/min and 272 ± 38 ml/min respectively [56]. The renal clearance of SB is higher than 
creatinine clearance(- 118 ml/min), suggesting that active tubular secretion is an important 
mechanism by which SBS is excreted. 
2.6.5 Multiple Dose Pharmacokinetics 
The pharmacokinetics of SBS following multiple dose administration were studied using 4 
mg tablets administered four times daily for five consecutive days [63]. Following the initial 
dose, the mean maximum plasma concentration was reported to be 8.2 ng/ml, which 
increased to 14.7 ng/ml at steady state. The minimum concentration at steady state was 
reported to be 9.9 ng/ml and the time taken to reach the peak concentration following each 
dose was 2.8 hr [63]. The pharmacokinetics of f3 agonists, including SBS, do not appear to 
change with continued administration, and pharmacokinetic parameters that are obtained 
from single dose studies can be used to predict long-term dosing requirements for this drug 
with a high degree of confidence [53]. 
2.6.6 Pharmacokinetics Following Administration of Sustained Release Dosage Forms 
The pharmacokinetics of SBS following administration of SR 4 mg and 8 mg formulations to 
patients with bronchial asthma are summarised in Table 2.1 . 
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Table 2.1 Single dose and steady state pharmacokinetic parameters ofSR formulations [64] 
Single Dose Steady State 
4mg 8 mg 4 mg 8 mg 
Cmax (nglml) 
tmax (min) 
Cmtn (ng/ml) 
4.6 (4.1- 5.1) 
300 
9.5 (8.5- 10.7) 8.2 (7.4-9.1) 16.1 (14.5- 17.9) 
360 300 240 
4.5 (4.0- 5.0) 8.7 (7.8- 9.7) 
AUC (0- 12) ng.min/ml 4507 (4094-4962) 8980 (8157- 9885) 
Following administration of a single 8 mg dose of SB the peak concentration 1s 
approximately double that observed following administration of a 4 mg dose. At steady state, 
peak plasma concentrations of SBS for both strengths are double those observed following 
the administration of a single dose of SBS [64]. The administration of SBS in SR 
formulations generally results in smooth plasma drug concentration profiles with minimal 
fluctuations observed at steady state [ 64]. 
2.7 SUSTAINED RELEASE SALBUTAMOL DOSAGE FORMS 
2.7.1 Commercially Available Formulations 
SB is marketed as Volmax® (GlaxoSmithKline, Uxbridge, Middlesex, UK), an osmotic 
pressure mediated SR dosage form consisting of a core of SBS surrounded by polymer that 
has a minute (250 J.Lm) laser-drilled hole which allows the API to be released at a constant 
rate [52,65,66]. SBS is also available as Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, 
India) which was used as the reference formulation in these studies. 
2. 7.2 SR Salbutamol Oral Dosage Forms 
The incorporation of SBS has been reported in SR formulations that include the use of lipidic 
[67- 69] and hydrophilic matrices [70,71], acrylic acid based resins [72,73] and novel 
delivery systems that include the use of microcapsules [74,75]. 
2. 7.2.1 Lipid and Wax Matrix Formulations 
Lipid and wax materials such as glyceryl monostearate, stearic acid and carnauba wax have 
been evaluated as SR platforms for the delivery of SBS [67,68]. SBS is poorly retained in 
these matrices, and dosage forms exhibited a burst-type release that is commonly observed 
for water-soluble compounds from these matrices. For example, when glyceryl monostearate 
was used as the matrix material, up to 40% of the dose was released within 1 0 min of the 
commencement of the dissolution studies. Similarly the use of carnauba wax and stearic acid 
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produced dissolution profiles in which between 20 and 40% of the dose was released rapidly, 
although this was dependent on the drug: wax ratio used to manufacture the matrices [68]. 
Composite mixtures of wax and other excipients, such as polyethylene glycol (PEG), 
hydrophilic polymers and surfactants, were used in an attempt to reduce drug release rates, 
and a combination of camauba wax, glyceryl monostearate and hydroxypropyl 
methylcellulose (HPMC) was found to be efficient in sustaining drug release for a period of 
up to 8 hr (67]. 
Murthy eta! [69] used combinations of carnauba wax and stearyl alcohol at concentrations 
ranging between 60 and 70% of the tablet weight; these were found to be useful for retarding 
the release rate of SBS from wax matrix granulation formulations for up to 24 hr [ 69]. 
Dynasan 118, a triglyceride ester of fatty acids, has been evaluated as a potential matrix 
forming polymer for the manufacture of SR formulations of SBS [76]. The in vitro release 
profiles of formulations containing 14% w/w Dynasan 118 exhibited very slow and 
incomplete drug release, and approximately 12% of the dose had been released after 8 hr. The 
incorporation of different diluents, viz., lactose, microcrystalline cellulose and calcium 
phosphate, resulted in an increase in the rate and extent of drug release from these dosage 
forms. It was observed that the rate and extent of release was dependent on the hydrophilicity 
of the diluents such that lactose-containing formulations exhibited the fastest release rate and 
the calcium phosphate-containing formulations resulted in formulations with the slowest 
release rates [76]. The application of the Higuchi [77,78] and Korsmeyer- Peppas [79] models 
to drug release data revealed that diffusion was the predominant factor in controlling or 
modulating drug release [76]. 
Polyglycolised glycerides such as Gelucire® have also been investigated as potential matrices 
for controlling or sustaining SBS release from oral delivery systems (80]. Gelucire® 
excipients are characterised by their hydrophilic-hydrophobic balance (HLB) and melting 
point which determine their physicochemical behaviour in vitro and in vivo. Studies have 
revealed that the use of Gelucire® with high HLB values results in drug release rates that are 
faster than those with low HLB values since water molecules are able to penetrate these 
matrices to a greater extent compared with more hydrophobic matrices, thereby promoting 
drug dissolution and liberation (80]. Drug release was postulated to occur according to an 
anomalous transport mechanism in which a combination of drug diffusion and erosion 
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occurs, and the value ofn was reported to vary between approximately 0.6 and 0.7 when data 
were fitted to the Korsmeyer- Peppas model [79]. 
2. 7.2.2 Acrylic Resin Formulations 
The feasibility of manufacturing SR formulations of SBS using Eudragit® Retard in 
combination with PEG has been reported [72]. These studies revealed that the rate of drug 
release was dependent on the hydrophilic/hydrophobic nature of the Eudragit® that was used 
when manufacturing formulations. The use of Eudragit® RL 100, which is relatively 
hydrophilic, resulted in a faster release rate than that observed when Eudragit® RS 100, a 
more hydrophobic polymer, was used [72]. 
The effect of using varying proportions of Eudragit® RS in combination with different 
diluents was investigated as a means of retarding the rate of release of SBS from solid oral 
dosage forms [73]. Microcrystalline cellulose, dibasic calcium phosphate and calcium 
sulphate were found to be unsuitable for the manufacture of SR formulations since complete 
drug release was observed within 2 hr of the commencement of dissolution testing. These 
studies revealed that drug release was diffusion controlled; a value of nS5 (Korsmeyer-
Peppas model [79]) was observed and is more than likely due to the limited relaxation of the 
Eudragit® polymer resins in these systems. The incorporation of Eudragit® S 100 to Eudragit® 
RS matrices resulted in a decrease in the burst release from such dosage fonus [73]. 
The combination of different ratios of poorly water permeable Eudragit® RSPM and water 
permeable Eudragit® RLPM resulted in a significant decrease in drug release rates compared 
with those observed for conventional formulations of SBS, although drug release from these 
formulations was complete after 4-6 hr [81]. 
2. 7.2.3 Hydrophilic Matrix Formulations 
Methocel® KlOOM has been investigated as a rate retardant in SBS formulations in which 
concentrations ranging between 20 and 60% w/w of the polymer were used, and the rate of 
drug release was observed to decrease with an increase in polymer concentration. 
Hydrophilic matrix forming materials such as Methocel® Kl OOM contain HPMC that swells 
in aqueous media to form gel-like structures that impede drug diffusion through that matrix 
[73]. 
Page 124 
Chapter 2. Salbutamol Literature Review 
Formulations of SBS manufactured using HPMC of different viscosity grades, specifically 
HPMC K4M, Kl5M and Kl OOM at a drug to polymer ratio of 1:1, were assessed as SR 
platforms [70]. The resultant release rates expressed as %.min·Y. were independent of the 
viscosity grade of the polymer used. The study also revealed that the mechanism of SBS 
release was well described using Higuchi kinetics [77,78] and that SBS was released 
primarily by a diffusion controlled mechanism with a minimal contribution by polymer 
erosion [70]. 
Hernandez et a! [71] manufactured two hydrophilic matrix formulations using HPMC 
Kl OOM and a combination of HPMC Kl OOM and sodium carboxy methyl cellulose (SCMC). 
The in vitro release profiles in these studies indicated that the formulation that contained 
HPMC showed a burst release; the rate of drug release decreased in the later stages of the 
dissolution test and the drug release was complete after 8 hr. The combination of HPMC 
Kl OOM and SCMC showed a linear rate of release for the duration of the dissolution test and 
drug release was also comp Jete after 8 hr [71]. 
The possibility of enantioselective release of SBS from matrix tablets that were manufactured 
using HPMC, which is a chiral excipient, has been reported [82]. The premise of these studies 
related to the possibility of a preferential interaction between the polymer and one enantiomer 
contained in a formulation manufactured using a racemic mixture. The manufactured 
formulations contained approximately 40% w/w HPMC and the results indicated that the 
release profile of SBS was asymptotic, with the rate of drug release decreasing with time. The 
drug release profiles of the R- and S- entantiomers of SBS were super-imposable, and there 
were no significant differences between release parameters such as mean dissolution time and 
kinetic constants [82]. The results also showed that approximately 90% of the dose was 
released within 9 hr and that the mechanism of drug release was due to a combination of 
diffusion and erosion processes, based on the value of the exponent n [79]. Furthermore, the 
mechanism of drug release was independent of the enantiomer present in the formulation, and 
there were no significant differences observed between the exponents and constants 
determined for the R- and S- enantiomers of SBS [82]. 
Srichana and Suedee [83] also reported that the release of SB from HPMC matrices is non-
stereo-selective; over 80% of both enantiomers were released from test formulations within 4 
hr of the commencement of testing and there were no significant differences in drug release 
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rates. It was also reported that tablet matrices were completely eroded by the end of the 
dissolution test, and it was postulated that the penetration of water into the matrix results in 
dissolution of the water-soluble filler used, which resulted in the rapid release rates observed 
from these formulations [83]. 
2. 7.2.4 Novel Delivery Systems 
Liu eta/ [84,85] investigated the use of pH-sensitive ion-exchange resins for the development 
of pulsatile release formulations of SBS. Methacrylic acid, which contains carboxylic acid 
functional groups, was incorporated onto a styrene backbone to create a pH-sensitive resin 
that was used to form microspheres loaded with SBS. At acidic pH, the carboxylic acid 
groups are unionised, and the interior of the resin does not interact extensively with the 
aqueous medium. The polymer remains intact thereby hindering the liberation of drug. 
However, when the pH is increased, ion-exchange occurs; the methacrylic acid becomes 
ionised and results in an interaction of the ionised groups with water causing polymer 
swelling and the promotion of drug release. SBS will therefore be released in a pulsatile 
manner from the formulation, and drug release is delayed for a 2- 3 hr period when the 
dosage form is in the stomach but drug is released in the intestines where the pH is alkaline 
[84]. 
Sirkia et a/ [86] investigated the feasibility of developing a novel press-coated SR solid oral 
dosage form of SBS that exhibited a biphasic release profile. Each press-coated tablet was 
comprised of a core made of lactose, polyvinyl pyrrolidone (PVP), talc and magnesium 
stearate. Coats were prepared from varying ratios of HPMC, drug, talc and magnesium 
stearate. Increasing the content of HPMC Kl OOM resulted in a decrease in the rate of drug 
release, and when high concentrations of the high viscosity grades of HPMC were used, 
biphasic drug release patterns were not readily attained or observed [86]. 
Microcapsules have also been investigated as novel delivery platforms for sustaining the 
release of SBS [74]. The coacervation method using ethyl cellulose as the coating agent with 
a core to shell ratio of 1: 1 was used to manufacture microcapsules, and it was reported that 
microencapsulation resulted in a decrease in the rate of drug release, such that 50% of the 
total dose incorporated was released in 90 min when compared with drug release from 
immediate release formulations [74]. 
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Beeswax and carnauba wax were compared as coating materials used to manufacture 
microcapsules of SBS [75]. The beeswax was ineffective in retarding the rate of drug release, 
although combinations of beeswax and camauba wax were found to be suitable for this 
purpose. Drug release from tabletted microcapsules was significantly reduced compared with 
that observed for respective batches of the microcapsules, and the mechanism of release from 
these formulations could best be described using a first order release model [75]. 
{3 -cyclodextrin and ethylated {3 -cyclodextrin complexes of SB at a molar ratio of 1: 1 have 
been investigated for retarding the release of SB from dosage forms (87]. Cylcodextrins have 
an amphiphilic character and consist of a hydrophobic interior and a hydrophilic exterior 
which interacts with water molecules in an aqueous environment. Modified cyclodextrin 
complexes may be useful for reducing the rate of drug liberation from pharmaceutical dosage 
forms [87]. The inclusion of SB in different grades of ethylated {3-cyclodextrin complexes 
resulted in lower rates of release compared with those observed from unmodified {3-
cyclodextrin complexes [87]. 
Solinis et al [82] investigated the possibility of usmg heptakis-(2,6-di-0-methyl)-{3-
cylcodextrin, a chiral excipient, to retard the release of SBS from dosage forms. Physical and 
freeze dried mixtures of these dosage forms were manufactured, and complete drug release 
was observed after 9 hr of dissolution testing. The inclusion of HPMC in cyclodextrin 
formulations resulted in a further reduction in drug release rates (82]. Although drug release 
is generally not stereo-selective, it was observed that slight stereo-selectivity may be possible 
from formulations that were manufactured from freeze dried mixtures of heptakis (2,6-di-0-
methyl)-{3 -cyclodextrin!SBS complexes (82]. 
Sulpho-butyl-{3 -cyclodextrin, heptakis (2,6-di-0-methyl)-{3 -cyclodextrin and y-cyclodextrin 
have also been investigated as matrix forming materials for the manufacture of SR SB 
formulations (83]. Freeze dried mixtures of equimolar concentrations of SB and cyclodextrin 
were mixed with lubricant and compressed into tablets that were coated with a 20% w/v 
mixture of Eudragit® E-1 00 in acetone: isopropanol (1: 1) mixture to form a 2 mm thick film. 
Drug release from sulpho-butyl-{3 -cyclodextrin formulations were not enantio-selective and 
over 80% of API was released within 8 hr, and almost 100% release was observed after 10 hr. 
Slight stereo-selectivity for release was observed from formulations containing heptakis (2,6-
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di-0-methyl)-,B -cyclodextrin although this was not evident in the early stages of the 
dissolution test. Up to 70% of the API was released from the formulation within 2 hr, and 
drug release was complete after approximately 6 hr. The incorporation of SB into complexes 
with y-cyclodextrin resulted in stereo-selective delayed release from formulations; between 
70 and 80% of the enantiomers were released within 8 hr, and drug release was complete 
after 12 hr [83]. The results also reveal that the rate of release of the eutomer, R-SB, from 
drug-y-cyclodextrin complexes is higher than that of the distomer, S-SB [83]. 
Egg albumin was also investigated as a potential rate-retarding matrix-forming material for 
SBS formulations [83], and tablets that contained 75 mg egg albumin in an 80 mg unit were 
manufactured by direct compression. Over 90% of the dose was released within 4 hr, and the 
tablets remained intact for the duration of the 8 hr dissolution test. It was also noted that there 
were no significant differences between the release rates of the two enantiomers of SBS from 
these formulations [83]. 
Citric acid/disodium phosphate and sodium bicarbonate/sodium carbonate buffers have been 
used to create microenvironments of pH 2.5 and 10, respectively [82]. Formulations of 
HPMC combined with drug in its native form, freeze dried mixtures of SBS and cyclodextrin, 
or a physical mixture of SBS and cyclodextrin were manufactured. The results indicated that 
that the pH of the microenvironment can be used to alter the rate and extent of drug release. 
The lower pH values of the core revealed faster rates of release compared with the 
formulations that were micro-buffered to pH 10, as would be expected for a weakly basic 
compound such as SBS. This is due to the higher solubility of SBS at acidic pH and therefore 
faster liberation of API from tablet matrices is evident [82]. 
Wu et a! [88] developed and optimised a novel osmotic pump formulation for SBS using 
ANN. The tablet cores were comprised of a granulation of API, SCMC and PVP that were 
compressed to form a tablet of 7 mm diameter. Tablets were coated using a 2.4% cellulose 
acetate methylene chloride - ethanol solution containing varying amounts ofHPMC and PEG 
1500. A 0.4 mm orifice was drilled by laser onto one side of the tablet and dissolution was 
performed using the paddle method over an 8 hr period. The amount of HPMC and PEG 
1500 and weight of coating were used as causal factors in training the ANN, and dissolution 
parameters were used to assess each product It was reported that the optimal formulation 
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contained 3.6 g/500 ml of HPMC and 1.5 g/500 ml of PEG 1500 in the tablet coat, which 
resulted in a drug release rate of0.9360 mglhr [88]. 
An elementary osmotic pump based on the pharmacokinetic parameters of SBS was designed 
by Sinchaipanid et al [89]. Tablet cores comprising 8 mg API and 272 mg sodium chloride as 
an osmogent, 2% talc and 0.3% colloidal silicon dioxide were manufactured by direct 
compression to form 8 mm tablets. The core tablets were coated with 3% w/v cellulose 
acetate in acetone solution to different thicknesses, and an orifice approximately 400 11m in 
diameter was drilled using carbon dioxide laser equipment. The rate of drug release was 
found to be dependent on the thickness of the coat, and the drug release rate decreased with 
an increase in film thickness. Increasing the amount of osmogent in each formulation resulted 
in an increase in drug release rates up to a maximum, after which the rate decreased as the 
amount of salt added was increased. This phenomenon was observed because the release of 
drug from elementary osmotic pump formulations is governed by two opposing forces. As the 
amount of salt increases, the osmotic pressure increases resulting in a greater force that 
expels drug from the tablet core. However, a large amount of osmogent in the core dilutes the 
drug concentration in the core; even though more of the saturated solution is pumped out, the 
concentration of API in the saturated solution decreases [89]. The mechanism of drug release 
from all formulations followed a zero order release pattern [89]. 
2.8 CONCLUSIONS 
SBS is a commonly used {32 agonist that is used for the treatment and alleviation of airways 
constriction as occurs in asthma and COPD. The use of SR formulations of SBS may produce 
clinical benefits compared with the administration of SBS in conventional immediate release 
dosage forms. Such benefits include an improved PEFR and FEV 1 and a reduced need for 
"rescue" bronchodilator therapy. 
The physicochemical properties of SBS make it an ideal candidate for use in SR 
formulations. However the primary challenge of using SBS is that it undergoes sulphate 
conjugation in the gut wall, and the use of a racemic mixture may result in variable 
absorption and pharmacological activity patterns. 
The development of several novel formulations of SBS bas been reported, and these include 
the use of lipid and hydrophilic matrices, microcapsules and osmotic systems. Hydrophilic 
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matrices are an attractive choice for further study and for the investigation of a design space 
within which product quality can be maintained. This is because they have been extensively 
studied and characterised, are easy to compress into dosage units, and provide a matrix that 
provides SR over varying periods of time depending on levels and/or combinations of 
polymers used. 
The use of SBS to investigate the practicality of developing a design space for a hydrophilic 
SR matrix formulation was therefore undertaken in these studies. 
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CHAPTER3 
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION 
3.1 INTRODUCTION 
3.1.1 Introduction to HPLC 
High performance liquid chromatography (HPLC) is a popular method for the quantitative 
analysis of SBS in pharmaceutical dosage forms [90-92] and for stability studies [93,94]. 
HPLC is recommended as the method of choice in official compendia including the British 
Pharmacopoeia (BP) [23] and the United States Pharmacopeia (USP) [95] indicating that the 
technique is suitable for the analysis of SBS during formulation development studies. 
The objective of these studies was to develop and validate an HPLC method for the 
quantitation of SBS in dosage forms and assessment of the rate and extent of drug release 
from SR formulations. The development of a simple, rapid, accurate and precise HPLC 
method for the assessment of SBS was therefore undertaken. 
3.1.2 Principles of HPLC Separation 
Analyte retention in HPLC is a complicated and poorly understood process which has been 
the focus of recent reports [96- 1 01]. An understanding of the interaction between an analyte 
and a stationary phase in HPLC is useful for developing an efficient and robust 
chromatographic separation. 
Three mechanisms of solute retention in HPLC have been proposed, viz., analyte partitioning 
between a mobile and stationary phase [102]; adsorption of an analyte onto non-polar 
surfaces of a stationary phase [103,104]; or a combination of partitioning and adsorption, 
where the mobile phase is preferentially adsorbed onto a stationary phase, followed by 
partitioning of an analyte into the adsorbed layer of mobile phase [ 1 05]. 
According to early partitioning models, the stationary phase is considered to be an amorphous 
medium and the analyte is distributed between the mobile and stationary phases, dependent 
on the relative affinity of an analyte for each phase. The two primary assumptions of this 
model are that the stationary phase plays a passive role in the retention process and there is 
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instantaneous equilibrium when an analyte distributes between a mobile and stationary phase 
[ 1 00]. The limitation of this model is that the stationary phase is indeed important in 
governing mechanisms of retention, and therefore the adsorption process is an important 
consideration in analyte retention. Adsorption is the accumulation of an analyte in close 
proximity to a hydrophobic stationary surface under the influence of surface forces [100]. At 
equilibrium, the amount of analyte accumulated on a stationary phase is in excess of that in 
the mobile phase. The adsorption model is considered to be a better model when compared 
with the partitioning model for describing retention mechanisms in HPLC, since column 
packing materials are composed of solid porous particles that are impermeable to analyte or 
mobile phase particles and provide a large surface area for analyte adsorption [1 00]. 
Alternatively, the combination of partitioning and adsorption processes may be used to 
explain retention mechanisms in HPLC. An organic modifier, e.g. acetonitrile (ACN) or 
methanol (MeOH), in the mobile phase may be adsorbed onto a hydrophobic stationary phase 
to form a thin layer. As a result, a two-stage model of adsorption followed by partitioning 
may be used to describe retention mechanisms in HPLC far more effectively [ 1 00]. In an 
isocratic elution process, the adsorbed (organic) layer can be considered to be a stationary 
layer, and an analyte is therefore able to partition from the mobile phase into this layer. The 
analyte is subsequently adsorbed onto the surface of a non-polar (reversed-phase) stationary 
phase. The overall retention characteristics of an analyte in HPLC are therefore a 
combination of these two consecutive processes. According to this model, the accurate 
prediction of analyte retention is based on the assumption that there is no disturbance of the 
adsorbed layer by a sample injected onto the system [ 1 00]. 
Analyte retention in HPLC also depends on the analyte-stationary phase interactions, which 
are influenced by the physicochemical nature of both an analyte and a stationary phase. It is 
generally recognised that sample retention and column selectivity can be affected by five 
significant factors [97 ,98], viz., 
i) Hydrophobic interactions between a dissolved solute and stationary phase, 
ii) Analyte shape selectivity, 
iii) Hydrogen bonding between acidic analytes and basic functional groups of the 
stationary phase, 
iv) Hydrogen bonding between basic analytes and acidic functional groups of the 
stationary phase, and 
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v) Cation-exchange with ionised silanol groups. 
It is apparent that retention mechanisms of analytes are complex and that a basic 
understanding of these processes is important in developing accurate and precise HPLC 
methods. 
3.1.3 Ion-Pair Chromatography 
Basic compounds are often poorly retained on silica based stationary phases, and resultant 
chromatograms show peak tailing and, consequently, poor chromatographic efficiency [106]. 
Peak tailing occurs as underivatised silanol residues on the stationary phase interact with 
analyte molecules. Ionised silanol groups ( -sw-) are able to retain protonated bases by 
cation-exchange processes, and neutral silanol groups ( -SiO H) are able to form hydrogen 
bonds with proton acceptor molecules, thereby influencing the retention characteristics of 
analytes [107]. Ion-pair chromatography is often used to obviate the shortcomings of HPLC 
analysis of basic samples. In ion-pair chromatography a charged ion is added to a mobile 
phase to improve the retention characteristics of an analyte. Common ion-pair reagents used 
in HPLC include alkylsulphonate and quaternary amine compounds [106]. 
The mechanism of solute retention m ion-pair chromatography is based on the initial 
adsorption of an ion-pair reagent such as sodium heptane sulphonate onto a hydrophobic 
stationary phase. The hydrophobic tail of the ion-pair reagent interacts with the silica-based 
stationary phase and the surface becomes negatively charged due to the presence of a polar 
head on the ion-pair molecule. Basic molecules are positively charged at low pH; they 
interact with the negatively charged surface of the stationary phase by ion-exchange and 
therefore the retention of a basic entity is achieved [106,108,109]. The use of ion-pair 
reagents for the analysis of weakly basic drugs improves interactions between an analyte and 
stationary phase, resulting in better peak shape and symmetry, and ultimately improves the 
accuracy, precision and sensitivity of an analytical method [106]. 
3.2 LITERATURE REVIEW 
A summary of the chromatographic conditions that have been used for the successful 
separation ofSBS from a variety of matrices is shown in Table 3.1. 
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Table 3.1 HPLC analytical methods ofSBS in the literature 
Column 
Shim-pack RP18, 4.6/-lm, 
250 mm x 4.6 mm 
Zorbax® Extend-C18, 3.5 
J.lrn, 100 mm x 2.1 mm 
(Agilent) 
Waters® J-1.-Bondapak C18, 
300 mm x 3.9 mm 
Spherical end capped C 18, 
5 J.liD, 150 mm x 3.9 mm 
Ll packing, 150 mm x 4.6 
mm 
Nova-Pak® C18, 4 J.l.m, 100 
x8mm 
Mobile phase Flow rate 
60% ACN in 0.05 M phosphate buffer, pH 4.3 1.5 ml/min 
30% MeOH in a buffer at pH 3 containing 3.15 g/1 ammonium 0.2 ml/min 
formate and 5.49 g/1 1-octanesulphonic acid, sodium salt 
20% MeOH in 5 mM hexanesulphonic acid sodium salt in 1% 1 ml/min 
glacial acetic acid 
22% ACN in phosphate buffer containing 2.87 g sodium l ml/min 
heptanesulphonate and 2.5 g/1 potassium dihydrogen phosphate, 
adjusted to pH 3.65 with dilute orthophosphoric acid 
40% MeOH in a solution containing 1.13 g sodium hexane 1.5 ml/min 
sulphonate, 12 ml of glacial acetic acid in 1200 ml of water 
Mobile phase A: 60% THF in distilled water containing 0.025 2.0 ml/min 
M Waters Pic B-8 Reagent Low UV. 
Mobile phase B: distilled water 
Mobile phase C: 50% MeOH in distilled water 
A mixture of 50% mobile phase A and mobile phase B were 
delivered up to 7.7 min, then composition changed linearly to 
60% mobile phase A, 15% mobile phase B and 25% mobile 
phase C at 13 min 
LiChrospher® 100 RP-18, 40% MeOH in in water containing 2 mM potassium hydroxide 0.4 mm 
5 11m, endcapped, 125 mm and I 0 mM hexanoic acid 
x4mm 
LiCbrosorb® RP-18, 5 J.l.ID 
125mmx4mm 
YMC phenyl, 5 J.l.m, 250 
mm x4.6 mm 
Gradient elution with ACN: Buffer 4:96 to 9:91 step gradient. 1.5 ml/min 
Buffer containing 40 mM sodium dihydrogen phosphate, 
containing 5.74 mM triethylamine, adjusted to pH 3.0 with 
phosphoric acid 
5% MeOH in a 25 rnM potassium dihydrogen phosphate buffer 1 .5 ml/min 
at pH = 3 
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Detection 
UV 243 nm 
Photodiode array 
274 nm 
UV 280 nm 
UV 220 nm 
UV276 nm 
uv 
UV 214 nm 
UV265 nm 
UV225 nm 
Retention time 
1.7 ± 0.02 min 
8.4 min 
Not specified 
-1.9 min 
Not specified 
3.2 min 
3.5 min 
-5.5 min 
9.6min 
Reference 
[90] 
[1 10] 
[93] 
[23] 
[95) 
[91) 
[Ill] 
[112] 
[92] 
Page 134 
Chapter 7. Artificial Neural Networks 
The analysis of SBS in dosage forms and solutions has been primarily performed on silica 
based C18 packing materials [90,91,93,110-112], and this stationary phase is recommended 
for use in official compendia [23,95). The use of alternative columns, such as phenyl 
columns, has also been reported [92). 
Organic modifiers such as ACN [23,90,112] and MeOH [92,93,95,110,111] are commonly 
used in analytical methods reported for the analysis of SBS. Tetrahydrofuran and Waters® Pic 
B-8 reagent have been used in a gradient method for the simultaneous determination of SBS 
and other bronchodilators in nebuliser solutions [91]. The use of ion-pair reagents in HPLC 
analysis of SBS has been reported, and sodium salts of alkylsulphonic acids are commonly 
used for this purpose [93,110]. Ion-pair reagent use is also reported in compendia! methods of 
analysis for SBS [23,95]. 
SBS is a weakly basic compound and buffered systems have also been used for the successful 
analysis of the drug using HPLC. Phosphate buffers ranging in pH between 3 and 4.5 are 
commonly used for SBS analysis [23,90,92,110,112], and some reports have described 
separations using buffer-free mobile phases [91,93,95). UV detection is the preferred method 
for monitoring SBS in sample matrices [23,90-93,95,110- 112). 
3.3 EXPERIMENTAL 
3.3.1 Reagents and Materials 
SBS standard, terbutaline sulphate (TBS) the internal standard, sodium hexane sulphonate, 
sodium heptane sulphonate and sodium octane sulphonate were purchased from Sigma 
Aldrich (StLouis, MO, USA). HPLC-grade ACN (far UV) and MeOH 215 were purchased 
from Romil Ltd, (Waterbeach, Cambridge, UK). Sodium hydroxide pellets and potassium 
dihydrogen phosphate were purchased from Merck Chemicals Ltd, (Modderfontein, Gauteng, 
South Africa). HPLC grade water was purified using a Milli-Ro® -1 5 water purification 
system (Millipore, Bedford, MA, USA), made up of a Super-Cili> carbon cartridge, two Ion-X~ 
ion-exchange cartridges and an Organex-Q® cartridge. The water was filtered through a 0.22 
mm Millipak® stack filter (Millipore, Bedford, MA, USA) prior to use. All reagents were 
used without further preparation and were at least of analytical reagent grade. 
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3.3.2 Instrumentation and Analytical Conditions 
The modular HPLC system used to collect data consisted of a Model PI 00 dual piston pump 
(Thermo Separation Products, San Jose, CA, USA); a Model ASIOO autosampler (Thermo 
Separation Products, San Jose, CA, USA), which was equipped with a Rheodyne® Model 
7010 injector (Rheodyne, Reno, NV, USA) fitted with a 20 Ill fixed volume loop and a 250 Ill 
GASTIGHT® Model 1725 syringe (Hamilton Co., Reno, NV, USA); a Linear UV/VIS-500 
Model 6200-9060 detector (Linear Instrument Co., CA, USA); and a Spectra Physics SP 
4600 integrator (Thermo Separation Products, San Jose, CA, USA). A Phenomenex® 
Hyperclone® column, 5 11m, 150 mm x 4.6 mm (Phenomenex, Torrance, CA, USA) was used 
at ambient temperature (22 °C), and the separation was achieved under isocratic conditions 
with UV detection at 220 nm. The volume of injection was 20 fJ.l and a flow rate of 1.0 
ml/min was used for the separation. 
3.3.3 Preparation of Stock Solutions 
A standard stock solution (500 J.lg/ml) of SBS was freshly prepared by accurately weighing 
approximately 10 mg ofSBS into a 20 ml A-grade volumetric flask and making up to volume 
with mobile phase. A 10 ml aliquot of the standard stock solution was diluted in a 100 ml A-
grade volumetric flask to produce a stock solution of approximately 50 llg/ml. Calibration 
standards in the concentration range 0- 50 J.lglml were prepared by serial dilution of the stock 
using A-grade volumetric flasks. Seven working standards of concentrations of 2.5, 5, 10, 20, 
30, 40 and 50 11g/ml were prepared when assaying dosage forms and for the analysis of 
samples collected during in vitro dissolution testing of SBS in SR formulations. 
A stock solution ofTBS was prepared by accurately weighing approximately 10 mg into a 20 
ml A-grade volumetric flask and making up to the volume with mobile phase. 5 ml of this 
solution was further diluted to 100 ml in an A-grade volumetric flask to produce a solution 
approximately 25 J..!g/ml. 
3.3.4 Preparation of Buffer Solutions 
An 18 rnM buffer solution was prepared by accurately weighing 2.50 g of potassium 
dihydrogen phosphate and 3.25 g sodium octane sulphonate (15 mM) into a 1000 ml A-grade 
volumetric flask. Approximately 700 mi HPLC grade water was added and the pH was 
titrated to 4 with a dilute solution of orthophosphoric acid. The pH was monitored using a 
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Crison Model GLP 21 pH meter (Crison Instruments, SA, Alella, Barcelona, Spain). The 
solution was then made up to volume using HPLC grade water. 
3.3.5 Preparation of Mobile Phase 
Appropriate volumes of buffer and ACN were measured separately using A-grade measuring 
cylinders and the individual components were then mixed in a 1000 ml Schott® bottle (Schott 
Duran GmbH, Wertheim, Germany). The mobile phase was filtered and degassed under 
vacuum using a Millipore® HVLP 0.45 Jlm filter membrane (Millipore, Bedford, MA, USA) 
and an Eyela Aspirator A-2S vacuum pump (Rikakikai Co., Ltd, Bunkyo-ku, Tokyo, Japan), 
respective! y. 
3.4 METHOD DEVELOPMENT AND OPTIMISATION 
3.4.1 Introduction 
Successful analytical method development depends on the careful consideration of the nature 
of the sample to be analysed, a review of literature and evaluation of analytical methods for 
the analyte of interest [106]. Furthermore an evaluation of methods for chemically related 
molecules and the application of methods must be reviewed in order to set appropriate 
standards for acceptance criteria of a method [ 1 06]. 
The physical and chemical nature and properties of SB and SBS have reported in Chapter 2 
of this dissertation. In summary SBS is a weakly basic water-soluble drug with a pKa of 9.3 
[28]. Therefore the retention of SBS in reversed phase HPLC is likely to require the use of 
buffers to modulate the pH of the mobile phase and may require the use of ion-pair reagents 
to improve peak shape and retention characteristics of the molecule on silica-based stationary 
phases. In addition the aqueous solubility of SBS would require the use of relatively low 
concentrations of organic modifier ( <40% v/v) in the mobile phase to allow for the 
achievement of a suitable retention time on the hydrophobic stationary phase [1 06]. 
The analytical method that is developed will be applied to assessing SBS content in dosage 
forms and evaluating in vitro release of SBS from manufactured formulations and will 
require multiple analyses. Consequently the method should have a relatively short analytical 
run time. In general, run times of less than 20 min are acceptable but run times of between 5 
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and 10 mm are preferable to prevent interference with un-retained compounds and to 
expedite analyses [ 1 06]. 
3.4.1.1 Column Selection 
Octadecyl silica is the most commonly used stationary phase reported for the analysis of SBS 
(Table 3.1) and therefore a bonded phase silica column was selected for use in these studies. 
Specifically, a Phenomenex® Hyperclone~ 150 mm x 4.6 mm (Phenomenex, Torrance, CA, 
USA) stationary phase with a 5 J..lffi particle size and 1 00 A pore size was selected for these 
studies. 
3.4.1.2 Method of Detection 
Sensitive and selective detector systems are required for the accurate and precise quantitation 
of an analyte of interest. UV and photodiode array detectors have been applied to the 
detection of SBS in dosage form and aqueous sample analysis (Table 3.1). SBS has an 
absorption maximum at a wavelength of 276 nm [23,25] indicating that successful detection 
can be achieved using UV spectroscopy. As shown in Table 3.1 , the majority of methods 
used for the analysis of SBS have used wavelengths in the UV range between 210 and 280 
nm. 
3.4.1.3 Quantitative Measurement 
Peak area and/or peak height measurements are used to construct calibration curves of 
detector response to solutions of standard concentrations. The amount or concentration of 
compounds of interest in samples of unknown concentration can be extrapolated from these 
curves. The peak area is determined by the sum of all individual responses of sample 
molecules over a given period from the start to the end of a peak, but the peak height is 
determined by the maximal concentration of a sample that passes through a detector flow cell 
(106]. 
Both the peak height or area of a detector response to the presence of an analyte may be 
influenced by prevailing experimental conditions and therefore the selection of suitable 
analytical conditions for the analysis of SBS was based on the possibility of variability of the 
environmental conditions and HPLC system used in these studies. Changes in column 
efficiency, composition of mobile phase and temperature are more likely to affect the peak 
height than peak area, whereas changes in the flow rate and imprecision in solvent flow as a 
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consequence of pump irregularities will have a greater impact on peak area [106]. The 
analytical conditions in our laboratory are such that column efficiency was monitored using 
test conditions as specified from the Certificate of Analysis provided with the column at the 
time of purchase. The mobile phase was prepared using A-grade glassware and the laboratory 
is air-conditioned to an ambient temperature of 22 °C. Despite this standardisation there are 
likely to be changes in flow rate during analysis which has a greater impact on peak area 
measurements compared with peak height measurements, and therefore peak height was 
chosen as the preferred method of quantitation in these studies. 
3.4.1.4 Internal Standard Selection 
Calibration may be performed with the use of internal standards where a different compound 
with similar structural and physicochemical properties, and hence chromatographic retention 
characteristics, is added at a known concentration to all samples containing the analyte of 
interest, prior to manipulation of those samples. The compound selected for use as an internal 
standard must be well resolved from the peaks of interest and the ratio of the measured 
response of the analyte to that of the internal standard is used for the generation of the 
calibration curve and for subsequent quantitative measurements [106,113]. Furthermore it 
should be commercially available as high purity material and be chemically stable with little 
or no reactivity with the analyte of interest and/or the mobile phase [ 1 06]. 
The use of an internal standard is recommended in cases where the variability of instrument 
response is prevalent and its use will enhance the precision of analytical methods. Sources of 
variability in HPLC analyses include injection variability, flow rate variation and different 
detector responses for samples of the same concentration. In such cases, the use of an internal 
standard compensates for instrumental variabili ty and results in an increase in the accuracy 
and precision of an analytical method [ 113]. 
Ethenzamide [114], fenoterol bromide [115], mepivacaine hydrochloride 1% [91] and 
bamethan sulphate [ 11 6] have been used as internal standards in chromatographic analyses 
developed for the quantitation of SBS. 
· Terbutaline (TB), 2-tert-butylamino-1-(3,5-dihydroxyphenyl) ethanol sulphate [117] is a [32 
agonist that has similar structural and chemical properties to SB as shown in Figure 3 .1. 
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Figure 3.1 Chemical structures of SB and TB 
Both molecules possess a P-phenyl-P-ethanol amine group but have different substituents on 
the phenyl ring. TB bas two hydroxyl functional groups on the phenyl ring whereas SB has a 
hydroxyl and an - CH20H substituent on the phenyl ring. The retention characteristics of SB 
and TB in HPLC are therefore likely to be similar. The sulphate salt ofTB was selected as an 
internal standard for the analytical method developed for the analysis of SBS. 
3.4.2 Mobile Phase Composition 
The chromatographic conditions described in the BP [23] and USP [95] were selected as the 
initial settings for the commencement of method development and optimisation. Mobile 
phase compositions of 40% v/v MeOH in a solution containing 1.13 g sodium hexane 
sulphonate and 12 ml of glacial acetic acid in 1200 ml of water [95], or 22% v/v ACN in 
phosphate buffer containing 2.87 g sodium heptane sulphonate and 2.5 g/1 potassium 
dihydrogen phosphate adjusted to pH 3.65 with dilute orthophosphoric acid [23], were used 
at the start of the study. The resultant chromatograms developed using these conditions are 
depicted in Figure 3.2. 
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Figure 3.2 Representative chromatograms developed using USP [95] (A) or BP [23) (B) 
chromatographic conditions 
The efficiency of each of the separations was assessed by considering the retention factor k, 
plate number N, peak asymmetry and peak tailing factors calculated using Equations 3.1 and 
3.2 and Figure 3.3, respectively. The results of these analyses are summarised in Table 3.2. 
k = tR-ta 
to 
Equation 3.1 
Equation 3.2 
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B 
Peak asymmdry t~H:tor = A A + B P~ak. tailing t(H:tor = 2A 
Figure 3.3 Schematic representation for the detemunation of peak asymmetry and peak tailing factors 
Table 3.2 Chromatographic parameters calculated using compendia! methods of analysis for SBS 
Chromatographic parameter USP Method BP Method 
Retention factor, k 1.11 1.79 
Plate number, N 222 1556 
Peak asymmetry factor 1.43 1.09 
Peak tailing factor 1.24 1.14 
The retention factor k refers to the position of a peak relative to the dead volume of the 
column or the retention of un-retained substances. If a molecule has a longer retention time 
than un-retained substances then the retention factor is larger than if the compound were 
retained for a shorter period, and therefore there is less likelihood of interference with un-
retained substances. The retention factor of SBS when BP conditions are used is higher than 
that observed when USP analytical conditions are used. The plate number N is an indication 
of column efficiency which is higher when BP test conditions, as opposed to USP conditions, 
are used. Both peak symmetry and peak shape are better when using BP conditions compared 
with the USP method, showing that peaks are more regular and would therefore permit more 
accurate quantitation. 
The differences in selectivity and efficiency of chromatographic separation observed when 
ACN and MeOH are used as organic modifiers are based on the ability of the organic phase 
to form hydrogen bonds with water. ACN is unable to accept or donate protons, whereas 
MeOH has the ability to form hydrogen bonds with water, and this affects the efficiency of a 
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separation [118]. This difference in interaction results in the production of sharper and more 
symmetrical peaks when ACN is used compared with MeOH as shown in Figures 3.2A and 
3.2B and summarised in Table 3.2. This phenomenon will affect the percent concentration of 
organic modifier that is required in a mobile phase, and higher concentrations of MeOH are 
required for the adequate retention of SBS compared with instances when ACN is used as the 
organic modifier [119]. 
The effect of changing mobile phase composition on the retention times in both mobile phase 
systems are shown in Figures 3.4 and 3.5 for the USP and BP methods respectively. 
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Figure 3.4 Effect ofMeOH concentration on the retention time ofSBS using the USP method 
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Figure 3.5 Effect of ACN concentration on the retention time of SBS using the BP method 
Both figures reveal that an increase in the organic modifier content results in a corresponding 
decrease in the retention time for SBS. As the percent of organic modifier increases, the 
solubility of the drug in the mobile phase increases promoting rapid elution of SBS from the 
column. When the concentration of MeOH is increased from 20% v/v to 50% v/v the 
retention time decreases from approximately 6 min to 3 min. When ACN is used over the 
concentrations of organic modifier studied, a rapid decrease in retention time of 
approximately 7 min is observed when the percent organic modifier is increased from 15% 
v/v to 18% v/v (from approximately 12.2 min to 5.5 min), and thereafter, the decrease in 
retention time observed for ACN concentrations between 18% v/v and 25% v/v is a further 2 
mm. 
The results indicate that a mobile phase composition of 20% v/v ACN based on the mobile 
phase specified in the BP [23] would provide a separation with an adequate retention time for 
SBS. TBS was then added to a solution of SBS and a representative chromatogram showing 
the separation of SBS and TBS under these chromatographic conditions is depicted in Figure 
3.6. 
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Figure 3.6 Typical chromatogram showing the separation of SBS and TBS using 20% v/v ACN in 18 mM 
phosphate buffer at pH 4, containing 15 mM sodium octane sulphonate 
The resolution of two adjacent bands in an HPLC separation can be calculated by Equation 
3.3 [106], where the resolution between two peaks is a function of the distance between the 
two peaks and the average of the peak width of the compounds of interest. 
Where, 
R5 = resolution factor 
ti = retention time for peak i 
wi = peak width of peak i 
Equation 3.3 
The resolution between the two peaks of interest was 0.366 which is indicative of a 
significant overlap, and therefore the chromatographic conditions were further optimised by 
changing the ion-pair reagent and adjusting the pH of the buffer used to prepare the mobile 
phase. 
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3.4.3 Effect of Ion-Pair Reagent 
The effect of using ion-pair reagents of different chain length was investigated as a means of 
improving the resolution between SBS and TBS peaks. The impact of using reagents with an 
increased alkyl chain length of the ion-pair reagent by two carbons from 6- 8 (i.e. 0.015M 
sodium salts of hexane, heptane and octane sulphonic acid) is depicted in Figure 3.7. 
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9 
It is apparent that the retention times of SBS and TBS are dependent on the length of the 
alkyl chain of the ion-pair reagent used in the mobile phase and that the retention times of 
both SBS and TBS increase with an increase in alkyl chain length. Furthermore the resolution 
between SBS and TBS is also enhanced with the increase in alkyl chain length ofthe ion-pair 
reagent. 
The resultant charge following binding of ion-pair reagents is a major factor that governs 
analyte retention on the surface of a stationary phase and it is not necessarily the interaction 
between non-polar alkyl chains and analytes that improves the separation [108]. There is a 
dependence of retention time on the length of the carbon chain of the ion-pair reagent but 
identical separations may be achieved with different ion-pair reagents. However, the 
concentration of ion-pair reagent required for shorter length alkyl sulphonates is higher than 
that required when using ion-pair reagents with longer alkyl chains [ 106,1 08]. If the same 
concentration of ion-pair reagent is used in a chromatographic separation, then longer length 
alkyl sulphonates will result in longer retention times as was observed in this study. The 
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separation achieved using sodium octane sulphonate was further optimised by changing the 
pH of the buffer used to prepare the mobile phase. 
3.4.4 Effect of Buffer pH 
The effect of buffer pH on the retention times of SBS and TBS in a solution containing 
sodium dihydrogen phosphate buffer and sodium octane sulphonate as an ion-pair reagent is 
shown in Figure 3.8. The pH range of the buffer tested was between 3.65 and 7 and the 
resultant effects on resolution and retention times are summarised in Table 3.3. 
Table 3.3 
pH 
3.65 
4 
5 
6 
7 
12 
11 
-= 
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6 6.5 7 
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7.5 
Figure 3.8 Effect of buffer pH on the retention time ofSBS and TBS 
Retention times and resolution of SBS and TBS as a function of pH 
Retention time of SBS Retention time of TBS Resolution 
8.31 9.65 0.766 
8.61 10.0 1.014 
8.16 9.45 0.860 
7.85 9.04 0.680 
7.53 8.50 0.554 
These results reveal that the retention time of SBS and TBS is pH dependent and that 
increasing the pH from 3.65 to 4 results in an initial increase in the retention time, which 
declines as the pH is further increased. This phenomenon is likely due to the mechanism of 
retention of basic entities in ion-pair chromatography. The surface of the stationary phase in 
alkyl sulphonate chromatographic systems is negatively charged, and at low pH, protonated 
basic molecules are highly retained on the analytical column. In ion-pair chromatography, 
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cation-exchange is the dominant process of analyte retention [106,109], but as the pH is 
increased, basic molecules become neutral and reversed-phase retention characteristics 
become prominent; a solute will therefore have a low affmity for the charged surface 
[106,109]. Consequently the retention time of weakly basic drugs such as SBS and TBS 
decreases as the pH of the buffer used in the mobile phase is increased, as shown in Figure 
3.8. 
The retention characteristics of SBS and TBS follow a similar trend, and optimum resolution 
was achieved using a buffer of pH 4. Although higher values for resolution are often 
recommended, this value was considered appropriate since baseline resolution was evident 
and the method would be appropriate for its intended purpose. 
3.4.5 Chromatographic Conditions 
The optimal chromatographic conditions that were established for the quantitative 
determination of SBS are summarised in Table 3.4, and a typical chromatogram of a 
separation achieved using the optimised conditions is shown in Figure 3.9. 
Table 3.4 Optimised chromatographic conditions for the quantitation of SBS in pharmaceutical dosage forms 
Column Phenomenext Hyperclone® C18, 5 J.un, 150 x 4.6 mm 
Mobile phase 20% v/v ACN in 18 mM phosphate buffer at pH = 4, containing 15 mM 
Detection wavelength 
Detection sensitivity 
Injection volume 
Chart speed 
Temperature 
SBS retention time 
TBS retention time 
sodium octane sulphonate 
220nm 
0.005 AUFS 
20 J.Ll 
2.5 nun/min 
22 oc 
8.10 min 
9.55 min 
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Figure 3.9 Representative chromatogram of SBS and TBS using the optimised mobile phase 
3.5 METHOD VALIDATION 
3.5.1 Introduction 
The objective of validation of an analytical procedure is to demonstrate that the method is 
suitable for its intended purpose [120]. Guidelines for the validation of analytical procedures 
have been issued by the ICH [ 120] and include specific identification tests, quantitative and 
limit tests for impurities and assay procedures. These parameters were used for the purposes 
of validating an analytical procedure for application in assaying and dissolution testing in this 
study. According to the ICH guidelines [ 120], typical validation characteristics that must be 
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investigated include the linearity, precision, accuracy, limits of quantitation and detection, 
and sample stability. 
3.5.2 Linearity 
The linearity of an analytical procedure is defined as the ability of that procedure to produce 
results that are directly proportional to the concentration of analyte in samples [120]. 
Calibration plots were constructed using seven concentrations in the range 0-50 flg/ml and 
were analysed in replicates (n = 5) to test the linearity of the response of the analytical 
method. The ratio of peak heights of SBS to TBS was plotted against the corresponding 
concentrations of SBS to produce a calibration curve. Linearity was evaluated by least 
squares linear regression analysis of the data using the Curve Fitting Toolbox on Matlab® 
R2008a (Mathworks Inc., Natick, MA, USA). 
The results of the linearity studies are summarised in Table 3.5 and Figure 3.10 shows a 
typical calibration curve generated using the analytical method developed in these studies. 
The linearity results indicate that the variability of the individual measurements is low and 
therefore error bars are not visible in Figure 3.1 0. 
Table 3.5 Statistical analysis of calibration curve data generated during HPLC analysis of SBS (n = 15) 
Regression equation, y = m.x + c 
Slope, m (95% CI) 
Intercept, c (95% CI) 
Sum square of errors (SSE) 
R2 
Kadjust.d 
Root mean square error (RMSE) 
0.0289 ± 0.000217 (0.0286, 0.0293) 
0.00169 ± 0.00236 (-O.Dl 10, 0.00756) 
0.000163 
0.9999 
0.9999 
0.00571 
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Figure 3.10 Calibration curve for the HPLC determination ofSBS, 
y = 0. 0289x + 0. 00170, R2 = 0. 9999 
so 
The range of an analytical method refers to the interval between the upper and lower 
concentrations of an analyte of interest in a sample matrix for which accuracy, precision and 
linearity have been demonstrated [120]. The range of the method was 0.395- 50 )lg/ml. 
3.5.4 Precision 
The precision of an analytical method refers to the closeness of agreement between a series of 
measurements obtained from multiple testing of the same homogenous sample under 
prescribed conditions. Precision may be defined at three levels, viz., repeatability (intra-day 
precision), intermediate precision (inter-day precision) and reproducibility [120]. 
3.5.4.1 Repeatability (Intra-assay precision) 
Repeatability refers to precision of measurements taken under the same operating conditions 
over a short interval of time [120]. Repeatability was calculated following replicate injections 
(n = 3) of freshly prepared SBS solutions at low, medium and high concentration located 
within the previously determined calibration range on Day 1. A summary of the intra-assay 
precision for the low, medium and high concentrations studied is listed in Table 3.6. 
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Table 3.6 Intra-assay precision data 
Low Medium High 
1 0.242 0.712 1.20 
2 0.243 0.714 1.19 
3 0.243 0.712 l.l9 
Average 0.243 0.713 1.19 
Standard deviation 0.000494 0.000737 0.000504 
%RSD 0.204 0.103 0.0421 
These results reveal that the method is precise and the % RSD values ranged between 0.0421 
and 0.204% RSD for the samples studied. 
3.5.4.2 Intermediate Precision (Inter-Day Precision) 
Intermediate precision refers to the precision of a method with reference to variability within 
a laboratory such as running analyses on different days and/or the use of different equipment 
or analysts [120]. The experiment was repeated by analysing freshly prepared solutions at the 
same concentrations on two additional and consecutive days to determine intermediate 
precision of the method. Peak height ratios of SBS: TBS were calculated and the percent 
Relative Standard Deviation (% RSD) of the peak height ratio was reported. Analysis of 
variance (ANOV A) was performed to determine if there were any significant differences 
between the results obtained on each of the days 1, 2 and 3. 
A summary of the data generated on three consecutive days of analysis, and the results of 
ANOV A conducted to establish whether differences between low, medium and high 
concentrations exist are shown in Tables 3.7 and 3.8, respectively. 
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Table 3.7 Intem1ediate precision data 
Low Medium 
Day 1 0.242 0.712 
0.243 0.714 
0.243 0.712 
Average 0.243 0.713 
Standard deviation 0.000494 0.000737 
%RSD 0.204 0.103 
Day2 0.242 0.713 
0.243 0.713 
0.243 0.7 12 
Average 0.243 0.713 
Standard deviation 0.000577 0.000577 
%RSD 0.238 0.0810 
Day 3 0.242 0.713 
0.242 0.712 
0.243 0.712 
Average 0.242 0.712 
Standard deviation 0.000577 0.000577 
%RSD 0.238 0.0811 
Table 3.8 Results of ANOV A of intermediate precision data 
Low 
Columns 
Error 
Total 
Medium 
Columns 
Error 
Total 
High 
Columns 
Error 
Total 
Sum of squares Degrees of Mean square 
4.51 e-008 
5.29e-007 
5.74e-007 
3.8 1e-007 
1.91e-006 
2.29e-006 
1.45e-006 
4.91e-006 
6.362e-006 
freedom 
2 
6 
8 
2 
6 
8 
2 
6 
8 
2.25e-008 
8.82e-008 
1.91 e-007 
3.18e-007 
7.25e-007 
8.19e-007 
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High 
1.20 
1.19 
1.19 
1.19 
0.000504 
0.0421 
1.19 
1.19 
1.20 
1.19 
0.00577 
0.484 
1.19 
1.20 
1.19 
1.19 
0.00577 
0.483 
F-ratio Prob >F 
0.26 0.782 
0.6 0.580 
0.89 0.460 
The intermediate precision of method was found to be adequate, and p values greater than 
0.05 indicate that there are no significant differences between the means of the peak height 
ratios that were generated on different days on which the analyses were conducted. 
3.5.5 Reproducibility 
Reproducibility is defined as the precision of a method conducted in different laboratories, 
such as for collaborative studies [120]. Reproducibility was not assessed in this study since 
the method was used for analysis in one laboratory by the same analyst. 
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3.5.6 Accuracy 
The accuracy of an analytical procedure is defined as the closeness of agreement between an 
accepted reference value and the value that is determined by use of an analytical procedure 
[ 120). The accuracy of the method was tested by analysing samples at low, medium and high 
concentrations located within the calibration range and assessing the percent recovery, bias 
and % RSD for each level tested. Peak height ratios of SBS: TBS were calculated and 
accuracy was reported as the percent recovered in the samples using a freshly constructed 
calibration curve. The accuracy results obtained for samples at low, medium and high 
concentrations are summarised in Table 3.9. 
Table 3.9 Results of accuracy studies 
Concentration 
Actual Determined RSD (%) Recovery (%) Bias(%) 
Low 8.48 8.69 0.397 102.4 -2.46 
8.48 8.48 0.138 99.95 0.0489 
8.48 8.51 0.103 100.3 -0.278 
Medium 25.5 25.4 0.0714 99.93 0.0646 
25.5 25.4 0.0984 99.67 0.321 
25.5 25.4 0.0666 99.82 0.183 
High 42.4 42.6 0.0873 100.3 -0.321 
42.4 42.0 0.0614 98.96 1.04 
42.4 42.1 0.0595 99.13 0.872 
The analytical method was determined to be accurate with the percent recovery ranging 
between 98.9 and 102.4% and the percent bias ranging between -2.46 and 1.04% under the 
conditions studied. 
3.5.7 Limits of Quantitation (LOQ) and Detection (LOD) 
The LOQ for an analyte using an analytical procedure is the lowest amount of analyte in a 
sample that can be measured with suitable precision and accuracy [120). The LOD for an 
analyte is the lowest amount of analyte in a sample that can be detected under the specified 
conditions, but not necessarily quantitated [120). The LOQ and LOD were established by 
injecting progressively decreasing concentrations in the range 0-2.5 J..l.g/ml of the working 
standard solution and constructing a calibration curve in this region. The LOQ and LOD were 
established using Equations 3.4 and 3.5. 
LOD = 3.3a 
s 
LOQ = 10a 
s 
Equation 3.4 
Equation 3.5 
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Where, 
cr = the standard deviation of the response 
S = the slope of the calibration curve 
The slope was estimated from the calibration curve in the region of the LOQ and LOD, and 
the standard deviation of the response was determined from the residual standard deviation of 
they-intercept of the regression lines in the range of the LOQ and LOD. Samples were tested 
in replicates (n = 6) and the% RSD was calculated from the variation in the peak height ratio 
of SBS to TBS. A calibration curve generated in the lower end of the concentration range for 
the analysis of SBS (0- 3 f.!g/ml) is depicted in Figure 3.11. 
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Figure 3.11 Calibration curve in the region of the LOQ and LOD for SBS, 
y = 0. 0244x + 0. 000502, R2 = 0. 9999 
3 
The LOQ and LOD were found to be 0.395 f.!g/ml (1.04 %RSD) and 0.131 f.lg/ml using the 
specified test conditions, respectively. 
3.5.8 Short-Term Sample Stability 
Short-term sample stability was determined over three consecutive days for drug sample 
solutions that were stored at ambient temperature (22 oq (i.e. on the laboratory bench), in a 
refrigerator ( 4 °C) and on a windowsill in direct sunlight. The chromatograms were compared 
with those developed from analysing freshly prepared standards. In particular, stability was 
assessed by interpolating the drug content using a freshly constructed calibration curve by 
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computing the SBS: TBS ratio and by visually inspecting the chromatograms for the presence 
of additional peaks that may be attributed to degradation. The resultant chromatograms did 
not reveal any additional peaks compared with freshly prepared samples and there were no 
significant differences between the peak height ratios of the freshly prepared and stored 
samples. Therefore, it may be concluded that analyses may be conducted over three days with 
no compromise in the precision or accuracy of the results with respect to sample stability. 
3.6 CONCLUSIONS 
The successful application of analytical methods in the pharmaceutical sciences for different 
purposes including assaying solid oral dosage forms and the generation of in vitro dissolution 
profiles during formulation development studies depends on the use of an optimised and 
validated analytical method. An appropriate analytical method must ensure that the 
compounds of interest are well resolved and free of possible interference from excipients that 
are used in pharmaceutical formulations. Successful chromatographic resolution is a function 
of the combination of many factors including the use of an appropriate column, mobile phase 
composition, buffer molarity and pH, temperature and flow rate. 
The use of silica columns for the separation of SBS is well documented and therefore a silica-
based C 18 column was chosen as an appropriate starting point for the optimisation of an 
analytical method for the analysis of SBS. TBS was used as an internal standard to improve 
the reproducibility of the method. A comparison of analytical methods that were described in 
the USP [95] and BP [23] revealed that the BP method resulted in chromatographic 
separations with better peak shape. This method was therefore optimised in terms of mobile 
phase composition, ion-pair reagent type and buffer pH to ensure an optimal separation. 
An increase in the organic modifier content of the mobile phase resulted in a decrease in 
retention time and it was observed that increasing the length of the carbon chain of the ion-
pair reagent resulted in better retention and resolution of SBS and the internal standard, TBS. 
Therefore a mobile phase comprised of 20% v/v ACN and 15 mM sodium octane sulphate 
was further optimised by adjustment of buffer pH to improve the resolution between the drug 
and internal standard. Increasing the pH of the buffer between 3.65 and 7 resulted in an initial 
increase in retention time at pH 4 followed by a gradual decrease in retention time between 
pH 5 and 7. A buffer of pH 4 was selected for the separation and therefore a mobile phase 
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consisting of 20% v/v ACN in 18 mM phosphate buffer at pH 4 and 15 mM octane 
sulphonate was used during method validation studies conducted according to ICH 
guidelines. 
The method was found to be linear within the range 0.395-50 !lg/ml and was found to have a 
coefficient of determination of 0.9999. The method was also precise, indicating the method 
was reproducible and day-to-day variation was minimal. Intra-assay precision ranged 
between 0.0421 and 0.203% RSD, and ANOVA revealed that there were no significant 
differences between SBS: TBS peak/height ratios for low, medium and high concentrations 
studied over three consecutive days. The method was also found to be accurate and the % 
bias ranged between -2.46 and 1.04%. The method can therefore be applied for the 
quantitation of SBS in dosage forms and to establish the rate and extent of drug release from 
SR dosage forms during dissolution studies. 
The application of an accurate, precise and reliable analytical method is critical to the success 
of formulation development activities using the principles of QbD and when establishing a 
design space. The method developed in this study was validated and was used to assist in 
making formulation decisions for the establishment of a design space for a SR dosage form 
for SBS. 
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DEVELOPMENT OF SUSTAINED RELEASE FORMULATIONS 
4.1 INTRODUCTION 
4.1.1 Sustained Release Dosage Forms 
Immediate release formulations are designed to release the entire dose of API from a dosage 
form following administration, in order to ensure rapid and complete absorption. The result is 
that there is a rapid onset of pharmacological activity, but following completion of the 
absorption phase the plasma profile declines if no other dose is administered. The resultant 
plasma profile is dependent on the pharmacokinetic characteristics of the API and often 
plasma levels fall below the minimum effective concentration of that API. If a drug candidate 
has a short half-life due to rapid plasma clearance, repeated administration of the compound 
is necessary to ensure that plasma levels are maintained above a minimum effective 
concentration in order to ensure a constant pharmacological response [ 65). 
In contrast, solid oral dosage forms manufactured as modified release formulations release 
API at a specific rate or are specifically designed to alter the time of API release in the GIT. 
The USP Subcommittee on Biopharmaceutics [121] defines a modified release dosage form 
"as one for which the drug-release characteristics of time course and/or location are chosen to 
accomplish therapeutic or convenience objectives not offered by conventional dosage forms 
such as solutions, ointments, or promptly dissolving dosage forms, as presently recognised". 
Several categories of modified release dosage forms have been documented including 
extended release drug products (including SR and controlled release technologies) which, in 
general, allow for at least a two-fold reduction in dosing frequency compared with immediate 
release dosage forms. Additional technologies include delayed release drug products that 
discharge API at a time other than immediately after administration and targeted release 
technologies that are designed to release API at or near the site of action [ 65]. The term SR 
will be used to describe the modified release dosage forms that were developed, 
manufactured and assessed in these studies. 
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Fallowing administration of a SR formulation via the peroral route, API is released from a 
dosage form at a steady rate and is continuously made available for absorption into the 
systemic circulation. Gradual absorption results in a steady increase in drug plasma levels 
that are maintained for longer periods compared with those observed following 
administration of immediate release dosage forms. Although there is a slow onset of action 
when an API is administered in a SR formulation the control of symptoms of diseases and 
therapeutic outcomes are often better than those observed when using treatment regimens in 
which immediate release dosage forms are administered [65,122]. 
The advantages of using SR formulations include the minimisation of fluctuations in drug 
plasma concentrations, which in turn provides a constant and consistent clinical response in 
patients, as long as plasma levels are maintained above a minimum effective concentration 
[65, 122). The development of SR formulations for an API that has a short half-life and/or a 
short duration of action may provide clinical benefits for patients since constant drug plasma 
concentrations may be achieved. In addition the administration of SR formulations often 
results in better patient adherence to therapy as a consequence of a reduced dosing frequency 
[65]. 
The use of SR formulations is not without limitations and these include variable and/or erratic 
drug absorption due to changes in GIT motility that may result in therapeutic failure. There is 
also a possibility of dose dumping of large doses of API due to dosage f01m failure since SR 
dosage forms are usually formulated with an excess of drug and such failure may result in 
GIT irritation and systemic toxicity. However, despite the limitations of these dosage forms, 
it is apparent that the use of SR formulations in therapy has significant advantages for the 
optimisation and achievement of appropriate therapeutic outcomes. 
4.1.2 Hydrophilic Matrix Formulations 
Hydrophilic monolithic matrix devices are commonly used as SR dosage forms due to their 
ease of manufacture and the nature of this relatively well understood technology. The rate of 
drug release from monolithic devices can be modulated by the level and type of polymer or 
combinations of polymers that are used to manufacture a formulation. The inclusion of 
polymeric adjuvants changes the microscopic porosity and tortuousity of matrices thereby 
affecting both the rate and mechanism of drug release [123). 
Page 159 
Chapter 4. Formulation Development 
Following immersion of hydrophilic matrix tablets into aqueous media, the polymer hydrates, 
swells and increases in size after which the matrix dissolves and/or erodes with time 
[124,125]. The penetration of an aqueous medium into the interior of the tablet matrix results 
in the formation of three distinct regions within the matrix, viz., the inner dry polymer where 
water has not yet penetrated, the outer rubbery hydrated phase, and a swelling or moving 
front that is located between the hydrated state and the outer rubbery hydrated gel phase 
[126,127]. The dissolution of a drug in the swollen matrix takes place at the interface 
between the inner dry matrix and rubbery polymer surface, and the dissolved drug diffuses in 
a radial direction from the swelling front towards the bulk aqueous medium [ 128]. 
Early studies have shown that drug release from swellable hydrophilic matrices is dependent 
on the thickness of the hydrated gel layer that is formed during the swelling phase of polymer 
hydration [124,125]. The degree of swelling determines the diffusional path length of a drug 
and the thicker the gel layer the slower the rate of drug release from a matrix [127]. The 
thickness of the gel layer increases during the swelling phase and then remains constant in 
what is known as the synchronisation phase (i.e. where the rates of swelling and erosion are 
equal) and eventually decreases as polymer erosion becomes dominant. The relative extent of 
swelling and erosion is dependent on the nature and characteristics of a polymer or polymer 
combinations that are used to manufacture a dosage form [129]. 
Hydrophilic matrix formulations can be manufactured by direct compression [130- 134], wet 
granulation [135-137], hot-melt extrusion [138] or roller compaction [139]. Direct 
compression is often the method of choice due to its relative simplicity, the ease of 
processing, and the possibility of developing a stream-lined and cost-effective manufacturing 
process for SR matrix systems. 
4.1.3 Polymeric Materials 
HPMC is one of the most commonly used hydrophilic matrix formers for SR formulations as 
it is non-toxic and has wide regulatory acceptance. The use of HPMC also makes it possible 
to incorporate large doses of drug into SR formulations and reports suggest that dosage form 
performance and product quality of HPMC matrices is not significantly affected by 
manufacturing process variables [ 140]. HPMC has been the polymer of choice for the 
manufacture of a number of SR formulations and its use and applications are well 
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documented [82,123,128,130,133,141,142]. The mechanism of drug release and swelling of 
HPMC matrices has also been extensively studied [128,131,135,143- 146]. 
Although HPMC is a commonly used matrix forming material, other polymers that have 
potential use as matrix forming materials include Carbopol~ [134,147,148], xanthan gum 
[127,149], sodium carboxy methylcellulose (SCMC) [128,150] and hydroxypropyl cellulose 
(HPC) [133, 145,151]. Therefore the use ofHPMC, as a primary excipient and other polymers 
as potential adjuvants, was investigated in these studies in order to evaluate their potential for 
the retardation of SBS release from hydrophilic matrix tablets. 
The objective was to assess the suitability of HPMC in combination with different polymers 
for the retardation of SBS release from formulations manufactured in our laboratory. In 
addition, risk assessment was conducted in order to facilitate the implementation of a well 
controlled statistically designed experiment (Chapter 6 vide infra) aimed at understanding the 
impact of formulation variables on SBS release and to manufacture optimised matrix 
formulations with predetermined drug release characteristics. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
SBS was donated by Aspen-Pharmacare (Port Elizabeth, Eastern Cape, SA). Methocelils-
K1 OOM and Methocel® K4M (HPMC) (Dow Chemical Company, Midland, MI, USA), 
Avicel® PH101 (FMC BioPolymer, Philadelphia, PA, USA), SCMC (Aspen-Pharmacare, 
Port Elizabeth, Eastern Cape, SA), Carbopol® 710 (Lubrizol, Wickliffe, OH, USA), Klucel® 
EF (HPC) (Aspen-Pharmacare, Port Elizabeth, Eastern Cape, SA), xanthan gum (Aspen-
Pharmacare, Port Elizabeth, Eastern Cape, SA), Surelease<J< (Colorcon, West Point, PA, USA) 
magnesium stearate (Aspen-Phamacare, Port Elizabeth, Eastern Cape, SA) and colloidal 
silica (Aspen-Pharmacare, Port Elizabeth, Eastern Cape, SA) were used as received. All other 
reagents were at least of analytical reagent grade and used as received. 
4.2.2 Manufacture of Formulations 
Hydrophilic matrix tablets were manufactured using direct compression. Batch sizes of 1000 
tablets were produced for each fornmlation that was manufactured. The API, SBS, Methocel® 
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KlOOM, additional polymers where required, and Avice!® PH101 were dry blended using a 
Sara!® Rapid Mixer and Granulator (Saral Engineering Company, Mumbai, Maharashtra, 
India) in a 5 L bowl using a speed of 100 rpm for the main impeller for 15 min. Thereafter 
1% w/w magnesium stearate and 0.5% w/w colloidal silica were added and the blend mixed 
at the same speed for a further 3 min. The blend was transferred to a feed hopper and tablets 
were compressed on a Manesty® F3 single punch tablet press tooled with 7 mm flat-faced 
round punches to a uniform weight of 140 mg. In-process control was achieved my 
monitoring environmental conditions such as temperature and humidity, and process 
conditions including, dry mixing time, speed of the motor, and tablet weight during the 
compression cycle. A summary of the composition of the batches that were manufactured is 
shown in Table 4.1. 
Table 4.1 Unit formulae for SBS tablets 
SBS-01 SBS-02 SBS-03 SBS-04 SBS-05 SBS-06 
(mg) (mg) (mg) (mg) (mg) (mg) 
SBS 9.6 9.6 9.6 9.6 9.6 9.6 
Methocel® K100M 70 70 70 70 70 70 
Methocel111 K4M 28 
SCMC 28 
Carbopol111 71G 28 
Klucei111 EF 28 
Xanthan gum 28 
Colloidal silica 0.7 0.7 0.7 0.7 0.7 0.7 
Magnesium stearate 1.4 1.4 1.4 1.4 1.4 1.4 
Avicei111 PH101 58.3 30.3 30.3 30.3 30.3 30.3 
4.2.3 Tablet Analysis 
Twenty tablets were weighed collectively and ground to form a homogenous powder using a 
mortar and pestle. An accurately weighed portion of the pooled sample, equivalent to the 
weight of one tablet (approximately 9.6 mg of SBS) was transferred to another mortar and 
mixed with approximately 70 ml of HPLC-grade water to form a paste. The paste was 
quantitatively transferred to a 100 ml volumetric flask and sonicated for 15 min, and the 
resultant solution was made up to volume with water to produce a solution of approximately 
96 Jlg/ml of SBS. A 5 ml aliquot of the solution was then transferred to a 20 ml A-grade 
volumetric flask and was mixed with the internal standard, TBS, to produce a solution in 
which the concentration of internal standard was approximately 25 Jlg/ml, and the solution 
was made up to volume. A 2 ml aliquot of this solution was filtered through a 0.45 Jlm 
Millipore® (Millipore, Bedford, MA, USA) filter prior to injection onto the HPLC system (§ 
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3.3.2). Tablet analysis was performed in triplicate (n = 3) and the results are expressed as the 
mean± SD. 
4.2.4 Weight, Diameter, Thickness and Crushing Strength 
Twenty tablets of each formulation were tested for weight uniformity using a Mettler-Toledo 
Model AG135 electronic balance (Mettler-Toledo, Inc., Columbus OH, USA). Tablet 
diameter, thickness and crushing strength were assessed using a PTB 311 Automated Tablet 
Testing Instrument (Pharma Test Apparatebau, Hainburg, Hesse, Germany) and the results 
are reported as the mean ± SD. 
4.2.5 In Vitro Dissolution Studies 
A VanK.el~ Bio-Dis dissolution tester (VanK.el Industries, Edison, NJ, USA) was used for the 
assessment of the in vitro release characteristics of these formulations. A model VK 750D 
digitally controlled water circulation/heater (VanKel Industries, Edison, NJ, USA) was used 
to maintain the temperature of the dissolution medium at 37 ± 0.5 °C. A mesh of pore size 
177 ~m was used to retain the dosage form in the inner tubes and a dip speed of 1 0 dpm was 
used as the agitation rate. The duration of dosage form exposure to buffers of different pH is 
summarised in Table 4.2. 
Table 4.2 Dissolution test conditions 
pH of dissolution medium 
1.2 
4.5 
6.0 
6.8 
6.8 
6.8 
4.2.6 Quantitative Analysis 
Duration (hr) 
1 
1 
2 
2 
2 
4 
2 ml aliquot of media from the dissolution vessels described in § 4.2.5 was measured out 
using a Boeco Germany electronic pipette (Boeckel & Co (GmbH & Co), Hamburg, 
Hamburg, Germany) and filtered through a 0.45 ~m Millipore® filter (Millipore, Bedford, 
MA, USA). A 1.5 ml aliquot was carefully placed in a sampling vial and 100 ~1 of a TBS 
solution at a concentration of 400 ~g/ml was added to the vial such that the fmal 
concentration of the internal standard was approximately 25 ~g/ml. The samples were 
assessed using the validated HPLC method described in Chapter 3 vide infra and compared 
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with the calibration curves prepared as described in § 3.3.3 to determine the percent drug 
released at different stages of the dissolution test. 
4.2. 7 Modelling of Dissolution Profiles 
In order to determine the possible mechanism of drug release from these matrix formulations, 
the in vitro release data were fitted to the Korsmeyer-Peppas power law [79] using the 
Curve-Fitting Toolbox ofMatlab® (Math Works Inc., Natick, MA, USA). The goodness of fit 
was determined by assessing the adjusted coefficient of determination, R~dj where the closer 
the value is to 1 the better the data fit to the model used to describe drug release patterns. The 
semi-empirical model used to describe the mechanism of drug release from the hydrophilic 
matrix dosage forms is shown in Equation 4.1. 
Where, 
.!!.!._ = fraction of drug released at time, t 
Moo 
Equation 4.1 
k = proportionality constant which accounts for the structural and geometric 
properties ofthe matrix 
n = diffusional exponent the value of which is indicative of the mechanism of drug 
release for a specific geometry 
4.3 RESULTS AND DISCUSSION 
4.3.1 Physical Properties of Tablets 
The physical appearance, tablet weight, thickness and crushing strength of batches of tablets 
manufactured in these studies are summarised in Table 4.3. 
The tablet weight, thickness and diameter ranged from approximately 140 to 142 mg, 2.98 to 
3.15 mm and 7.14 to 7.22 mm, respectively for the batches tested. The manufactured tablets 
remained intact for the duration of the study, with no visible signs of tablet fracture, chipping 
or capping and therefore were suitable for their intended use. 
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Table 4.3 Physical properties of tab lets 
SBS-01 SBS-02 SBS-03 SBS-04 SBS-05 SBS-06 
Weight (mg) 141.0 l ± 2.53 140.02 ± 1.59 140.68 ± 1.74 141.11 ± 1.21 141.22 ± 2.19 141.95 ± 3.67 
Thickness (mm) 2.99 ± 0.06 3.07 ± 0.04 3. 17 ± 0.08 3.03 ± 0.03 3.13 ± 0.05 2.98 ± 0.11 
Diameter (mm) 7.16 ± 0.01 7.16 ± 0.01 7.22±0.01 7.16±0.01 7.14 ± 0.01 7.16±0.03 
Crushing strength (N) 81.82 ± 4.41 85.66 ± 5.36 55.16± 5.80 123.64 ± 5.63 76.34 ± 3.95 78.44 ± 8.05 
Assay (mg) 9.64 ± 0.09 9.59 ± 0.11 9.62 ± 0.12 9.58 ± 0.23 9.57 ± 0.12 9.61 ± 0.20 
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Tablet crushing strength was consistent for each of the manufactured batches although the 
crushing strength values for each batch were formulation specific. The addition of other gel 
forming materials such as Methocel® K4M (SBS-02), Klucel® (SBS-05) and xanthan gum 
(SBS-06) did not result in significant changes to tablet crushing strength when compared with 
that of the primary formulation, SBS-0 1. It is apparent that the inclusion of SCMC (SBS-03) 
resulted in the production of relatively weak tablets and that the inclusion of Carbopol~& 
(SBS-04) resulted in the manufacture of the hardest tablets compared with tablets of batch 
SBS-01. 
The small standard deviations of measurements indicate that the tablets showed little 
variability and it can be concluded that the method of manufacture of the formulations is 
appropriate for the production of good quality SR matrix tablets of SBS. 
4.3.2 In Vitro Release Studies 
The in vitro release profiles for formulations containing Methocel® Kl OOM as the primary 
matrix forming polymer are depicted in Figures 4.1 and 4.2. Batch SBS-01 contains 50% w/w 
Methocel® KlOOM and was used as the reference formulation against which all the other 
formulations were compared. 
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Figure 4.1 In vitro dissolution profiles of preliminary formulations SBS-01 , SBS-02 and SBS-03 
The dissolution profile for tablets from batch SBS-0 1 showed that the API is rapidly released 
from the formulation and that approximately 35% of the dose is released within 1 hr of the 
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commencement of testing. This is a typical characteristic observed for SR dosage forms in 
which water-soluble drugs are formulated and the API is usually rapidly released from 
hydrophilic matrix formulations. Hydrophilic matrices generally exhibit an initial burst 
release followed by a gradual decreasing rate of release over the course of a dissolution test 
[ 150]. The in vitro release profile also reveals that the release of SBS from the matrices is 
almost complete after 12 hr and the inclusion of additional polymers may result in a reduction 
in both the burst and overall release rate of SBS. HPMC contains linear hydrophilic 
polymeric chains which do not cross-link but form a gelatinous layer on the surface of tablets 
which is subsequently susceptible to erosion. When the polymer concentration is increased 
the linear polymer chains entangle and form what may be considered "virtual cross-linking" 
which impedes drug liberation initially but as the polymer eventually erodes, so drug release 
rates change (134,152]. 
Methocel® polymers are available in a variety of grades that exhibit different viscosities in 
solution (153]. Methocel® K100M and Methocel® K4M are high and low viscosity grades, 
respectively. The addition of a low viscosity grade HPMC to a high viscosity grade is a 
possible formulation strategy that may be used to modulate drug release from matrix 
formulations (153]. The addition ofMethocel® K4M at 20% w/w resulted in a decrease in the 
drug release rate from batch SBS-02 as shown in Figure 4.1. The inclusion of additional 
polymer to a matrix results in a thicker gel layer being formed and consequently a greater 
barrier to drug diffusion is created in the matrix. 
Batch SBS-03 was formulated with SCMC as an adjuvant, and the results reveal that there is 
an initial burst, equivalent to approximately 25% of the dose that is released within an hour of 
the commencement of dissolution testing. The amount of drug released as a result of the burst 
for this formulation is lower than that observed for batch SBS-01, which is in agreement with 
findings that have been previously reported [136]. The combination of an anionic polymer 
such as SCMC with non-ionic polymer such as HPMC has been shown to result in a 
synergistic increase in viscosity of the gel layer that is formed on hydration and therefore a 
greater barrier to drug diffusion with a consequent decrease in burst release. The change in 
release is attributed to the formation of hydrogen bonds between the carboxyl groups of 
SCMC and the hydroxyl groups of HPMC, leading to stronger physical entanglement of the 
polymer chains compared to either pure polymers (136). It is also apparent that the release 
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rate between 1 and 8 hr of the dissolution test is linear compared with the release pattern that 
is observed for batch SBS-0 1. The linear pattern that is observed shows that during this 
period drug release follows a zero order mechanism. 
The impact of the addition of Carbopol® 71 G (SBS-04), Klucel® (SBS-05) and xanthan gum 
(SBS-06) at concentrations equivalent to 20% w/w of the tablet weight on drug release 
profiles is shown in Figure 4.2. 
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Figure 4.2 In vitro dissolution profiles of preliminary formulations SBS-0 I, SBS-04, SBS-05 and SBS-06 
The inclusion ofCarbopol® 710 (SBS-04) to the primary formulation (SBS-01) resulted in a 
decrease in both the burst and overall release rate of SBS from the formulations as shown in 
Figure 4.2. Carbopol® polymers are high molecular weight cross-linked synthetic polymers of 
acrylic acid that are insoluble in water, although they readily absorb water and swell. This 
property makes them ideal candidates for inclusion in the formulation of hydrophilic devices 
for oral SR delivery [134,152]. On hydration Carbopol® polymers form a gelatinous layer 
that has a significantly different structure to that formed by HPMC described previously. The 
gel layer is comprised of discrete microgel portions that are made up of many polymer 
particles within which the API is dispersed. The cross-linked nature of the network results in 
the entrapment of drugs in the hydrogel domains thereby hindering drug diffusion from these 
matrices. The addition of Carbopol® polymers therefore results in a reduction in drug release 
as observed in Figure 4.2 [134]. 
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The swelling of Carbopol® is also dependent on the pH of the medium to which it is exposed. 
The p.Ka of Carbopol® ranges between 6 ± 0.5, and at acidic pH the polymer is unionised and 
difficult to hydrate, whereas at pH 4.5 the polymer begins to ionise, therefore hydrates readily 
and subsequently swells [152]. This bas important implications when designing SR 
formulations since pH dependent swelling kinetics present a means of controlling the initial 
burst release observed for water-soluble compounds during the early stages of dissolution 
testing. 
The addition of K.lucel® EF to the primary formulation results in an overall decrease in the 
release rate of SBS from batch SBS-05 compared with that of batch SBS-0 1. K.lucel® is HPC, 
a non-ionic polymeric matrix material that has been used to manufacture monolithic 
hydrophilic matrix formulations [151]. HPC swells when placed in an aqueous medium and 
therefore retards the release of drug by hindering drug diffusion from the centre of the matrix 
to the bulk medium. K.lucel® shows similar swelling behaviour to that observed for HPMC 
matrices, although the differences observed are likely due to the differences in hydrophilicity 
of the matrix materials [I 51]. The incorporation of additional K.lucel® to formulations (SB S-
05) may result in a decreased rate of release to that observed in Figure 4.2 due to increased 
hindrance to diffusion as a result of the presence of more polymer. 
It is clearly evident in Figure 4.2 that the inclusion of xanthan gum (SBS-06) to the primary 
formulation results in a decrease in the burst effect and the overall release rate of SBS for the 
duration of the dissolution test. The use of xanthan gum as a drug release control material has 
been reported [149] and characteristics such as the compaction behaviour, in vitro release rate 
and rate of polymer hydration of xanthan gum were compared with those of HPMC. The use 
of xanthan gum eliminates the burst effect and results in release rates of API that are 
significantly lower than those observed when HPMC-based matrices were used [149]. The 
lower burst release following the inclusion of xanthan gum is due to the higher degree of 
hydration compared with HPMC which results in an increased hindrance of drug liberation 
that was also observed for SBS [149]. Interestingly, the addition of xanthan gum to 
ethylcellulose matrices has been reported to result in a proportional increase in drug release 
rates which has been attributed to the swelling of the xanthan gum in an aqueous medium, 
resulting in greater liquid uptake, polymer swelling and a consequent increase in API 
dissolution from polymeric matrices [ 13 8]. 
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4.3.3 API Release Rate and Mechanism of Release 
The diffusion of an API through a gelatinous layer and subsequent erosion of a polymeric 
matrix may contribute to the mechanism of release although one of the processes usually 
dominates in hydrophilic matrices [151]. The relative contribution of these processes is 
dependent on the specific polymer combinations and ratios that are used in formulating an SR 
dosage form. For example, if a durable and viscous matrix forming polymer is used to 
manufacture SR formulations, then water-soluble drugs such as SBS are released primarily 
by diffusion controlled kinetic processes and drug release rates decrease over time. In cases 
where an erodible polymer combination is used in a formulation, polymer erosion will 
contribute significantly to the mechanism of release and API release rates remain constant 
throughout period of use of the delivery system. 
A mathematical representation of the Korsmeyer- Peppas model is shown in Equation 4.1 
[79] and the model is often used to deduce release mechanisms from SR formulations. 
Specifically the value of the exponent n is used to infer the drug release mechanism. The 
dissolution data shown in Figures 4.1 and 4.2 were used to determine the mechanism of 
release for the batches under investigation for a percent SBS released <60% and the resultant 
parameters generated following modelling of the data are summarised in Table 4.4. 
Table 4.4 Drug release parameters for preliminary formulations 
SBS-01 SBS-02 SBS-03 SBS-04 SBS-05 SBS-06 
k 0.3465 0.2958 0.2699 0.2841 0.2908 0.2752 
n 0.4946 0.5058 0.5434 0.4518 0.5193 0.5380 
R1adj 0.9994 0.9996 0.9998 0.9997 
RMSE 0.007094 0.0001538 0.004434 0.003249 0.004138 0.0009134 
Drug diffusion through polymeric matrices can be described by three types of release 
mechanism viz., Fickian, anomalous and/or swelling controlled diffusion [154]. The 
numerical value of the exponent n describes the mechanism of drug release from a dosage 
form and is specific for a particular geometry. For a cylinder such as the matrix tablets that 
were manufactured in this study, when n = 0.45, the mechanism of release is considered to be 
governed by Fickian diffusion and is termed Case I transport. When 0.45<n<0.89 then mass 
transfer of an API from the matrix is considered to follow an anomalous transport mechanism 
that is a function of both drug diffusion and polymer relaxation. When the exponent n >0.89 
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the release mechanism is considered to be swelling-controlled and is referred to as Case II 
transport. 
Fickian diffusion controlled release occurs by molecular diffusion of a drug along a 
concentration gradient and Case II transport is associated with stress and a state-transition in 
the hydrophilic glassy polymers that swell in aqueous and/or biological media [155,156]. 
Anomalous diffusion is used to describe API release from initially dry, hydrophilic glassy 
polymers that swell when added to water as a result of a relaxation of the macromolecules 
that make up the polymer. The thermodynamic state of a polymer determines whether Fickian 
or anomalous diffusion predominates. Fickian diffusion occurs at low penetrant 
concentrations below the glass transition temperature and anomalous diffusion occurs at 
higher penetrant concentrations above the glass transition temperature of the polymer [154]. 
Case II transport is characterised by linear drug release kinetics, a sharp diffusion front and 
generally occurs in polymer-penetrant systems in which the penetrant results in substantial 
swelling of the polymer [154]. 
The value of the exponent obtained following modelling the dissolution profiles generated 
after testing of HPMC matrices was 0.4946, indicating that drug release is primarily 
controlled by a diffusion mechanism and that drug transport is dependent on the 
concentration gradient that exists between the tablet matrix and the aqueous dissolution 
medium. The drug moves from a region of high concentration in the tablet matrix to a region 
of low concentration in the bulk aqueous medium. These results are in agreement with those 
previously reported [143,146] in which it was shown that the liberation of water-soluble 
drugs from hydrophilic matrices is primarily diffusion controlled. The inclusion of low 
viscosity Methocel® K4M in batch SBS-02 did not cause a significant change in the 
mechanism of drug release and the value for n was 0.5058. 
The dissolution profile for batch SBS-03 revealed that linear release kinetics occur between 1 
and 8 hr indicating that drug release is directly proportional to time. The combination of 
HPMC and SCMC has previously been reported to result in zero order release patterns of 
drug molecules from matrix formulations [130,136,157]. The exponent n, in this case, was 
0.5434 indicating that an anomalous transport process predominates due to both diffusion and 
polymer relaxation, although diffusion is still a significant contributor to the release process. 
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The low dose and high aqueous solubility of SBS resulted in rapid drug release during the 
initial stages of dissolution testing and therefore a deviation from a true zero order release 
pattern was observed. By altering the ratio of HPMC: SCMC it is possible to achieve true 
zero order release formulations as has been previously reported [ 157]. 
The release of drug from Carbopol® matrices has been reported to exhibit both diffusion 
controlled [158] and zero order release profiles [147 ,148,159]. The inclusion of Carbopol~ to 
matrix formulations that contain HPMC results in a shift in the mechanism of drug release as 
was observed for batch SBS-04. The value of n decreased from 0.4946 to 0.4518 when 
Carbopol® was added to the HPMC containing formulation. This is indicative that diffusion 
is the primary mechanism that controls drug release and there is only a small contribution 
from polymer relaxation. The inclusion of Carbopol® results in increased polymer hydration 
rates thereby increasing the molecular volume of hydrated polymer present and reducing the 
free volume available between the microgel structure within the matrix with the result that 
there is an increase in diffusion control of the drug release process. 
The inclusion of Klucel® EF to the formulation did not result in a significant change in the 
release mechanism and a value for n of 0.5193 was generated. This is likely since Klucel® EF 
is similar to HPMC and undergoes a similar swelling process to that observed in HPMC 
matrices [ 151]. 
The inclusion of xanthan gum in the tablet matrices resulted in a change in the mechanism of 
drug release and a value of 0.5380 for n was observed. It has been reported that that the 
mechanism of drug release from xantban matrices follows a more linear pattern compared 
with those observed for HPMC matrices that tend to exhibit Higuchi-type release kinetics 
[149]. However, in these studies the influence of HPMC as a rate retardant matrix is 
significant since a high proportion of HPMC was used in the formulation compared with 
xanthan gum. 
4.4 CONCLUSIONS 
Preliminary screening studies are an important part of any formulation development process 
as they provide a database for making scientifically sound decisions for future product 
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development in addition to increasing the understanding of formulation behaviour. HPMC 
was chosen as the primary polymer for manufacturing SR dosage forms since it is a well 
understood technology whose performance is not adversely affected by manufacturing 
processes to any great extent. 
The inclusion of additional rate retarding adjuvants was investigated as a means of 
modulating drug release and xanthan gum and Carbopol~ were found to be suitable for 
further investigation since the preliminary results indicate that these had a significant effect 
on the rate and mechanism of drug release. These polymers were therefore used in a 
statistically designed experiment for the optimisation of a formulation with release 
characteristics that would be similar to the reference formulation, Asthalin®8 ER (Cipla Ltd., 
Mumbai, Maharashtra, India). 
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CHAPTERS 
RISK ASSESSMENT OF QUALITY 
5.1 INTRODUCTION 
Risk is defined as "the combination of the probability of occurrence of harm and the severity 
of that harm" and in the context of pharmaceutical technology this is dependent on an 
evaluation of risk, based on sound scientific principles and knowledge, with the ultimate aim 
being the minimisation of risk to the patient [2]. 
The composition of a pharmaceutical product, manufacturing process and intended clinical 
use involve some degree of risk for a patient that must be managed and/or controlled to 
ensure patient safety. It is therefore important that pharmaceutical products of consistent 
quality are produced throughout the product lifecycle, and product attributes that are 
important to quality, viz., CQA must remain consistent through clinical studies, trials and 
subsequent clinical use [2]. In addition to ensuring that product quality is maintained 
throughout the lifecycle of the product, an effective quality management approach must also 
provide a proactive means of identifying and controlling potential quality issues that may 
arise during formulation and manufacturing process development [2]. In the event that there 
are quality issues with respect to a medicinal product during formulation development and 
manufacturing, knowledge of potential risk areas facilitates intelligent problem solving and 
decision making [2]. The principles of risk management are intimately linked to the concepts 
of QbD (Chapter 1 vide infra). 
5.2 QUALITY RISK MANAGEMENT 
Quality risk management ts a systematic approach for the assessment, control, 
communication and review of risks that impact the quality of pharmaceutical product 
throughout the product lifecycle [160). An overview of a typical quality risk management 
process, which incorporates the consideration of elements that must be discussed during the 
quality risk management process, is depicted in Figure 5.1 [2]. 
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Figure 5.1 Typical risk management process, redrawn from [2) 
The risk assessment process includes risk identification, subsequent analysis and evaluation. 
The initial stages of a quality risk management process involve identifying the potential 
sources of risk that may impact product quality in order to facilitate sound scientific decision 
making. 
Risk identification is a systematic use of information to identify hazards that refer to the risk 
question, and risk analysis is an important aspect of product development in order to estimate 
the risk associated with recognised hazards, whereas risk evaluation compares the identified 
and analysed risks against specific risk criteria [2]. Appropriate risk assessment and 
management tools are used to evaluate risk following the appropriate definition of risk. The 
overall output of a risk assessment process is the establishment of quantitative estimates of 
risk or qualitative descriptions of the range of risk likely to be encountered within a system 
[2]. 
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The control of risk involves decision making to reduce or accept the potential risk with the 
ultimate goal of reducing the risk associated with a process to an acceptable level. Risk 
reduction focuses on processes for mitigation or avoidance of risk if and when risk exceeds a 
specified level, and risk acceptance is a conscious decision to accept the risk associated with 
a process [2, 160]. 
Risk must also be communicated to all relevant stakeholders and must be reviewed on a 
continuous basis during the lifecycle of a product [160). The term "unacceptable" in Figure 
5.1 refers to the statutory, legislative or regulatory requirements of risk management and 
when the control of risk is not possible the risk assessment process must be revisited [2]. 
5.3 RISK MANAGEMENT METHODOLOGY 
Risk has been traditionally managed using informal methodologies that are empirical and/or 
internal procedures that are based on the compilation of observations and trends. However 
formal risk management tools including Failure Mode Effects Analysis (FMEA), Fault Tree 
Analysis (FTA), Hazard Analysis and Critical Control Points (HACCP), Cause and Effect 
(Ishikawa) diagrams, flowcharts and check sheets, exist and provide a more meaningful and 
sustainable approach to risk management [2). 
A Cause and Effect diagram was selected as the tool for conducting a risk assessment in this 
study since it is relatively simple to use and allows for an exhaustive analysis to be conducted 
including all the factors that may affect a process. It is also easy to identify links and 
interrelationships between factors using a Cause and Effect diagram. 
5.4 RISK IDENTIFICATION 
Several aspects of the composition of a formulation and the associated manufacturing process 
may affect product quality and the aim of the risk assessment exercise was to identify these 
areas of concern. A Cause and Effect or Ishikawa diagram as depicted in Figure 5.2 was used 
to determine the formulation and process variables that are likely to affect product quality and 
therefore to determine areas of concern that must be controlled or monitored in statistically 
designed formulation development and assessment experiments. 
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The main sources of risk that impact the in vitro dissolution profile of an API from a dosage 
form were based on sound science and prior knowledge. The sources of product variability 
may include raw materials, manufacturing plants, manufacturing processes, granulation, 
drying and tablet compression in addition to analytical methods that are used to assess the 
data that is generated [ 161]. 
The synthetic procedure used to produce an API must be optimised · to ensure that dosage 
form performance and product quality are not compromised, and steps that are likely to 
influence the physicochemical properties of an API must be emphasised and controlled [162]. 
The partiele size distribution of the final product must also be well controlled as this is likely 
to affect in vitro dissolution rates and ultimately in vivo performance, especially for poorly 
water-soluble compounds [162]. Excipients can be used to control drug dissolution rates for 
both immediate release [163] and SR dosage forms [139], and the types, levels and quality of 
materials used in a formulation must be carefully controlled. Therefore the identification of 
critical formulation attributes that are likely to impact dosage form performance is crucial to 
ensure successful dosage form development [162]. 
The adequate control of any manufacturing process is vitally important in assuring the 
quality, safety and efficacy of a pharmaceutical product. The method of manufacture and all 
necessary processing steps must be well documented and controlled to ensure consistent 
dosage form manufacture and ultimately performance [162]. The conditions in a 
manufacturing plant and processing parameters are known to impact product quality. For 
example, in a wet granulation procedure, variables, such as the impeller and chopper speeds, 
rate of granulation fluid addition and wet massing time, can and often do affect granule 
quality [164- 166]. 
Specific measures of dosage form performance including in vitro dissolution testing, 
analytical methods and data handling are also important considerations in ensuring product 
quality and must also be considered. It bas been reported that between 20 and 38% of dosage 
form performance variability may be a consequence of the apparatus and related procedures 
used for data generation [ 161]. Specification tests including product assay, in vitro 
dissolution testing and analytical methods must be appropriately validated to ensure that 
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suitable conclusions regarding dosage form performance are made during formulation 
development studies [ 162]. 
5.5 RISK CONTROL 
Risk assessment and analysis is important m ensunng the control of those areas of 
formulation development and manufacturing that must be monitored and controlled so as to 
ensure product quality and minimise the risk of product variability. 
The same batch of each API and various excipients that were used in subsequent studies had 
the same batch number. For instance, the same batch ofMethocel® KIOOM that was obtained 
from Dow Chemical Company (Midland, MI, USA) was used in the future studies. In this 
way the potential impact of different lot numbers was eliminated as a potential source of 
variability. 
Furthermore the same manufacturing plant, granulation equipment and tablet press were used 
to ensure that the effect of using different equipment that would be a potential source of 
variation was eliminated. It was also important to ensure that the same manufacturing 
conditions were used and therefore careful monitoring and recording of environmental 
conditions was undertaken during manufacturing in order to determine if these conditions 
may potentially introduce variability into the batches of product. The analytical methods that 
were used in the study were validated to ensure that they were suitable for their intended use 
(see Chapter 3, vide infra) and the dissolution test equipment and other instruments, including 
weighing balances, hardness tester for analysis underwent regular maintenance procedures to 
ensure that they were in good working condition. 
5.6 CONCLUSIONS 
When conducting statistically designed experiments, external factors that do not intend to be 
investigated in a study but have the potential to impact the measured outcomes of that study, 
must be controlled. This strategy ensures that any observed changes in product performance 
may be fully attributed to the factors under investigation. Therefore manufacturing and 
processing conditions were carefully monitored to ensure that the statistically designed 
experiment was not affected by these factors. 
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Therefore, following risk analysis to ensure the control of variability and completion of 
preliminary studies, the impact of Methocel® K1 OOM, xanthan gum, Carbopol® as polymeric 
components of hydrophilic matrices and Surelease® as a granulation fluid on in vitro 
dissolution rates were further studied using a central composite design approach and the 
results are discussed in Chapter 6. The well documented use of these polymers for SR 
applications has made them suitable for further study [134,138,149,152,153,167]. Surelease®, 
an aqueous dispersion of ethylcellulose, was selected as a granulating fluid as this has been 
shown to retard drug release from monolithic matrix formulations [137,168]. 
The use of a risk assessment tool, preliminary formulation studies and prior knowledge are 
therefore essential in designing and conducting robust statistical experiments for the 
establishment of an appropriate design space for a SR product of SBS. 
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6.1 INTRODUCTION 
6.1 .1 Pharmaceutical Optimisation 
The use of mathematical and statistical models for the optimisation of pharmaceutical 
formulations and processes has been reported from as early as 1970 [ 169- 171]. The use of 
statistical methodology for the optimisation of SR formulations has been reported more 
recently [172- 179] where the application of these methods has been used to enhance an 
understanding of the underlying principles of pharmaceutical formulations. In addition, the 
application of statistical methodology has been recommended by the ICH in the 
Pharmaceutical Development guideline, Q8 (R2) [1] in order to ensure the development of 
quality pharmaceutical products and for the establishment of an appropriate design space for 
a product. 
Pharmaceutical optimisation has been defined as the implementation of systematic 
approaches to establish the best possible combination of product and/or process variables 
under a given set of conditions, that will result in the production of a quality pharmaceutical 
product with predetermined and specified characteristics each time it is manufactured [180]. 
There are four primary methods that can be used to optimise pharmaceutical products, viz., 
the one-factor-at-a-time approach, a direct optimisation technique, a non-systematic approach 
or the use of statistical design [ 181]. 
The use of the one-factor-at-a-time approach entails a formulator changing one formulation 
variable at-a-time in order to determine an optimal value for that variable. This strategy 
continues using single factor iterations until optimal dosage form performance is achieved. 
This approach may not be appropriate if multiple performance objectives must be met and in 
situations where strong interactions between the variables being studied prevail [ 180,181]. 
Direct optimisation methods are particularly useful for establishing an experimental domain 
for formulation or process variables, whereas non-systematic approaches are based on 
knowledge and intuition of a formulator in order to produce a quality pharmaceutical product. 
Although the intuitive approach is often successful it is also possible that a formulator is 
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unsuccessful and therefore time and valuable resources may be wasted [181]. Statistically 
designed experiments are planned as a matrix in order to estimate coefficients from 
mathematical models, which relate input factors or variables to measured responses that can 
be used for the optimisation of formulations or manufacturing processes. Statistical 
methodologies are considered to be a powerful approach for use in pharmaceutical 
formulation and process optimisation, provided that experimental domains or zones have 
been correct! y identified and defmed [ 181]. 
The objective of this study was to develop an optimised hydrophilic matrix formulation for 
SBS with an in vitro release profile that is similar to a reference formulation, viz., Asthalin®? 
ER (Cipla Ltd., Mumbai, Maharashtra, India). The preliminary formulation information 
reported in Chapter 4 was used to define an experimental domain for a statistically designed 
formulation experiment approach. 
6.2 RESPONSE SURFACE METHODOLOGY 
6.2.1 Introduction 
RSM is a combination of mathematical and statistical techniques used for developing, 
improving and optimising processes including industrial procedures, chemical and biological 
science applications, amongst others [182- 184]. RSM has been applied to the optimisation of 
dosage forms and manufacturing processes and has been widely accepted as being suitable 
for these purposes [185- 187]. With respect to the pharmaceutical sciences, the primary 
objective of RSM is to determine the optimal operational conditions or formulation 
compositions that will result in the development of products with appropriate CQA and 
performance characteristics, or the identification of an experimental region that will meet the 
predetermined and relevant product specifications [ 188]. 
RSM usually comprises three sequential steps, viz., performing a senes of statistically 
designed experiments, developing a mathematical model through multiple linear regression 
and finally determining an optimal set of experimental parameters that will produce a desired 
response [188]. 
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6.2.1.1 Statistically Designed Experiments in Formulation Development 
The development and optimisation of pharmaceutical formulations or manufacturing 
processes involves studying the variables that must be monitored and optimised to ensure the 
production of a quality product. The input factors or independent variables are those 
parameters that influence the final characteristics of a formulation and are under the direct 
control of formulation scientists. In the case of a SR matrix formulation, these variables 
typically include polymer type and composition, compression force, length of mixing time 
and the percent composition of a specific excipient, amongst others. The appropriate ranges 
for the input factors to be studied are defined from preliminary studies and are coded in such 
a way such that there are low (- 1), medium (0) and high (+1) levels [180). 
The dependent or response variables are measurable characteristics of a dosage form that are 
assessed following the conduction of an experimental design experiment. Typical examples 
of these characteristics include the dissolution rate profile, particle size distribution of a 
granulation and tablet crushing strength [180). 
The implementation of RSM involves the use of formal statistical experimental designs and 
the subsequent generation of mathematical equations and graphical outcomes to depict a 
complete picture of the variability of a response as a function of previously defined input 
factors. Empirical data is fitted to statistical or mathematical models that are used to predict 
formulation or process performance and to optimise defined critical response variables [180). 
The most common experimental techniques used for the optimisation of pharmaceutical 
formulations include factorial [172), central composite [173-177), Box- Behnken [178] and 
D-optimal designs [179). 
6.2.1.2 Mathematical Models 
The polynomial models that are generated from statistically designed experiments can be 
used to summarise empirical data and to predict the relationship between input and response 
variables [189]. The polynomial equations may be first, second or third order in nature 
although first and second order models are more commonly applied to pharmaceutical 
systems [181 ,189]. 
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First order models as shown in Equation 6.1 are usually selected when it is expected that 
important variables do not vary extensively over an experimental domain and when there are 
no interactions between input variables that may impact a defined or measured response 
[181]. 
Where, 
y = the estimated response 
xi = the input factors 
Po= constant that represents the intercept 
Pi= coefficients of first order terms 
Equation 6.1 
Second order models as shown in Equations 5.2 and 5.3 are generally used to create linear 
and quadratic equations for responses that vary extensively over the experimental domain and 
that show interactions between input variables that affect the responses. These are the most 
commonly used relationships in pharmaceutical optimisation processes and are used in 
experimental designs with up to five input variables [ 181]. 
Where, 
y = the estimated response 
xi = the input factors 
Po = constant that represents the intercept 
Pi = coefficients of first order terms 
PH =coefficients of second order terms 
Pii = coefficients of second order interaction terms 
Equation 6.2 
Equation 6.3 
The coefficients that are defined in the models are estimated by multiple linear least square 
regression of empirical data, and the sign and magnitude of the coefficients indicate the 
impact (increase or decrease) and extent or magnitude of the effect(s) of input variables on a 
defined measured response [1 81]. 
A mathematical model that is dependent on at least two factors can be graphically illustrated 
using a response surface that depicts the effect of an independent variable(s) on a measurable 
response. A response surface is a three dimensional illustration of how measured response 
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variables change as the level of an input variable(s) is altered over the experimental domain, 
and which may be used to acquire knowledge of underlying relationships between input 
factors and a measurable response. Alternatively the geometric illustration of a response 
obtained by plotting one independent variable against another, while holding the magnitude 
of the response and other variables constant, is known as a contour plot and represents two 
dimensional slices of the corresponding response surface plot [ 180, 189]. 
6.2.1.3 Optimisation 
Optimisation aims at determining the experimental conditions that lead to the generation of a 
desired value for the responses that are to be measured or monitored in a study. The values 
are often set as either a minimum or maximum, although optimisation may also be aimed at 
achieving a single desired or target value. The primary objective of an optimisation procedure 
is to identify either a single point or an optimum zone that satisfies the criteria to be measured 
and is therefore defined within the experimental region or domain [180]. 
Response surface plots that are generated may be used to optimise a response to a desired 
level and to determine what regions of the input variable domain to be studied would lead to 
the production of a desirable product. An important assumption for the successful 
optimisation of a product or process is that independent variables that are studied in an 
experimental design are continuous and controllable in experiments with the potential for 
negligible error [181,189]. 
6.2.2 Advantages of Response Surface Methodology 
Experimental design studies that use RSM are useful for conducting experiments in a rational 
and systematic manner thereby generating precise information from fewer experiments 
compared with the one-factor-at-a-time approach (180]. In addition the application of RSM 
has the potential to increase an understanding of the principles of pharmaceutical sciences 
with respect to formulation composition and is also useful for predicting dosage form 
performance from mathematical models that are developed. 
The use ofRSM is also important for the identification of input variables that are important in 
determining CQA that will ensure the production of a quality pharmaceutical product. 
Furthermore the application of RSM may be useful for detecting potential interactions and 
synergies between input variables that could be critical for the optimisation of formulations 
Page 185 
Chapter 7. Artificial Neural Networks 
[ 180). An enhanced understanding of process factors is also imperative for the successful 
scale up of formulations from laboratory to manufacturing scale [180]. 
6.2.3 Limitations of Response Surface Methodology 
Response surfaces are particularly useful for mapping simple relationships that exist between 
input factors and measured response variables and therefore are not likely to be suitable in 
situations where complex interactions and relationships between the variables to be studied 
exist. Considerable time and other resources may be necessary in order to investigate such 
complex relationships thoroughly, thereby limiting the potential usefulness of RSM in 
formulation optimisation studies. This is especially true when CQA are influenced by 
opposing processing and formulation variables. For instance the impact of relative humidity 
on a dissolution profile may be negligible for a particular formulation but may have a 
negative impact on the compression characteristics of the powder blend. fu such cases 
optimisation procedures become complex and the solution may require trade-offs of one 
CQA in favour of another [ 190]. 
Another limitation in the use of RSM for formulation optimisation is that experimental 
designs such as full factorial and Box-Behnken designs are only useful for evaluating a small 
number of critical input factors. As the number of factors to be evaluated increases an 
unrealistic number of experiments are required in order to conduct a valid and reliable study. 
Furthermore the polynomial relationships that are estimated by linear regression become 
increasingly complex as the number of factors evaluated increases and this further 
complicates the optimisation procedure [ 180). 
6.2.4 Central Composite Design 
Factorial design experiments are frequently used for exploring a response surface(s) and for 
the optimisation of pharmaceutical formulations [ 172,191, 192). A factorial design experiment 
is one in which all levels of a particular factor are combined with all levels of every other 
important factor to be considered in that experiment [180]. Full factorial design experiments 
are based on studying the effect(s) of all factors (k) at all levels (x), including interactions 
between them, with the result that the total number of experiments to be conducted can be 
determined by xk. If the number of levels to be considered is ~3 then second order 
mathematical models can be used to estimate the non-linear or quadratic effects of that 
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model. However as the number of factors increases, the number of experiments that are 
required in a full factorial study increases to an unmanageable number. For example 81 
experiments would be required to study potential interactions between 4 factors at 3 different 
levels. 
A method proposed by Box and Wilson [193) and referred to as a central composite design 
can be used to minimise the number of studies to be conducted and is now considered the 
cornerstone of RSM. The method is commonly used to map non-linear relationships that 
require second order models [ 189]. A central composite design is constructed from three sets 
of data points which are described as follows [180,189,194): 
1. The zk vertices of a k-dimensional cube for k :::; 4, or a fraction of a cube for 
k ;::: 5, which is a zk full factorial design if k :::; 4 or a partial factorial design if, 
k;::: 5, 
n. The zk vertices of a k-dimensional "star" which are paus of points on the 
coordinate axes that are all located at a distance of a from the origin, where a is 
selected based on the ratability of a design. This is often a number between 1 and 
1.5 from the centre point and is often selected as ,J2 distance from the centre point 
and, 
111. A number of centre points that permit careful estimation of coefficients with 
minimal error. 
The star points allow for the estimation of curvature and for the establishment of new 
extremes of high and low settings for all factors. A diagrammatic representation of a central 
composite design with only two factors, x1 and x2 and a ± ..J2 is shown in Figure 6.1. 
-1 (I 1 
Figure 6.1 Diagrammatic representation of a central composite design with full factorial points and star 
points, adapted and redrawn from [ 180] 
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Due the advantages of a central composite design discussed above, this method was selected 
for the optimisation of a SR hydrophilic matrix formulation of SBS. 
6.3 MATERIALS AND METHODS 
6.3.1 Materials 
Carbopol® 974P NF (Lubrizol, Wickliffe, OH, USA) and Surelease® (Colorcon, West Point, 
P A, USA) were used as received. All other materials and reagents are similar to those 
reported in § 4.2.1. All other reagents were at least of analytical grade and were used without 
further modification. 
6.3.2 Experimental Design 
A central composite design for formulation optimisation was generated and analysed using 
the Model Based Calibration Toolbox of Matlab~ R2008a (Math Works Inc., Natick, MA, 
USA). The independent variables, viz., the amounts of Methocel® KlOOM, xanthan gum, 
Carbopol® 974P and percent composition of Surelease® as the granulating fluid that were 
assessed are given in Table 6.1, which shows the composition of the input variables at the 
low, medium, high and ± a levels. Tablet crushing strength, percent API released at different 
times of the dissolution test, viz., 1, 2, 4, 6, 8 and 12 hr, and the constant and exponent 
generated by using the Korsmeyer- Peppas model [79] were used as the response variables. 
The constraints for the percent released for all formulations was determined following 
analysis of the dissolution profile generated for the reference product, Asthalin®8 ER (Cipla, 
Ltd., Murnbai, Maharashtra) using USP Apparatus 3 and the dissolution test conditions 
described in§ 4.2.5. 
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Table 6.1 Factor and level of variables studied 
Factors 
x 1 = Mcthoccl® KlOOM 
Xz = Xanthan gum 
-a 
Omg 
Omg 
Omg x3 = Carbopo1" 974P 
x 4 = Surclease® 4%w!w 
Dependent variables 
Tablet crushing strength 
Ythr = % dissolution after 1 hr 
Yzhr = % dissolution after 2 hr 
y 4-hr = % dissolution after 4 hr 
Y6hr =%dissolution after 6 hr 
Yahr = % dissolution after 8 hr 
Y12hr = %dissolution after 12 hr 
-1 
30mg 
25 mg 
5mg 
8%w/w 
k = Rate of release (from Korsmeyer- Peppas model) 
n = Korsmeyer- Peppas release exponent 
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Levels studied 
0 
60mg 
50mg 
l Omg 
12% w/w 
Constraints 
2: 40N 
35 .:::; Yth!· .:::; 39 
49 ::; Yzhr ::; 53 
66 :5 Y4hr:5 70 
77 :5 Y6hr :5 81 
85 :5 Yahr :5 89 
93 _:::; Yt2hr 5 97 
+ 1 
90mg 
75 mg 
15 mg 
16% w/w 
+a 
120mg 
100 mg 
20mg 
20%w/w 
A summary of the different compositions that were manufactured using a central composite 
design approach is shown in Table 6.2. The table shows the randomised order in which the 
formulations were manufactured and subsequently analysed. 
Page J89 
Chapter 7. Artificial Neural Networks 
Table 6.2 Formulation comEositions ofh;tdroehilic matrix tablets ~enerated using a central composite design 
Carbopol® 974P Surelease® Formulation Methocel® KIOOM Xantban gum 
(mg) (mg) (mg) (% w/w) 
SALOOl 120 50 10 12 
SAL002 60 50 10 12 
SAL003 60 50 10 4 
SAL004 60 50 20 12 
SALOOS 90 75 15 16 
SAL006 60 50 10 20 
SAL007 90 25 15 16 
SAL008 30 75 15 16 
SAL009 60 50 10 12 
SALOIO 90 75 5 8 
SA LOll 0 50 10 12 
SAL012 30 25 5 16 
SAL013 60 50 10 12 
SAL014 30 25 15 8 
SALOIS 60 50 10 12 
SAL016 60 100 10 12 
SAL017 90 75 5 16 
SALOIS 30 25 15 16 
SAL019 90 25 5 8 
SAL020 90 75 15 8 
SAL021 30 75 5 16 
SAL022 30 25 5 8 
SAL023 30 75 5 8 
SAL024 90 25 15 8 
SAL025 60 50 0 12 
SAL026 90 25 5 16 
SAL027 60 0 10 12 
SAL028 60 50 10 12 
SAL029 60 50 10 12 
SAL030 30 75 15 8 
6.3.3 Manufacturing Procedure for Matrix Tablets 
Surelease® is a 25% w/w aqueous dispersion of ethylcellulose; dilutions of Surelease® for use 
as the granulating liquid were prepared by accurately weighing the correct amount of 
dispersion on a top loader balance (Mettler Toledo Inc., Columbus, OH, USA) and diluting 
by weight with HPLC-grade water to the required concentrations of 4, 8, 12, 16 and 20% 
w/w. 
Batch sizes of 1000 tablets were prepared for each formulation. Matrix tablets were 
manufactured by dry blending SBS and the appropriate quantities of Methocel® Kl OOM, 
xanthan gum, Carbopol® 974P and Avicel® PHlOl in a Saral<P.' Rapid Mixer and Granulator 
(Saral Engineering Company, Mumbai, Maharashtra, India) in a 5 L bowl using a speed of 
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100 rpm on the main impeller for 15 mm. Thereafter 120 g of Surelease<K" diluted to the 
desired concentration with water ( 4-20% w/w) was gradually sprayed onto the powder blend 
using speeds of 120 rpm and 1000 rpm for the main impeller and chopper, respectively. The 
wet mass was further mixed for an additional 5 min at the same speed and removed from the 
granulator to dry on wax paper for at least 24 hr at a temperature of 22 °C until a constant 
weight had been achieved. Thereafter the granules were sieved and the fraction between 315 
and 800 mm was collected and weighed. Prior to the addition of lubricant and glidant, the 
granules were characterised according to the procedures described in § 6.3.4. Thereafter, an 
equivalent 1% w/w magnesium stearate and 0.5% w/w colloidal silica were sieved and added 
to the blend that was mixed for a further 3 min at 100 rpm using the main impeller. Finally, 
the lubricated granules were compressed into tablets using 9 mm biconvex punches on a 
Manesty® B3B rotary tablet press to a uniform weight of 220 mg. In-process control was 
achieved my monitoring environmental conditions such as temperature and humidity, and 
process conditions including, dry mixing and wet massing time, speed of the motor, current 
on the main impeller and the chopper and tablet weight during the compression cycle. 
6.3.4 Characterisation of Granules 
Prior to compression the granules were evaluated to determine their suitability for 
compression into tablets. 
6.3.4.1 Bulk Density 
The bulk density of the selected fraction of the granulation was assessed by filling the 
granulation into a measuring cylinder up to the 100 ml mark. The graduated measuring 
cylinder was weighed and the bulk density, Pb was calculated as the ratio of the sample 
weight to volume. 
6.3.4.2 Tapped Density 
The graduated measuring cylinder(§ 6.3.4.1) was then manually tapped 50 times at a rate of 
1 tap/sec on a flat surface from a constant height of 5 em and the tapped density, Pt was 
calculated as the ratio of the sample weight to the final volume after 50 taps. 
6.3.4.3 Carr's Compressibility Index 
The changes that occur in powder packing were also expressed as the Carr's Index (CI) that 
was calculated using Equation 6.4. 
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Equation 6.4 
6.3.4.4 Angle of Repose 
The angle of repose was determined using the fixed funnel method [195]. A plastic funnel 
was secured with its tip at a specific height (H) above a piece of Cartesian graph paper that 
had been placed on a flat, horizontal surface. The granulation was carefully poured into the 
funnel and allowed to flow until an apex had formed at the top of the conical pile of granules 
and that touched the tip of the funnel. The mean diameter (2 x R) of the base of the powder 
cone was measured and the tangent of the angle of repose was calculated according to 
Equation 6.5. 
tane = H/R Equation 6.5 
Where, 
e = calculated static angle of repose. 
6.3.5 Characterisation of Tablets 
Tablets were assayed for SBS content as previously described in § 4.2.3 and were 
characterised for tablet weight, thickness, diameter and crushing strength as previously 
described in § 4.2.4. In vitro dissolution studies and quantitative analysis of drug release were 
conducted according to the procedures described previously in § 4.2.5 and § 4.2.6 
respectively. 
6.3.6 Data Analysis 
6.3.6.1 Response SUiface Analysis 
The Model Browser in the Model-Based Calibration Toolbox of Matlabil!l R2008a 
(MathWorks Inc., Natick, MA, USA) was used to assess the response models that depict 
relationships between input variables and the resultant responses that were considered 
appropriate and that are listed in Table 6.1. 
The Root Mean Square Error (RMSE) was used to determine the goodness and degree of fit 
for the linear and quadratic models used to fit the data generated. The RMSE estimates the 
standard deviation associated with any experimental error and measures the average variance 
between each experimental data point that is generated by the model used to fit the data. The 
lower the value for RMSE, the closer the model fits the data and if the fitted data passes 
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through each experimental data point then the value for RMSE will be zero [ 196). The 
limitation of using only the RSME as a means of model evaluation is that minimisation of the 
RMSE can result in over-fitting of the data, which leads to poor model performance at 
regions distant to the experimentally derived data points. Therefore the Predicted Error Sum 
of Squares (PRESS) was also used to determine which model best fits the experimental data 
generated in these studies [ 196]. 
Mathematical models were used to fit the experimental data and were subsequently assessed 
to determine which of the input factors had a significant impact on measured responses by 
minimising the PRESS for each model. The use of PRESS is appropriate for working towards 
a regression model that provides good predictive capabilities for an experimental domain. 
When PRESS is evaluated in data modelling, if there are n runs in the data set, then the 
model equation is assessed by fitting n - 1 runs to the model under investigation. The 
difference between a recorded experimental data value and the value predicted by the model 
with n - 1 data points is termed the prediction residual and PRESS is the sum of the squares 
of the prediction residuals for each point in a data set [196]. Models were evaluated using 
stepwise regression by minimising the PRESS statistic for each coefficient in the model. A 
Student' s t-test was used to evaluate whether a coefficient was statistically different from 
zero with a 5% level of significance [196] and only significant factors were included in the 
evaluation of models selected for further investigation. 
Two types of model diagnostic plots, viz., the actual data vs. predicted data and studentised 
residuals vs. predicted data graphs, were constructed to evaluate the goodness of fit of the 
proposed models to experimental data and these results are shown in Appendix 3. The plot of 
experimental data vs. predicted response data generated from a model is particularly useful 
for detecting outliers [ 180]. The studentised residual values provide an indication of the 
magnitudinal differences between observed and predicted responses from a mathematical 
model and these are plotted vs. the predicted values of the response parameters under 
investigation [ 180]. 
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6.3. 6.2 Curve Fitting 
In order to elucidate the possible mechanism of SBS release from matrix formulations, the 
dissolution profile was fitted to the Korsmeyer-Peppas power law [79] as discussed in§ 4.2.7 
using the Curve-Fitting Toolbox ofMatlab® R2008a (Math Works, Inc., Natick, MA, USA). 
6.3. 6.3 Optimisation ofF ormulations 
The Calibration Generation Browser on the Model-Based Calibration Toolbox of Matlab® 
R2008a (MathWorks, Natick, MA, USA) was used to optimise the formulation to achieve a 
release profile similar to the reference product. A Normal Boundary Intersection method was 
used to solve the multi-objective problem using the constraints listed in Table 6.1 as the 
limits for the optimisation. 
6.3.6.4 Comparison of Formulations 
Moore and Planner [197] proposed the use of the similarity factor [2 for the comparison of 
dissolution profiles; this parameter can be calculated by fitting dissolution data from a test 
and reference product to Equation 6.6. 
Where, 
{[ 1 ]-0.5 } [ 2 = 50 log 1 +;;: L~=1 wtCRt - Tt) 2 x 100 
n = is the number of dissolution sample times, 
t = the time sample index 
Equation 6.6 
Rt = the mean percent dissolved at time t for the reference dissolution profile 
Tt = the mean percent dissolved at time t for the test dissolution profile 
The similarity factor [2 is a logarithmic transformation of the sum-squared error of the 
differences between a test and reference product over all time points. The factor falls between 
0 and 100 and a value of 100 indicates that the dissolution profiles of a test and reference 
product are identical. At least three or four dissolution time points are needed to calculate the 
similarity factor [2 [197], and only one point may be used after 85% dissolution has occurred. 
In general an [2 value that falls between 50 and 100 is indicative that the two dissolution 
profiles being compared are similar [ 197]. The similarity factor was used to determine the 
similarity of drug release between the reference and optimised formulations. 
6.4 RESULTS AND DISCUSSION 
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6.4.1 Micromeritic Analysis of Granules 
The characterisation of granules is an important step in the development of high quality 
pharmaceutical dosage forms that conform to physical quality testing criteria such as 
uniformity of weight, thickness, diameter and crushing strength. For instance the packing 
geometry of materials to be compressed must be evaluated by determining parameters such as 
Carr's Index prior to compression of a granulation into tablets. In general, tightly packed 
powders require a larger driving force to ensure uniform powder flow compared with more 
loosely packed particles of the same powder [ 198]. This is an important consideration during 
the tablet compression cycle since uniform flow of powders from a hopper into a die cavity 
will result in the production of tablets with minimal weight variation. The micromeritic 
characteristics of the granules manufactured in these studies, viz., batches SAL001- SAL030, 
were evaluated and the results are summarised in Table 6.3. 
Table 6.3 Granule characteristics of manufactured formulations 
Formulation Bulk density (g/cm~) Tap density (g/cm3) Carr's Index(%) Angle of repose (0 ) 
SALOOI 0.404 0.441 8.41 33.9 
SAL002 0.413 0.462 10.6 33.7 
SAL003 0.453 0.487 7.06 34.8 
SAL004 0.511 0.527 3.13 33.0 
SALOOS 0.486 0.534 9.09 33.2 
SAL006 0.478 0.519 8.00 32.4 
SAL007 0.424 0.464 8.64 37.7 
SAL008 0.525 0.552 5.00 33.3 
SAL009 0.368 0.421 12.5 43.6 
SALOIO 0.389 0.432 10.0 36.0 
SALOl I 0.563 0.614 8.33 38.7 
SAL012 0.379 0.400 6.54 37.1 
SAL013 0.476 0.510 6.67 35.8 
SALOI4 0.437 0.483 9.59 34.8 
SALOIS 0.474 0.501 5.36 33.9 
SALOI6 0.409 0.436 6.19 32.9 
SAL017 0.486 0.514 5.45 35.0 
SALOIS 0.428 0.474 9.88 35.4 
SALOI9 0.378 0.407 7.06 35.3 
SAL020 0.456 0.540 15.4 34.1 
SAL021 0.446 0.486 8.16 32.9 
SAL022 0.361 0.395 8.60 34.3 
SAL023 0.483 0.530 8.93 35.0 
SAL024 0.440 0.474 7.27 19.3 
SAL025 0.420 0.065 9.09 35.5 
SAL026 0.354 0.394 10.1 36.5 
SAL027 0.329 0.364 9.57 36.0 
SAL028 0.460 0.510 9.68 33.0 
SAL029 0.454 0.481 5.63 20.1 
SAL030 0.478 0.520 8.08 32.9 
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Carr's Index is an indication of the compressibility of a powder, expressed as a percentage, 
which is a direct measure of the potential powder arch or bridge strength and stability and is 
particularly useful for predicting the flow properties of a powder. In general powders that 
have a compressibility index between 5 and 15% exhibit excellent flow properties whereas 
powders with indices in excess of 21% tend to flow poorly and inconsistently [198]. Carr's 
Index is a one point determination and does not always reflect the ease with which a powder 
blend consolidates into compacts, as some powders that have a high index can and do 
consolidate readily. Rapid consolidation is essential for uniform die filling on tablet presses 
as the powder flows into a die cavity [199]. Carr's Indices for the batches manufactured in 
these studies ranged between approximately 3 and 15%, indicating that the granules have 
relatively good flow properties and that they were suitable for compression into solid oral 
dosage forms. 
The static angle of repose is also an important indicator of powder flow and is related to the 
nature of inter-particle cohesion. In general powders that have an angle of repose greater than 
50° tend to exhibit poor and unsatisfactory flow properties, whereas powders that have 
minimum angles of repose close to 25° generally exhibit very good flow properties [198). 
The granules manufactured in these studies appear to have acceptable flow properties and are 
suitable for compression into tablets as the experimentally determined angles of repose 
ranged between 30 and 40° for most of the formulations that were manufactured as shown in 
Table 6.3. 
6.4.2 Physical Properties of Tablets 
The manufactured tablets were small and cream coloured with no evidence of chipping, 
cracking or capping and remained intact following compression. No visible signs of breaking 
were observed throughout the study. The tablet weight, thickness and diameter data are 
summarised in Table 6.4. 
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Formulation 
SALOOl 
SAL002 
SAL003 
SAL004 
SALOOS 
SAL006 
SAL007 
SAL008 
SAL009 
SALOlO 
SALOll 
SAL012 
SAL013 
SAL014 
SALOIS 
SAL016 
SAL017 
SALOIS 
SAL019 
SAL020 
SAL021 
SAL022 
SAL023 
SAL024 
SAL025 
SAL026 
SAL027 
SAL028 
SAL029 
SAL030 
Physical characteristics of tablets 
Tablet weight Tablet 
(mg) thickness (mm) 
22 1.25 ± 1.07 4.93 ± 0.08 
223.23 ± 2.37 
221.72 ± 1.26 
221.85 ± 1.50 
222.53 ± 1.15 
220.83 ± 1.47 
224.15±2.19 
223.12 ± 1.39 
223.42 ± 0.64 
223.45 ± 0.82 
224.63 ± 1.14 
221.12 ± 1.39 
221.20 ± 0.60 
221.90 ± 1.15 
221.93 ± 1.38 
210.Q7 ±2.89 
220.53 ± 1.40 
221.95 ± 1.71 
221.88± 1.16 
220.63 ± 3.44 
222.57 ± 0.89 
222.40 ± 1.31 
221.45 ± 1.29 
222.00 ± 0.84 
222.70 ± 1.21 
221.90 ± 1.20 
220.77 ± 1.04 
222.30 ± 1.12 
221.95 ± 1.11 
221.12 ± 2.26 
4.71 ± 0.10 
4 .67 ± 0.06 
4.80 ± 0.10 
5.05 ± 0.04 
4.81 ± 0.09 
4.95 ± 0.1 6 
4.86 ± 0.05 
4.84 ± 0.15 
4.85 ± 0.08 
4.66 ± 0.09 
4.50 ± 0.05 
4.84± 0.12 
4.73 ± 0.07 
4.84 ± 0.11 
5.04 ± 0.04 
4.88 ± 0.05 
4.66± 0.04 
4.77 ± 0.03 
5.12±0.3 1 
4.70 ± 0.08 
4.58 ± 0.05 
4.65 ± 0.03 
4.81 ± 0.06 
4.75 ± 0.09 
4.85 ± 0.04 
4.59 ± 0.06 
4.76 ± 0.09 
4.69 ± 0.03 
4.77 ± O.Q7 
Tablet 
diameter (mm) 
8.73 ± 0.20 
8.81 ± 0.02 
8.71 ± 0.01 
8.82 ± 0.06 
8.81 ± 0.05 
8.77 ± 0.01 
8.83 ± 0.04 
8.87 ± 0.06 
8.79 ± 0.01 
8.82± 0.03 
8.84± 0.03 
8.82 ± O.Q3 
8.74 ± 0.17 
8.77 ± 0.07 
8.80 ± 0.02 
8.85 ± 0.08 
8.85 ± 0.05 
8.84± 0.04 
8.78 ± 0.01 
8.84 ± 0.03 
8.84 ± 0.03 
8.98 ± 0.39 
8.80± 0.04 
8.83 ± 0.06 
8.81 ± 0.02 
8.79 ± 0.05 
8.80 ± 0.03 
8.85 ± 0.05 
8.83 ± 0.03 
8.75 ± 0.03 
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Tablet crushing 
strength (N) 
33.27 ± 2.13 
31.53 ± 3.91 
30.18 ± 1.95 
25.53 ± 2.11 
16.40 ± 3.21 
21.82 ± 1.83 
36.57 ± 3.95 
28.97 ± 1.91 
29.08± 4.38 
14.20±2.14 
13.68 ± 3.04 
48.88± 5.09 
24.93 ± 3.23 
42.22± 4.23 
24.78 ± 4.10 
13.45 ± 6.43 
11.22 ± 1.49 
30.00± 4.20 
43.67 ± 1.36 
16.73 ± 8.45 
31.82 ± 1.88 
59.48 ± 6.83 
23.27 ± 2.50 
34.33 ± 4.00 
32.85 ± 2.71 
44.62 ± 2.44 
70.40 ± 2.26 
23.58 ± 2.97 
29.97 ± 3.51 
31.95 ± 14.63 
Tablet assay 
(mg) 
9.34 ± 0.36 
9.57±0.16 
9.72 ± 0.32 
9.64 ± 0.07 
9.58±0.17 
9.61 ± 0.16 
9.54 ± 0.39 
9.59 ± 0.14 
9.48 ± 0. 15 
9.43 ± 0.35 
9.53 ± 0.15 
9.61 ± 0.12 
9.47±0.11 
9.71 ± 0.23 
9.55 ± 0.77 
9.61 ±0.13 
9.57 ± 0.39 
9.50 ± 0.21 
9.51±0.20 
9.71±0.19 
9.41 ± 0.45 
9.74 ± 0.15 
9.55 ± 0.09 
9.50 ± 0.24 
9.61 ± 0.10 
9.64 ± 0.15 
9.72± 2.04 
9.58 ± 0.13 
9.49 ± 0.22 
9.69 ± 0.13 
The tablet weight ranged between approximately 220 and 225 mg for all batches 
manufactured and the tablet thickness and diameter ranged between 4.50 and 5. 12 mm, and 
8.71 and 8.85 mm, respectively. The low standard deviation values for the measurements are 
an indication that the tablets showed little variability, and it may therefore be concluded that 
the method of manufacture of the formulations is suitable for the manufacture of SR matrix 
tablets of SBS. 
The tablets that were produced were fairly soft and forces ranging between 15 and 70 N were 
required to fracture the dosage forms. Although the tablets were fairly soft, they remained 
intact for the duration of all tests conducted in these studies and were therefore deemed 
suitable for their intended purpose. 
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6.4.3 Tablet Crushing Strength 
The impact of formulation variables on tablet crushing strength were investigated using RSM 
to establish which of the input factors had a significant effect on the measured response, i.e. 
crushing strength. The quadratic model shown in Equation 6.7 was used to describe the 
relationship between selected input factors and tablet crushing strength. 
YH = 27.5- 23.3x2 - 4.55x3 + 15.9xi + 16.8x2x3 Equation 6.7 
The equation represents the quantitative effect of significant independent variables such as 
Carbopol® 974P and xanthan gum content and their effect on tablet crushing strength. It is 
clear that increasing the content of xanthan gum and Carbopol® 974P results in the 
production of softer tablets, whereas the interaction between these polymers results in an 
increase in tablet crushing strength. 
The crushing strength of tablet compacts that are manufactured using xanthan gum has been 
reported [149,200]; it was shown that the use xanthan gum resulted in the production of soft 
tablets with crushing strength values equivalent to approximately 75 N when compacts were 
prepared from pure polymer, but values were as low as 15 N for ternary mixtures for 
compacts that contained 50% w/w of xanthan gum [149]. Similar results were reported for 
tablets that contained 12-28% w/w of xanthan gum in combination with an API, 
microcrystalline cellulose and with or without PEG 6000 [200]. These results suggest that the 
use of xanthan gum in tablet matrices results in the formation of mechanically weak tablets. 
The results generated in these studies reveal that Methocel® Kl OOM does not have a 
statistically significant effect on tablet crushing strength whereas xanthan gum does. HPMC-
based compacts with and without API and adjuvants result in the formation of harder tablets 
compared with those manufactured using xanthan gum, ranging in crushing strength from 
65- 180 N compared with only 15- 75 N for xanthan gum matrix compacts [149]. HPMC and 
xanthan gum undergo plastic deformation and polymer fragmentation when they are 
compressed into tablets. However, both plastic deformation and polymer fragmentation are 
higher for HPMC matrices compared with those observed in xanthan gum matrices, which 
results in increased bonding when HPMC is compressed into compacts. This ultimately 
results in the formation of harder tablets when HPMC is used as a matrix forming polymer as 
opposed to those manufactured using xanthan gum [ 149]. The consequent elastic recovery 
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that follows tablet compression of both polymers is relatively high, however the bonds that 
are formed are strong enough to keep the tablets intact following manufacture [149]. 
A three dimensional response surface that depicts the relationship between xanthan gum and 
Carbopol® 974P and tablet crushing strength is depicted in Figure 6.2. In this case the 
composition of Methocel® KlOOM and Surelease® was maintained at the medium level for 
the purposes of this comparison. 
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Figure 6.2 Response surface plot depicting the effect of and xanthan gum and Carbopol® 974P on 
tablet crushing strength with Methocel® Kl OOM and Sure lease at the centre levels 
The response surface plot reveals that the hardest tablets are produced when the amount of 
both polymers in the formulation are at their lowest levels and increasing the concentration of 
xanthan gum at low levels of Carbopol® 974P results in the formation of weaker tablets. 
When the Carbopol® 974P content is high, increasing the content of xanthan gum results in 
an initial decrease in tablet crushing strength followed by a slight increase at even higher 
levels. The response surface also shows that at low levels of xanthan gum, increasing the 
content of Carbopol® 974P results in the formation of mechanically weaker tablets, whereas 
at high xanthan gum levels increasing the content of Carbopol® 974P has the opposite effect. 
These results suggest that there is a significant interaction between the two polymers that 
have an impact on tablet crushing strength. Evidence of an interaction between Carbopol® 
polymers and xanthan gum has not been previously reported, but may be linked to the 
chemical structure of the two polymeric materials. Carbopol® polymers are high molecular 
Page 199 
Chapter 7. Artificial Neural Networks 
weight acrylic acid polymers that contain free carboxylic acid groups and xanthan gum 
contains repeating sugar residue units, including glucose, mannose and glucuronic acid [20 1]. 
It is possible that the free carboxylic acid residues located on the Carbopol® backbone can 
react with the free hydroxyl functional groups located on the sugar residues. This may be 
evident in formulations containing high levels of xanthan gum, where an increase in the 
content of Carbopol® can result in stronger bonds being formed and which therefore will 
increase the integrity of the matrix and hence result in the production of harder and/or 
stronger tablets. This effect however is not apparent at low concentrations of xanthan gum 
due to the possible formation of weaker bonds and interactions between the reactive groups 
of the polymer chains. 
The contour plot shown in Figure 6.3 shows the relationship between the impact of xanthan 
gum and Carbopol® 974P content on tablet crushing strength. 
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Figure 6.3 Contour plot depicting the effect of and xanthan gum and Carbopol' 974P on tablet crushing 
strength 
with Methocel~ K I OOM and Sure lease at their centre levels 
The contour plot shown in Figure 6.3 reveals that as the levels of both polymers are 
increased, there is initially an almost proportionate and linear decrease in tablet crushing 
strength. The decline in tablet crushing strength becomes non-linear after the incorporation of 
approximately 50 mg of xanthan gum per tablet. Tablets that are crushed by a force of less 
than 30 N will be produced after incorporating at least 40 mg xanthan gum in formulations in 
which high concentrations of Carbopol® 974P (> 10 mg) are included. The weakest tablets 
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will be produced when the content of xanthan gum is at least approximately equivalent to 70 
mg and that ofCarbopol® 974P is less than approximately 12 mg per tablet. 
6.4.4 In Vitro Dissolution Results for Manufactured Formulations 
The in vitro release profiles generated for manufactured formulations derived using 
experimental design are depicted in Figures 6.4- 6.9. The formulations have been classified 
according to similar composition for ease of comparison and to gain an insight into 
qualitative factors that can impact in vitro release of SBS from these hydrophilic matrix 
tablets. The notation used to depict the formulation composition uses ratios of Methocel® 
KlOO: xanthan gum: Carbopol® 974P: Surelease®, and this convention has been adopted in 
the following discussion. 
The effect of extremes ofMethocel® KlOOM and xanthan gum concentration compared with 
a formulation with a composition that represents the centre points in the experimental design, 
viz., 60:50:10:12, is shown in Figure 6.4. A comparison of the in vitro release profile of 
formulations located at the centre points with those generated at the low and high extremes of 
other formulation variables provides an insight into the qualitative relationships, if any exist, 
between the input factors and measured responses for the formulations under investigation. 
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Figure 6.4 In vitro release profiles for formulations that contain Methocel® KIOOM and xanthan gum at at the 
lower and upper limits of composition compared with the centre formulation 
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The in vitro release profile of the centre point formulation shows that approximately 35% of 
the dose is released within the first hour of dissolution testing and that the balance of the dose 
is released gradually over the following 11 hr. It is evident that the rate of release decreases 
as the in vitro release dissolution test progresses. This type of dissolution profile is typical of 
water-soluble API release from hydrophilic matrix formulations in which HPMC is used as 
the matrix forming polymer and in which diffusion controlled lcinetics are displayed [149]. 
It is evident from the in vitro dissolution profiled depicted in Figure 6.4 that the addition of 
twice the amount ofMethocel® KlOOM in the formulation, 120:50:10:12 resulted in a marked 
decrease in both the burst and overall drug release rate from these matrix tablets compared 
with that observed for the centre point formulation. At the other extreme, the exclusion of 
Methocel® K100M from the formulation results in a rapid release of SBS initially and 
complete drug release is observed within 6 hr of commencement of the test compared with 
that observed for formulations that contained 60 mg of Methocel® K1 OOM. These results 
indicate that the inclusion of Methocel® K1 OOM as a rate controlling polymer is essential for 
modulating SBS release rates from hydrophilic matrix formulations. 
Similarly the inclusion of 100 mg xanthan gum per tablet (60:100:10:12) indicated that a 
significant reduction in the initial burst · and overall drug release rate was possible. The 
exclusion of xanthan gum from the matrix formulation, 60:0:10:12 resulted in a marked 
increase in the burst effect and drug release rates thereby validating the potential usefulness 
ofxanthan gum in controlling the rate of SBS release from hydrophilic matrix formulations. 
The dissolution profiles depicted in Figure 6.4 suggest that xanthan gum has a better retardant 
effect on the SBS release rates compared with when Methocel® K1 OOM is used in these 
formulations. Increasing the xanthan gum content by 100% resulted in a greater decrease in 
overall drug release rate compared with that observed when the content ofMethocel® KlOOM 
in the formulation was doubled. In the absence of these matrix forming polymers, the percent 
SBS released after 1 hr is approximately 38% and 53% for formulations that did not contain 
Methocel® Kl OOM and xanthan gum, respectively. It is apparent from these results that the 
inclusion ofMethocel® K100M and xanthan gum is important in controlling the initial release 
of SBS from these formulations . However, the exclusion of xanthan gum from the matrix 
formulations resulted in a greater burst release than that observed when Methocel® Kl OOM 
was excluded from the formulations. This implies that the initial rate of hydration of xanthan 
Page 1102 
Chapter 7. Artificial Neural Networks 
gum is faster than that for Methocel® Kl OOM and results in a better barrier to drug liberation 
from these matrix formulations. These results are similar to those observed by Talukdar et al 
[ 149] who reported that the incorporation of xanthan gum in matrix formulations results in a 
lower burst effect compared with that observed when HPMC was used in matrix 
formulations. 
The impacts of Carbopol® 974P and Surelease® on SBS release when included at the lower 
and upper extreme of composition, i.e. ±a, are shown in Figure 6.5. 
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Figure 6.5 In vitro release profiles for formulations that contain Carbopol® 974P and Surelease® at the lower 
and upper limits of composition compared with the centre formulation 
The resultant in v·itro dissolution profiles reveal that the exclusion of Carbopol® 974P from a 
formulation (60:50:0:12 vs. 60:50:10:12) results in a decrease in the overall rate of SBS 
release. This finding is contrary to what was expected because the exclusion of a polymer 
generally results in an increased rate of API release. Furthermore, the use of Carbopol® 974P 
at an extreme level ( 60:50:20: 12) resulted in a further decrease in the rate of SBS release, 
which implies that the relationship between the level of Carbopol® 974P and the in vitro 
release profile is a rather complex one. The relationship may possibly be described by a non-
linear model that is characterised by an initial increase in the drug release rate to a maximum 
as the polymer level is increased, followed by a subsequent decrease in SBS release rates as 
the polymer content in the formulation is further increased. These relationships show that 
there is a possible interaction between Carbopol® 974P and the other polymers used in the 
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manufacture of these hydrophilic matrix formulations. The impact of Carbopol® 974P on the 
initial burst release shows the same trend as that observed for the overall drug release rate. 
The addition of Surelease® has an impact on the both the initial burst and overall SBS release 
rates as shown in Figure 6.5. Decreasing the concentration of Surelease® in the formulation 
does not appear to have a significant effect on the initial release (up to 1 hr) of SBS with an 
equivalent of approximately 38% SBS released when formulations 60:50:10:4 and 
60:50:10:12 were tested. However the overall drug release rate is slightly higher for 
formulations that were manufactured with more dilute dispersions of Surelease®. It is also 
apparent that using more concentrated dispersions of Surelease® resulted in a decrease in both 
the burst and overall rate of SBS release. This is because when Surelease® is used for coating 
or is sprayed onto a powder blend, a water-insoluble rate controlling membrane which 
controls drug diffusion is formed [202,203]. It is apparent that the thicker the membrane, the 
greater the retardant effect on drug release [202,203]. 
The effect of Carbopol® 974P and Surelease® on formulations that contain Methocel® 
KlOOM and xanthan gum at their high levels, i.e. 90 mg and 75 mg respectively, is illustrated 
in Figure 6.6. 
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Figure 6.6 In vitro release for formulations that contain high levels ofMethocel® KlOOM 
and high levels of xanthan gum 
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It is evident from Figure 6.6 that using a higher concentration of Surelease® results in an 
overall decrease in the release rate of SBS when comparing formulations 90:75:5:8 vs. 
90:75:5:16. Similarly, the use of higher levels of Carbopol® 974P at these levels of 
Methocel® K100M and xanthan gum results in a decrease in the overall release rate of SBS. 
The combination of Carbopol® 974P and Surelease® at their high levels (90:75:15:16) 
resulted in an additive reduction of the extent of drug release and which is lower than that 
observed when low concentrations ofboth polymers are used in the matrix formulations. 
Examination of the in vitro release profiles reveals that the initial burst release, i.e. the 
percent drug released within an hour of the dissolution test, does not appear to be affected by 
the presence of Carbopol® 974P and Surelease® when included in these formulations when 
high levels of Methocel® Kl OOM and xanthan gum are used. 
The in vitro release profile of SBS from matrix formulations that contain high levels of 
Methocel® KlOOM and low levels of xanthan gum with varying levels of Carbopol<!Y 974P 
and Surelease® is shown in Figure 6.7. 
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Figure 6.7 In vitro release of formulations that contain high levels ofMethocel® KIOOM 
and low levels of xanthan gum 
It is evident in Figure 6. 7 that, at the levels of Methocel® Kl OOM and xanthan gum used, 
increasing the concentration of Surelease® at both high and low levels of Carbopol® (974P, 
90:25:5:8 vs. 90:25:5:16 and 90:25:15:8 vs. 90:25:15: 16) did not result in a significant change 
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in the in vitro release profiles for SBS, and the resultant dissolution curves are almost 
superimposable. However, it is apparent that the use of higher levels of Carbopol® at both 
low (90:25:5:8 vs. 90:25:15:8) and high (90:25:5:16 vs. 90:25:15:16) levels of Surelease® 
resulted in a decrease in the extent of SBS release from the formulations. Further examination 
of the dissolution profiles shown in Figure 6. 7 indicates that there are no observable changes 
to the initial burst release from the formulations and approximately 30% of the dose is 
released within 1 hr of the commencement of dissolution testing for all formulations. This is 
in agreement with the results shown in Figure 6.6 where the incorporation of Carbopol® 974P 
and Surelease® did not appear to have an impact on the initial release of SBS during the first 
hour of testing. 
The in vitro release profiles of formulations that contain low levels ofMethocel® K100M and 
high levels ofxanthan gum are shown in Figure 6.8. 
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Figure 6.8 In vitro release of formulations containing low levels of Methocel® K I OOM 
and high levels ofxanthan gum 
It is clear from the in vitro release profiles depicted in Figure 6.8 that the use of different 
levels of Carbopol® 974P and Surelease® does not have a significant impact on the initial 
burst release of SBS from all formulations. However, the rate and extent of in vitro release of 
SBS from these formulations is highest for the formulation that contains low levels of both 
Carbopol® and Surelease® (30:75:5:8). Increasing the content of both Carbopol® 974P and 
Surelease® to their high levels, i.e. 30:75:1 5:8 and 30:75:5:16, resulted in a decrease in the 
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extent of drug release from these matrix formulations compared with the formulation 
30:75:5:8. However, when Carbopol® 974P and Surelease® are increased to their high levels, 
i.e. 30:7 5: 15: 16, a further and significant decline in the extent of drug release is not observed. 
Since this curve is nearly superimposable with the in vitro release profile obtained for 
formulations 30:75:15:8 and 30:75:5:16, there is evidence that at these levels of Methocel® 
KlOOM and xanthan gum, the impact of Carbopol® 974P and Surelease® on the dissolution 
rate of SBS is not enhanced. 
The in vitro release profiles of formulations that contain low levels both Methocel® KlOOM 
and xanthan gum are depicted in Figure 6.9. 
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Figure 6.9 In vitro release profiles of formulations containing low levels ofMethocel® KIOOM 
and low levels of xanthan gum 
The in vitro dissolution profiles for the formulations shown in Figure 6.9 reveal that there is a 
high initial burst release within the first hour of the dissolution test and approximately 35-
45% of the dose is released within that hour. Interestingly, formulations that contain high 
levels ofSurelease® and low levels ofCarbopol® 974P (30:25:5:16) showed the lowest burst 
effect for SBS and increasing the concentration of Carbopol® (30:25:15:16) resulted in an 
increase in the burst release from these formulations. The complexity of the relationship 
between Carbopol® 974P and the rate and extent of SBS release has been previously noted 
and will be further investigated using RSM. 
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The overall rate and extent of drug release from formulations that contain high and low levels 
of Surelease® (30:25:5:8 and 30:25:5:16) are similar indicating that the impact of Surelease® 
on the extent of drug release at low levels of Methocel® Kl OOM and xanthan gum is limited. 
When Carbopol~ 974P is used at high levels (30:25:15:8 and 30:25:15:16), the use of a 
higher concentration of Surelease® resulted in an initial faster rate of release, but the overall 
extent of drug release in the latter stages of the in vitro release test decreased. 
It is apparent from Figures 6.4-6.9 and the preceding discussion that the relationship between 
the levels of polymer and the rate and extent of drug release is complicated and is further 
confounded by interactions between the formulation variables and their relative 
compositions. The use of RSM may be applied to investigate and understand the nature of the 
complex relationships that exist between the input variables and resultant responses selected 
for investigation in these studies. 
6.4.5 Analysis of In Vitro Release Data and Response Surface Modelling 
The extent of drug release following the early stages of in vitro release testing, i.e. between 1 
and 8 hr, is best described by use of quadratic equations (Equations 5.8 to 5.12), whereas a 
linear model was best suited to describe the relationship between the input factors and the 
extent of drug release after 12 hr of testing (Equation 6.13). The polynomial models used to 
investigate these relationships are summarised in Table 6.5. 
Table 6.5 Polynomial models that depict the relationships between input variables and responses 
Ythr = 30.5- 7.67x1 - 8.43x2 + 9.55x1x2 + 9.78xi- 5.66x2 x3 - 2.88xi 
Yzhr = 41.8- 8.52x1 -10.2x2 - 2.2Sx4 + 9.49x1x2 + ll.Oxi- 4.67x2x3 - 3.17x~ 
Y4hr = 60.3- 10.2x1 - 9.4Sx2 - 2.8lx3 - 3.46x4 - 7.4lx1 x2 - 4.90x~ 
Y6hr = 72.1- 13.5x1 - 8.08x2 - 4.0lx3 - 4.43x4 + 10.4xf + 4.49x1x2 - 5.29xj 
Yahr = 82.7- 12.0x1 - 7.06x2 - 4.26x3 - 4.91x4 + 6.37xf + 4.70xj 
Ytzhr = 94.3- 7.71x1 - 6.87x2 - 3.2lx3 - 3.98x4 
Equation 6.8 
Equation 6.9 
Equation 6.10 
Equation 6.11 
Equation 6.12 
Equation 6.13 
Coefficients with more than one factor represent interactions between factors, whereas 
coefficients with second order terms are indicative of the quadratic nature of relationships. A 
positive value for a coefficient represents an effect that will favour a measured response 
whereas a negative value indicates that an inverse relationship exists between a factor and a 
measured response. 
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It is apparent from the equations listed in Table 6.5 that the inclusion of both Methocel® 
Kl OOM and xanthan gum results in a significant decrease in the extent of drug release at all 
stages of the dissolution test. The relative contribution of both polymers to the in vitro release 
profile depends on the stage of the dissolution test, where it is apparent that xanthan gum has 
a higher retardant effect in the early stages of the dissolution test (y1hr and Yzhr ), whereas 
Methocel® KlOOM has a greater impact on the extent of drug release as observed in the latter 
stages of the dissolution test (>y4hr ). These results are corroborated by those observed by 
Talukdar eta/ [149] who showed that the use ofxanthan gum resulted in a lower burst release 
compared with that observed when HPMC was used as a matrix forming polymer. These 
results are also in agreement with those depicted the in vitro release profiles shown in Figure 
6.4 where the exclusion of xanthan gum resulted in a higher burst effect compared with that 
from formulations that contained no Methocel® Kl OOM. The impact of these polymers on the 
extent of drug release is due to the formation of a hydrophilic gel layer when these matrices 
are immersed in an aqueous medium. The thickness of the gel layer hinders drug diffusion 
from the interior of the matrix to the bulk dissolution medium, and therefore increasing the 
relative content of these polymers in a formulation results in an overall decrease in the extent 
of drug release at all stages of the dissolution test. 
Close inspection of the equations listed in Table 6.5 reveals that both Carbopol® 974P and 
Surelease®, at the levels that were studied in the experimental domain under investigation, do 
not appear to have a significant impact on drug release during the initial stages of the 
dissolution test, i.e. Ylhr· 
The addition of Carbopol® 97 4 to the matrix has in fact a negative effect on the extent of drug 
release in the latter stages of the dissolution test. Carbopol® polymers on hydration form a 
gelatinous layer composed of discrete micro gels that are made up of many polymer particles 
within which SBS is dispersed. This cross-linked network entraps SBS in the hydrogel 
domains and hinders drug diffusion from the matrix. It is also apparent that the interaction 
between Carbopol® and other matrix forming materials is significant in the early stages of the 
dissolution test. 
The use of Surelease® as a granulating fluid also results in a reduction in the extent of drug 
release at the latter stages of dissolution testing i.e. from at least 2 hr from commencing in 
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vitro dissolution testing. Surelease® is an aqueous dispersion of ethylcellulose that contains 
fractionated coconut oil, dibutyl sebacate and ammonium hydroxide and, when Surelease® is 
sprayed onto a powder blend, a water-insoluble rate controlling polymer, which controls the 
passage of an API through a membrane, may be formed [202,203]. The concentration of the 
dispersion used when manufacturing the formulation determines the thickness of a membrane 
and in general, the thicker the membrane, the slower the rate of drug release [202,203]. 
The impact of formulation variables on the rate and extent of drug release at different stages 
of the dissolution test is shown as response surface and contour plots in Figures 6.1 0- 6.30. 
The response surface and respective contour plots for the in vitro release data in the early 
stages of the dissolution test with Carbopol® 974P and Surelease® held at the centre levels are 
depicted in Figures 6.10-6.13. 
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after 2 hr with Carbopol'® 974P and Surelease~ concentrations at the centre level 
The response surface plots shown in Figures 6.10 and 6.12 illustrate that the percent SBS 
released is highest when low levels of the two polymers are used in formulations. It is evident 
that at low levels of Methocel® K1 OOM the inclusion of xanthan gum in progressively 
increasing concentrations results in a consequent decline in the extent of drug release. 
Similarly at low levels of xanthan gum, increasing the concentration of Methocel® Kl OOM 
also results in a decrease in the extent of SBS release at the initial stages of dissolution 
testing. 
An interesting observation is there is evidence of an interaction between Methocel® KIOOM 
and xanthan gum during the early stages of dissolution testing, i.e. at times of 1 and 2 hr as 
shown in Figures 6.10 and 6.12. The addition of Methocel® K100M to formulations that 
contain high concentrations of xanthan gum resulted in a slight increase in the extent of SBS 
release from these formulations. This observation is in contradiction to the assumption that 
using high concentrations of polymer in pharmaceutical formulations results in a decrease in 
the extent of drug release. It is apparent from examining both the topographical surface plots 
and the respective equations for Ylhr (Equation 6.8) and Yzhr (Equation 6.9) that the 
interaction between Methocel® KlOOM and xanthan gum results in an increase in the extent 
of drug release, when the polymers are used in combination. 
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The contour plots that represent the relationship between Methocel® KlOOM and xanthan 
gum and the extent of SBS release (Figures 6.11 and 6.13) also depict the complex nature of 
the relationship that exists between the input factors and measured responses under 
investigation. In the early stages of the dissolution test, i.e. at times 1 hr and 2 hr, it is 
apparent that the addition of increasing quantities of polymer results in a progressive decline 
in SBS release rates and the decline occurs in an almost linear fashion. However as the 
polymer levels are increased, drug release follows a quadratic pattern that is evidence of the 
inherent complexities of the interaction and relationships that exist in this formulation. The 
lowest extent of SBS release would be observed when the xanthan gum content used is >80 
mg and that ofMethocel® KlOOM is >20 mg and >50 mg in order to minimise drug release at 
times 1 hr and 2 hr, respectively. 
The response surface and contour plots that depict the relationship between Methocel® 
KlOOM and xanthan gum in the latter stages of the dissolution testing are shown in Figures 
6.14- 6.19. 
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after 4 hr with Carbopof~ 974P and Surelease® concentrations at the centre level 
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Figure 6.16 Response surface plot depictin~ the effect of Methocel® Kl OOM and xanthan gum on percent SBS 
released after 6 hr with Carbopol 974P and Surelease® concentrations at the centre level 
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Figure 6.17 Contour plot depicting the effect ofMethocel® KlOOM and xanthan gum on percent SBS released 
after 6 hr with Carbopol® 974P and Surelease® concentrations at the centre level 
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released after 8 hr with Carbopololil 974P and Surelease'!. concentrations at the centre level 
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Figure 6.19 Contour plot depicting the effect ofMethocel~ KlOOM and xanthan gum on percent SBS released 
after 8 hr with Carbopol~ 974P and Surelease" concentrations at the centre level 
In general the response surface plots for these data reveal that percent SBS released is highest 
when low levels of the polymers are used in the formulations and this is the case for the latter 
stages of dissolution testing. It is apparent that, at low and high levels of Methocel® K100M, 
the inclusion of xanthan gum in progressively increasing concentrations results in a 
synergistic decline in the extent of SBS release at all dissolution time points. Similarly, after 
4 hr of dissolution testing (Figure 6.14), increasing the Methocel® K100M content at low 
levels of xanthan gum results in a decrease in the extent of drug release. However, after 6 hr 
and 8 hr of dissolution testing, the inclusion of Methocel® Kl OOM gum in formulations that 
contain both low and high levels of xanthan results in an initial decrease in extent of release 
followed by a slight increase in the extent of SBS as is seen in the topographical surface plots 
depicted in Figures 6.16 and 6.18. 
The impact of xantban gum on the extent of SBS dissolution decreases as the dissolution test 
progresses as is apparent in the topographical surface plots depicted in Figures 6.14, 6.16 and 
6.18. In addition the equations listed in Table 6.5 further support this conclusion. The 
magnitude of the coefficient related to xanthan gum decreases, i.e. x2 , which is mirrored by a 
decreasing gradient in the response surface plots in the region associated with increasing 
xanthan gum content. These findings are slightly different to those in which the impact of 
Methocel® KIOOM on the extent of dissolution is depicted in the equations shown in Table 
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6.5; these show drug release to increase to a maximum value at 6 hr after which the 
magnitude of the effect of this polymer decreases as the dissolution test progresses. 
The contour plots (Figures 6.15, 6.17 and 6.19) that depict the relationship between the levels 
ofMethocel® KIOOM and xanthan gum in the latter stages of the dissolution test, i.e. at 2:4 hr, 
also show the same relationships as described above. In general, it is apparent that increasing 
the polymer content results in a progressive decrease in the extent of drug release at these 
stages of the dissolution test. However, closer examination of the contour plots reveals that 
there is a shift in the relationship between the polymer content and extent of drug release. The 
extent of drug release tends to become less quadratic and more linear in nature as the 
dissolution test progresses. 
Evaluation of Figure 6.20 reveals that the percent SBS released after 12 hr of dissolution 
testing has a linear relationship with the input factors that were studied. Furthermore the 
extent of drug release decreases with increasing levels of polymers, and the lowest overall 
drug release percent will be observed when at least 80 mg and 60 mg of Methocel® Kl OOM 
and xanthan gum, respectively are used in formulations. 
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Figure 6.20 Contour plot depicting the effect of Methocel® K I OOM and xanthan gum on percent SBS released 
after 12 hr with Carbopol® 974P and Surelease~> concentrations at the centre level 
The relationships between the input variables and responses are summarised in Table 6.5 
which shows that there is an interaction between xanthan gum and Carbopol® 974P in the 
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early stages of the dissolution test. The response surface and contour plots that illustrate the 
effect of xanthan gum and Carbopol® 974P with Methocel® KlOOM and Surelease® 
concentrations at the centre level are shown in Figures 6.21-6.24. 
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Figure 6.21 Response surface plot depicting the effect ofxanthan gum and Carbopol"" 974P on percent SBS 
released after 1 hr with Methoce(f Kl OOM and Surelease® concentrations at the centre level 
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Figure 6.22 Contour plot depicting the effect of xanthan gum and Carbo pol~ 974P on percent SBS released 
after I hr with Methocel® Kl OOM and Surelease® concentrations at the centre level 
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Figure 6.24 Contour plot depicting the effect of xanthan gum and Carbopol~ 974P on percent SBS released 
after 2 hr with Methocel® K I OOM and Surelease~ concentrations at the centre level 
The topographical surface plots depicted in Figures 6.21 and 6.23 show that when low levels 
of xanthan gum are used, increasing the amount of Carbopol® 974P in the formulation results 
in an increase in the overall extent of SBS release. These results are surprising since the 
inclusion of additional polymer will often result in a decrease in the overall rate and extent of 
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drug release. However in cases where the xanthan gum content is high, increasing Carbopol® 
974P content results in a decrease in the extent of drug release. The response surface plots 
depicted in Figures 6.21 and 6.23 show evidence of an interaction between the two polymers 
since at both low and high levels of Carbopol® 974P, increasing the xanthan gum content 
results in an initial decrease followed by increase in the extent of drug release. 
Inspection of the equations listed in Table 6.5 reveals that there is no interaction between 
xanthan gum and Carbopol® 974P in the latter stages of dissolution testing. This observation 
may be related to the difference in the pH of the dissolution media used in the early and latter 
stages of dissolution testing. During the first two hours, the pH is acidic and is then increased 
to at least pH 6 over the next 10 hours. The interaction may be direct consequence of the 
ionisation state of Carbopol® 974 at acidic pH where the polymer is unionised and difficult to 
hydrate, but at pH 4.5 the polymer begins to ionise, hydrates and begins to swell [152]. 
Unionised carboxylic acid functional groups may interact with the hydroxyl groups on the 
sugar moieties of the xanthan gum backbone by forming hydrogen bonds that either weaken 
or strengthen the gel layer depending on the concentration of either polymer in the 
formulation. When the xanthan gum content is low, increasing the Carbopol® 974P content 
results in the formation of a gel phase that has little integrity and that permits rapid drug 
liberation from the matrices. However at high xanthan gum concentrations it is possible that 
the interaction results in the formation of a gel layer that has greater integrity and that hinders 
drug diffusion as the concentrations ofCarbopol® 974P are increased. 
The contour plots depicted in Figures 6.22 and 6.24 depict an interaction between the two 
polymers and show a curvature, evident from the response surface plots, that indicates an 
initial decrease and a subsequent increase in the extent of drug release as xanthan gum is 
added to formulations that contain Carbopol® 974P. 
The impact of Surelease® on in vitro dissolution profiles is not evident in the first hour of 
dissolution testing but becomes significant after 2 hr, shown during in vitro release studies 
and in the equations summarised in Table 6.5. The response surface and contour plots 
depicted in Figures 6.25-6.30 show that at the later stages of dissolution testing i.e. ~4 hr an 
interaction between Surelease® and Carbopol® 974P, exists. 
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Figure 6.25 Response surface plot depicting the effect of Carbopol® 974P and Surelcase® on percent SBS 
released after 4 hr with Methocel® Kl OOM and xanthan gum concentrations at the centre level 
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Figure 6.26 Contour plot depicting the effect ofCarbopol® 974P and Surelease'!l on percent SBS released 
after 4 hr with Methocel~ Kl OOM and xanthan gum concentrations at the centre level 
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Figure 6.28 Contour plot depicting the effect of Carbopof~ 974P and Surelease-~>~ on percent SBS released after 
6 hr with Methocel" K I OOM and xanthan gum concentrations at the centre level 
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The topographical surface plots depicted in Figures 6.25, 6.27 and 6.29 show that at low and 
high levels of Carbopol~· 974P an increase in the concentration of the aqueous ethylcellulose 
dispersion results in a decrease in the extent of SBS release. However, the addition of 
increasing concentrations of Carbopol® 974P at both high and low levels of Surelease® 
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results in an initial increase and then a subsequent decrease in the extent of SBS release. The 
curvature in the plot is indicative of the presence of an interaction between these factors. 
Surelease® contains ethylcellulose, fractionated coconut oil, dibutyl sebacate and ammonium 
hydroxide which may interact with the ionisable groups on the Carbopol® 974P backbone and 
result in the patterns that are observed in the response surface and contour plots. The contour 
plots shown in Figures 6.26, 6.28 and 6.30 also show similar responses and relationships. 
The response surfaces and contour plots that have been shown in Figures 6.10-6.30 
demonstrate the complex nature of the relationships that exist between the levels of input 
factors used and the extent of SBS release at different stages of dissolution testing. In order to 
undertake formulation optimisation experiments to develop a pharmaceutical product with 
optimal in vitro release characteristics it is essential to have an understanding of the 
interactions that may exist between formulation factors. 
6.4.6 Drug Release Rate and Mechanism of Release 
6.4.6.1 Overview 
A summary of the release parameters for SBS derived from fitting drug release data to the 
Korsmeyer- Peppas model viz., the exponent n that describes the nature of SBS release 
kinetics and the rate of release k for the manufactured formulations are shown in Table 6.6. 
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Table 6.6 Kinetic parameters for SBS release derived from the Korsmeyer- Peppas model 
SALOOl 0.2840 
SAL002 0.3083 
SAL003 0.3394 
SAL004 0.2644 
SALOOS 0.2571 
SAL006 0.2691 
SAL007 0.2852 
SAL008 0.2979 
SAL009 0.3075 
SALOlO 0.2785 
SA LOll 0.3704 
SAL012 0.3727 
SAL013 0.3258 
SAL014 0.4461 
SALOIS 0.2748 
SAL016 0.2623 
SALOI7 0.2680 
SALOIS 0.4764 
SAL019 0.2915 
SAL020 0.2640 
SAL021 0.3224 
SAL022 0.3982 
SAL023 0.3299 
SAL024 0.2749 
SAL025 0.2843 
SAL026 0.2795 
SAL027 0.5337 
SAL028 0.2671 
SAL029 0.2864 
SAL030 0.2987 
6.4.6.2 Drug Release Rate 
0.4833 
0.4725 
0.4678 
0.5022 
0.4799 
0.4784 
0.4622 
0.4799 
0.4699 
0.5137 
0.4334 
0.4469 
0.4623 
0.3517 
0.4858 
0.4842 
0.4789 
0.3482 
0.4745 
0.5044 
0.4538 
0.4166 
0.4945 
0.4718 
0.4999 
0.5066 
0.3482 
0.5036 
0.4647 
0.4727 
0.9996 
0.9995 
0.9997 
0.9996 
0.9997 
0.9996 
0.9999 
0.9994 
1 
0.9994 
0.9992 
0.9997 
1 
0.9999 
0.9996 
0.9997 
1 
0.9999 
0.9999 
0.9997 
The relationship between polymer levels and interactions that impact the overall release rate 
of SBS from the manufactured formulations is shown in Equation 6.14. 
k = 0.304- 0.0764x1 - 0.0876x2 + 0.0953x1 x2 + 0.0955x~- 0.0555x2 x3 - 0.0281xj 
Equation 6.I4 
It is clearly evident that the inclusion of Methocel® Kl OOM and xanthan gum results in a 
significant decrease in SBS release rates, although an interaction between xanthan gum and 
Carbopol® 974P and the quadratic term for Carbopol!E- 974P are important factors that must 
be considered. The equation also shows that the magnitude of the effect of xanthan gum on 
the overall rate of SBS release is greater than that for Methocel® Kl OOM in the formulations 
that were studied. 
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The relationship and impact of the levels of Methocel(!,) Kl OOM and xanthan gum on the rate 
of drug release from the hydrophilic matrix formulations that were manufactured are shown 
in Figures 6.31 and 6.32. 
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Figure 6.31 Response surface plot depicting the effect of Methocel" K I OOM and xanthan gum on SBS 
release rate with Carbopol~ 974P and Surelease~ concentration at the centre level 
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Figure 6.32 Contour plot depicting the effect ofMethocel~ KIOOM and xanthan gum on SBS release rate 
with Carbopol lll 974P and Surelease'® concentrations at the centre level 
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The topographical surface plot depicted in Figure 6.31 reveals that, at low levels of 
Methocel® K1 OOM, increasing levels of xanthan gum result in a decrease in the rate of SBS 
release. However at high levels ofMethocel® KlOOM the inclusion ofxanthan gum results in 
an initial decrease and then a subsequent increase in the release rate of SBS. Similarly the 
addition of Methocel~ K 1OOM to formulations that contain low levels of xanthan gum results 
in a decrease in the release rate of SBS, but at high concentrations of xanthan gum the 
addition of Methocel® Kl OOM results in a slight increase in the rate of SBS release. 
The interaction between xanthan gum and Carbopol® 974P that impacts on the release rate of 
SBS is shown in Figures 6.33 and 6.34. 
0.7 
0.6 
~0.5 
~ ~0.4 
,.:;:: 
0.3 
0.2 
100 
Xanthan gum (mg) 
: ... 
.... : .. ···· 
0 0 
0.35 
0.3 
20 
0.25 
Carbopol® 974P (mg) 
Figure 6.33 Response surface plot depicting the effect of xanthan gum and Carbopol ' 974P on the rate of SBS 
release with Methocel1s. Kl OOM and Surelease"il concentrations at the centre level 
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of Carbopol® 974P results in a decrease in the value of the exponent. It is apparent that the 
inclusion of xanthan gum results in the largest deviation from a truly diffusion controlled 
matrix system and that the interaction between MethocelQ!. KlOOM and xanthan gum results in 
a decrease in the value of the exponent. 
The response surface and contour plots that depict the relationship between Methocel® 
KlOOM and xanthan gum on the mechanism of drug release are shown in Figures 6.35 and 
6.36. 
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Figure 6.35 Response surface plot depicting the effect ofMethocelt- KlOOM and xanthan gum on 
the mechanism ofSBS release with Carbopol® 974P and Surelease® concentrations at the centre level 
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Figure 6.36 Contour plot depicting the effect ofMethocel® KIOOM and xanthan gum on the mechanism 
of SBS release with Carbopol-~> 974P and Sureleasett concentrations at the centre level 
The relationship between Methocel® Kl OOM and xanthan gum and their impact on drug 
release mechanisms is shown in Figure 6.35. It is apparent, and supported by the contour plot 
in Figure 6.36, that increasing the concentration of both polymers results in an increase in the 
value of the exponent from 0.45 towards 0.50, indicating the dominance of diffusion 
controlled mechanisms in these systems. The inclusion of Methocel® KlOOM and xanthan 
gum results in an increase in the value of the exponent towards a value that is indicative of a 
diffusion controlled mechanism (i.e. as n approaches 0.45). 
It is also apparent from Equation 6.15 that the inclusion of Carbopol® 974P in the 
formulation results in a decrease in the value for the exponent, and the interaction between 
xanthan gum and Carbopol® 974P is depicted in Figures 6.37 and 6.38. 
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Figure 6.37 Response surface plot depicting the effect of xanthan gum and Carbopol® 974P on the 
mechanism of SBS release with Methocel~ KIOOM and Surelease~ concentrations at the centre level 
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Figure 6.38 Contour plot depicting the effect ofxanthan gum and Carbopol® 974P on the mechanism 
ofSBS release with Mcthocel® KIOOM and Surelease® concentrations at the centre level 
As shown in Equation 6.15, it is clear that Surelease® does not appear to have to a significant 
impact on the mechanism of SBS release from the manufactured formulations. However, an 
interaction between xanthan gum and Surelease® impacts the mechanism of release as shown 
in Figures 6.39 and 6.40. 
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Figure 6.39 Response surface plot depicting the effect of xanthan gum and Surelease® on the mechanism of 
SBS release with Methocel® Kl OOM and Carbopol-!ll 974P concentrations at the centre level 
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Figure 6.40 Response surface plot depicting the effect of xanthan gum and Surelease"' on the mechanism of 
SBS release with Methocel~ KlOOM and Carbopol® 974P concentrations at the centre level 
It is apparent when evaluating Figures 6.39- 6.40 that lowering the concentration of xanthan 
gum results in a decrease in the value of the exponent and that a maximum value between 
0.45 and 0.5 is obtained when these formulation compositions are used to prepare hydrophilic 
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matrix formulations. In general, increasing the concentration of Surelease® in the formulation 
results in an increase in the value of the exponent indicating that a diffusion controlled 
mechanism predominates. The interaction that exists between xanthan gum and Surelease® is 
evident since the impact of increasing the xanthan gum concentration at low and high levels 
of Surelease® is different, and this is clearly evident from the different gradients in these 
regions of the topographical surface plot. 
6.4.7 Formulation Optimisation 
Objective slice graphs for the optimisation of the hydrophilic matrix formulation of SBS with 
desirable in vitro release characteristics are shown in Figure 6.41. 
Page ! 133 
Chapter 7. Artificial Neural Networks 
60 ~ H 50 Y1h 40 30 .---20 . 
80 
I I 
., 
70 
Yzh 60 50 
40 
30 
90 I I 80· Y4h 70 60 . r~ 50 J. -
100 
I I ·: 90 Y6h 80 ----: r: 70 60 .I 
100 . I l t 90 .. Yah 80 70 60 
105 l I Y12t. 95 - I I 850 20 40 60 80 100 120 0 20 40 60 80 100 0 5 10 15 20 5 10 15 20 
Methocel® KlOOM (mg) Xanthan gum (mg) Carbopol® 974P (mg) Surelcasc® (% v/v) 
Figure 6.41 Objective slice graph for the optimisation of a hydrophilic matrix formulation for SBS 
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The objective graphs show the relationship between input factors and each response 
characterised using a curve that depicts the change in each response as the level of the input 
factor is changes. The vertical orange line depicts the amount of excipient that is required in a 
formulation to produce tablets with the desired release characteristics for SBS. The 
composition of the optimised formulation that was evaluated using this approach is described 
in § 6.3.6.3 and the predicted in vitro release data are shown in Table 6.7. The f2 similarity 
factor was used to compare the dissolution profile of the predicted formulation to that of the 
reference formulation; the results show that the f 2 = 89.7 indicating that the predicted in vitro 
release profile was indeed similar to that of the reference formulation. 
Table 6.7 Optimised formulation 
Formulation Predicted dissolution proflle 
Methocel® Kl OOM 29.77 mg Y1h 38.73% 
Xanthan gum 35.31 mg Yzh 50.05% 
Carbopol® 974P 10.01 mg Y4h 66.00% 
Surelease® 18.5% w/w Y6h 80.73% 
Avicel® 91.32 mg Yah 87.09% 
Colloidal silica 0.5%w/w Ytzh 97.00% 
Magnesium stearate l%w/w Ji factor 89.7 
The physical characteristics of the manufactured formulations were evaluated and are 
summarised in Table 6.8. It is apparent that the tablets that were produced had satisfactory 
performance qualities and were deemed suitable for their intended use. 
Table 6.8 Physical properties of tablets manufactured using the optimised formulation 
Granule characteristics Physical characteristics 
Bulk density 0.437 g/cm Tablet weight 
Tap density 0.466 g/cm3 Tablet thickness 
Carr 's Index 6.25% Tablet diameter 
Angle of repose 43.9° Tablet crushing strength 
Assay 
222.58 ± 0.94 mg 
4.73 ± 0.09 nun 
8.84 ± 0.04 nun 
43.90 ± 2.70 N 
9.59 ± 0.04 mg 
The in vitro dissolution profile generated following testing of the optimised formulation 
compared with the target and predicted formulations is shown in Figure 6.42. It is clearly 
evident that there is a degree of similarity that exists between the manufactured formulation 
and that of the reference formulation, Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, 
India). The f2 similarity factor of the manufactured formulation compared with the reference 
formulation was 83.0. 
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Asthalin®8 ER 
Predicted formulation 
Manufactured formulation 
10 12 14 
Figure 6.42 In vitro release profile of the optimised formulation compared with that of the predicted 
formulation and the reference formulation, Asthalin®8 ER 
The relationship between the results for the optimised formulation that was manufactured and 
that predicted from the optimisation procedure is shown in Figure 6.43. 
100 
20 40 60 80 100 
Predicted formulation(% release) 
Figure 6.43 Percent release of the manufactured formulation vs. predicted formulation, y = x- 2. 6, R2 = 
0. 9928 
The results show that the relationship between the predicted and manufactured formulations 
was nearly linear showing excellent predictability for the optimisation by use of RSM. 
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6.5 CONCLUSIONS 
The optimisation of a pharmaceutical formulation is complicated by the need for a precise 
combination of input factors (formulation components) and the relationships between the 
levels of polymers that are used in a formulation. Furthermore, the nature of these effects on 
measurable responses must also be investigated. Multi-objective optimisation is a more 
complicated procedure compared with single-objective optimisation since trade-offs may be 
necessary to produce an optimal formulation composition. 
The selection of a central composite design to optimise pharmaceutical formulations in these 
studies reduces the number of experiments that are required to estimate quadratic surface 
effects compared with the use of full factorial design procedures. In addition the use of a 
central composite design allows for the establishment of high and low limits to expand the 
experimental domain under investigation. The compositions of Methocel® Kl OOM, xanthan 
gum, Carbopol® 974P and Surelease® were chosen as formulation variables to determine how 
these may impact tablet crushing strength, in vitro release characteristics, and both the rate 
and mechanism of drug release from these formulations. 
Response surface and contour plots were used to examine the nature of these complex 
relationships. It is apparent that the incorporation ofxanthan gum and Carbopol® 974P had an 
impact on tablet crushing strength, and using high levels of xanthan gum in tablet 
formulations resulted in the production of soft tablets. Although the handling and transport of 
soft tablets is a major quality concern, the formulations remained intact during these studies 
and therefore were deemed suitable for use in these experiments. 
The in vitro release profile of SBS at different stages of dissolution testing was characterised 
by quadratic relationships and, in general, Methocel® Kl OOM and xanthan gum had the 
greatest impact on the extent of drug release at all stages of dissolution testing. It is evident 
that increasing the content of these polymers in formulations results in retardation of drug 
release from the prepared solid oral dosage forms. The content of Carbopol® 974P and 
Surelease® had a lower impact on drug release, but it was apparent that interactions between 
these formulation variables were important in controlling the extent of SBS release from 
manufactured formulations. 
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The rate and mechanism of drug release was assessed using the Korsmeyer- Peppas model 
and it was apparent that Methocel® KlOOM and xanthan gum had the greatest impact on the 
overall rate and mechanism of SBS release from these formulations. The mechanism of drug 
release from the formulations is primarily a diffusion controlled process, and increasing the 
concentration of Methocel® Kl OOM and xanthan gum resulted in the value of the 
Korsmeyer- Peppas exponent ranging between 0.45 and 0.50. 
The Calibration Generation Browser in Matlab® R2008a (Mathworks Inc., Natick, MA, 
USA) was used to determine the composition of an optimised formulation that would have 
satisfactory physical characteristics and the desired in vitro release profile. The positive result 
is an indication of the potential application of RSM for pharmaceutical formulation 
optimisation in drug product development studies. 
The use ofRSM has been recommended for the establishment of a design space within which 
product quality can be assured. Consequently the RSM outputs that were generated were used 
to establish a design space that could be used to ensure that SR dosage forms of SBS satisfy 
the in vitro release and quality standards required, and are consistently produced. This 
approach will be described in Chapter 8 of this dissertation. 
Furthermore, the in vitro release profile data that were generated from the central composite 
design were subsequently used to train an ANN for application in formulation optimisation. 
The ANN approach is described in Chapter 7 of this dissertation. The output generated by the 
ANN was compared with that from RSM studies for the optimisation of formulations and for 
the establishment of an appropriate and suitable design space for SR SBS matrix tablets. 
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CHAPTER 7 
THE APPLICATION OF ARTIFICIAL NEURAL NETWORKS 
FOR FORMULATION OPTIMISATION 
7.1 INTRODUCTION 
Pharmaceutical formulations are complex systems in which the properties and performance 
characteristics are influenced by numerous formulation and process factors that may not be 
easy to understand. The use of statistical methodologies for the development of 
pharmaceutical formulations with desirable physical characteristics and optimal dosage form 
performance was discussed in Chapter 6 vide infra. 
The use of statistical methodologies for studying the impact and interaction of factors that 
affect dosage form performance often requires simplification and reduction of the problem 
from many possible causes to a few factors in order to be able model the situation adequately. 
Although these approaches are often successful for pharmaceutical optimisation, the 
application of statistical tools is limited by the assumption that the measurable attributes of 
pharmaceutical. systems can be defined by mathematical models. As a result this approach 
may not always be appropriate for modelling complex input-output or factor-response 
relationships. Furthermore the use of RSM for optimisation experiments limits the number of 
factors that can be realistically studied to not more than five, since an increased number of 
experiments would be required to investigate all factors completely [ 190]. 
The use of artificial intelligence is a rapidly growing field in knowledge discovery and data 
mining and has been applied in the pharmaceutical sciences for the development and 
optimisation of dosage forms [190,204- 208]. The complex relationships between input and 
output factors may be inferred from data mining methods such as ANN, Neurofuzzy Logic 
and Fuzzy Logic that are used to map associations between input or causal factors and 
responses that may not be obvious when only statistical methodologies are used [ 190]. These 
methods can be used for dosage form development to identify and learn correlative patterns 
that exist between formulation and process variables with predetermined CQA [190]. 
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Therefore the development of an ANN model for the optimisation of a hydrophilic matrix 
formulation for SBS was undertaken. In addition, the use of an ANN model for constructing a 
design space was also investigated and will be reported in Chapter 8 of this dissertation. 
7.2 ARTIFICIAL NEURAL NETWORKS 
7.2.1 Introduction 
ANN are computational tools that emulate the interconnected neurological structures of the 
human brain and the ability of the human brain to learn and solve problems through pattern 
recognition [ 190]. ANN simulate the learning behaviour of the human brain by modelling 
data and recognising patterns for complicated multi-dimensional relationships that exist 
between input and output sets of data. Once trained an ANN can be used to predict and 
forecast outputs for a given a set of input conditions and may therefore be used to optimise 
both formulation and process variables in order to engineer and manufacture high quality, 
safe and effective dosage forms [209]. This approach has the potential to streamline resource 
allocation and to facilitate formulation development thereby reducing the cost and overall 
time associated with drug product development. 
ANN are constructed in such a way so as to model real neurons in the human brain and the 
basic processing unit is referred to as a neuron or a node. Analogous to biological neurons, 
mathematical neurons take a range of inputs, weight and add them together in order to 
produce an output signal which may be passed onto adjacent neurons in the network if the 
resultant signal is strong enough. In a similar way to biological neurons, mathematical 
neurons are only effective when they are interconnected in a network [190]. 
The interconnections between neurons in a network can be feed-forward or feed-back 
connections: in feed-back models, connections are characterised by cycles between the 
neurons but these connections do not form cycles in feed-forward models [207]. An example 
of a basic feed-forward artificial neuron which takes a range of inputs, weights and adds them 
together and finally performs a transformation which results in an output is shown in Figure 
7 .1. This neuron may also be referred to as an elementary perceptron [21 0]. 
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Figure 7.1 A simple artificial neuron, adapted from [209,211) 
Each input to an ANN is associated with a weight that defines its significance to the model 
that is being constructed. The neuron computes the sum of weights of all inputs through a 
summation function and then calculates an output which is further modified via a transfer 
function prior to being forwarded to another neuron [209]. 
For a standard neural network, such as a single unit perceptron, the relationship between the 
input, x = x1 . .. Xp, and the output y is represented by a multiple linear regression model as 
shown in Equation 7 .1. 
Equation 7.1 
Where, 
w0 = bias term 
wi,j = 1 ... p =connection weights or strengths 
Neural computations occur in three basic phases, viz., learning, recall and generalisation. 
During the learning phase an ANN is presented with a series of input and output or target 
data sets derived from empirical experiments and the network attempts to determine and 
recognise patterns between variables, should they exist. In the recall phase, a trained ANN 
will generate responses from the input data that was used in the training phase. Finally, in the 
generalisation phase the ANN is used to generate responses from new input data and can be 
used to predict outputs for a given set of input information [209]. 
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ANN are generally characterised by network architecture, transfer function and learning 
paradigms. These are all important elements of an ANN that must be understood in order to 
optimise the utility of these models [212]. 
7.2.2 Neural network architecture 
Neural network architecture describes the way neurons in an ANN are organised and shows 
the interconnections between individual processing elements and their counterparts. The 
multilayer perceptron (MLP) configuration is a commonly used neural network architecture 
in the pharmaceutical sciences and is composed of a series of highly interconnected layers of 
neurons or nodes. It has been reported that when a MLP ANN is given sufficient processing 
elements it can approximate any linear function with reasonable accuracy [213]. 
A MLP consists of three layers, viz., an input, hidden and output layer. Each layer has a 
number of neurons or nodes that are fully interconnected with neurons in the neighbouring 
layers as shown in Figure 7 .2. 
Yt Yz Output layer 
Hidden layer 
Input layer 
Figure 7.2 MLP architecture for ANN where x1 - x 4 are inputs and y 1 and y 2 
represent response factors, adapted and redrawn from [209,211] 
The input layer consists of one or more input nodes or processing elements that distribute 
input data to nodes located in the hidden layer of the ANN. Each node in the input layer can 
represent an independent variable such as for example, an amount of polymer in a 
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formulation, machine operating conditions, temperature or humidity. The input layer does not 
process any information but serves as a distribution point for information to be delivered to 
the hidden layer. 
The hidden layer can. be made up of one of more layers of parallel nodes (Figure 7 .2Figure 
7.2 shows one layer). The nodes in the hidden layer perform a weighted summation of the 
inputs followed by a non-linear transformation as shown in Figure 7.1, which then relays that 
data to the output layer as shown in Figure 7.2. The number of nodes in the hidden layer is 
critical to the efficiency of a network and if the hidden layer has too few nodes, the ANN will 
lack the power needed to classify the data provided to it. Conversely if there are too many 
nodes, patterns in the input data will be memorised and therefore the ability of the network to 
interpolate data will be diminished [211,212]. 
The output nodes represent measureable properties of pharmaceutical formulations and may 
include parameters such as, for example, tablet crushing strength and percent drug released at 
different stages of a dissolution test [211,212,214]. 
7 .2.3 Transfer function 
The transfer function computes the output value determined by the nodes in the hidden layer 
based on the summation of weighted inputs (Figure 7.1 ). The transfer function can control or 
scale the output value via the use of a threshold specification. Examples of transfer functions 
include sigmoid, sine and hyperbolic tangent functions [211] although the sigmoid function is 
most commonly used in ANN for pharmaceutical applications [209,211 ,212]. The sigmoid 
function output delivered from each node is shown in Equation 7.2. 
Where, 
1 f('L) = l+e-I: 
r. = sum of the input to the node. 
Equation 7.2 
The output from a hidden layer is usually limited to values between 0 and 1. The advantage 
of using a sigmoidal function is that a normalisation process may be used for non-linear 
outputs and their use prevents domination or overload effects in a network that may result 
from a single large input value [212]. Furthermore the use of a sigmoidal function facilitates 
rapid network learning [211,212]. 
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7 .2.4 Training Paradigm 
ANN are presented with a sequence of stimuli or input factors and a set of expected responses 
or targets during the training phase. The training of an ANN begins by randomly assigning 
weights for each input node and a bias term, after which an output from the last layer of the 
network is generated. Each iteration performed by the ANN is made up of two steps, a feed-
forward step and a back-propagation step. In the feed-forward step, training data is presented 
to the ANN model, and in the back-propagation step, the weights are adjusted during 
successive iterations and are determined by minimising the sum of squares of the deviations 
between experimental data and the output values generated by the network. During training 
the difference between the actual target values and model predicted outputs are propagated 
back through the architectural structure of the network. Therefore new interconnected 
weights are computed to minimise or reduce the total error until a minimum total error value 
is calculated [190,207,209,212]. This process is known as back-propagation of errors since 
the process returns the error information backward from the output nodes to the hidden nodes 
so as to allow modification of the weights and bias of the network [215]. 
Pharmaceutical applications commonly use multilayer back-propagation neural networks 
since they are ideal for generating general purpose, flexible non-linear models that can 
predict response values with a high degree of accuracy. Furthermore they are also capable of 
handling complicated non-linear patterns (211]. The back-propagation network is the most 
common type of network used in pharmaceutical applications [209 ,212,214]. 
The usual procedure for training a network is to partition experimental data sets into three 
subsets, viz., a training, test and validation set. Training data sets can be presented to a neural 
network using an incremental training technique where the data set is presented on an 
example-by-example basis, or by using the entire data set which is then handled by a process 
known as batch training [216]. The weights used in the network are subsequently adjusted 
after processing each sample for incremental training or following use of the entire data set 
for batch training. During the training phase of a network, each cycle in which input data is 
fed through a network is called an epoch. 
The errors of the training, test and validation sets are monitored when developing a neural 
network. Convergence is the process of searching for a set of weight factors such that there is 
a reduction in the prediction of errors of an ANN model. The most common criterion for 
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establishing that convergence has occurred is based on the sum of squared errors (SSE), 
which can be calculated using Equation 7.3. 
Where, 
- 1 "\'N "\'M ( )2 SSE - N L.op=l L.oi=l tpi - Opi 
opi = actual output of the ith node, from the /h sample 
tpi =target output of the i1h node, from the ih sample 
N = number of input nodes 
M = number of output nodes 
Equation 7.3 
During the training phase of an ANN, the SSE of the training data set reduces indefmitely 
with an increasing number of epochs and the number of hidden nodes that are used in a 
network. The initial rapid decrease in the SSE is due to rapid learning by the network from 
the input data and the subsequent gradual decline of the SSE can be attributed to 
memorisation or over-fitting of the data provided to the network, due to excessive numbers of 
hidden nodes or the use of a large numbers of training cycles [207]. The training error is not a 
reliable indicator of the ability of a network to generalise, therefore test and cross-validation 
error must be monitored independently of the training error. 
The error of the test data initially decreases but subsequently increases due to memorisation 
and over-fitting of data in an ANN model. The training phase of an ANN should therefore be 
stopped when the test error starts to increase and an optimal number of nodes for a network 
must be selected so as to minimise the test error [207]. In general, if the test error is low then 
there is a good chance that the network will be able to produce reliable simulations for data 
that are within the limits of the network that has been trained. 
Cross-validation is performed to evaluate how well the network classifies the data provided 
to it from outside the training set and to ensure that a network does not memorise solutions to 
solve problems. Although the training error decreases monotonically during training, the 
cross-validation error reaches a minimum early in training while the training error is still 
decreasing. The cross validation error can be calculated using Equation 7.4 [211]. 
Equation 7.4 
Where, 
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Neural networks can learn by two methods viz., supervised and unsupervised learning. In the 
supervised learning approach a network is presented with a set of input variables and their 
resultant outputs or targets which are then compared with the outputs generated by the 
network. The error is computed from the network and is back-propagated through the system. 
Weights are then adjusted and the network attempts to regenerate an output: this process 
continues over several iterations until an output with minimal error is generated after which 
training ceases. In the unsupervised learning approach a network is provided with a set of 
input factors and targets but there is no feed-back on what the outputs mean or whether they 
are correct or not. The network is expected to discover patterns and correlations between the 
input and output variables without assistance. Back-propagation supervised learning is the 
most commonly used method used for training ANN for pharmaceutical applications 
[211 ,212]. 
7 .2.5 Formulation Optimisation of Sustained Release Formulations using Artificial 
Neural Network Approaches 
Several authors have reported the use of formulation variables such as the level of excipients 
used in a formulation as input or causal factors and the percent drug released at different 
stages of a dissolution test as response factors for ANN [206,217 ,218]. However, Takayama 
et a! [206] and Ibric et al [219] used response factors from dissolution models to train and 
optimise pharmaceutical formulati<;>ns. In these studies the predicted values from an ANN 
model were found to be in close agreement with those ·of experimentally generated data. 
Ibric et al [219] used a generalised regression neural network to optimise SR formulation 
compositions for aspirin. The amount of polymer and the compression pressure were used as 
causal factors and the in vitro dissolution test sampling time points and Korsmeyer-Peppas 
model parameters were used as response factors. The optimised generalised regression neural 
network was used to predict the formulation composition of an optimal formulation for 
aspmn. 
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Formulation optimisation using ANN models has also been performed using a generalised 
distance function with optimal drug release parameters being used as response factors [206]. 
The f1 or difference and f 2 or similarity fit factors are typically used for the comparison of 
experimentally generated and predicted in vitro dissolution profiles when conducting 
optimisations with ANN models [217 ,219]. 
7.2.6 Advantages of Artificial Neural Networks 
The advantages of using an ANN include the fact that they can handle multiple independent 
and dependent variables in one model, and functional relationships between independent and 
dependent variables do not need to be known prior to constructing an ANN model [207]. 
ANN can also be paired with other artificial intelligence methods including genetic 
algorithms and fuzzy logic to improve the data mining capability of this tool [190]. 
Although a basic understanding of network architecture and function may be important in 
constructing an ANN model, the inner working of an ANN model does not need to be well 
understood by end users and therefore the use of ANN models may be considered a black box 
approach to formulation optimisation [207]. 
The ability of an ANN model to predict appropriate data is highly dependent on the data set 
that is used to train the network, and the predictive ability of an ANN is usually defined 
within the limits of the input and output data originally provided to the network. In general, 
interpolation within a model is usually accurate but extrapolation outside the experimental 
domain may result in the generation of highly erratic results [207]. 
Data from experimental design methodologies are often used to construct ANN models since 
the experimental design approach usually ensures independency of the formulation factors 
used to evaluate a system [207]. The use of experimental design for developing training data 
for ANN has been reported and includes the use of a three factor, three level, central 
composite design [220], two-factor spherical second order composite experimental design 
[221] and a four component simplex centroid mixture design [209]. However it has been 
shown that the use of experimental design approaches such as Box- Behnken and central 
composite designs are not appropriate for modelling highly curved responses and extensive 
internal mapping of the experimental domain is required to construct a highly predictive 
ANN model [222]. 
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7.2.7 Limitations of Artificial Neural Networks 
Although ANN can be used to recognise patterns between input and output data they cannot 
be used to elucidate mechanistic correlations between the input and response factors [207]. 
The combination of RSM described in Chapter 6 and ANN may be important in depicting 
interactions between input and output factors. Furthermore, in order to obtain reliable data 
when using ANN, a large data set may be required to fully study relationships between the 
input variables and responses. It is also important to realise that although ANN provide an 
efficient method for the optimisation of formulations, not all challenges may be solved using 
mathematical algorithms and/or computer software and the intuition and instinct of the 
formulation scientist must not be ignored [207]. 
7.3 METHODS 
7.3.1 Approach to ANN 
Commercially available software, Matlab® R2008a (Math Works Inc., Natick, MA, USA) was 
used to write mathematical code for training and evaluating the ANN developed and used for 
formulation optimisation. 
Four input factors corresponding to different'levels ofMethocel® KlOOM (x1) , xanthan gum 
(x2 ) , Carbopol® 974P (x3 ) and Surelease® (x4 ) were used as units in the input layer of the 
ANN. The data generated from the central composite design reported in Chapter 6 was used 
as the training data set for the ANN. 
The response factors used from the central composite design, i. e. percent drug dissolved at 
different stages of the dissolution test, were used as output layers or the target data during 
ANN training. Specifically, Yi hr =% SBS released, such that i = 1, 2, 4, 6, 8 and 12 hr. 
7.3.2 Neural Network Training 
An ANN designed in Matlab® R2008a (MathWorks Inc., Natick, MA, USA) can be trained 
for function approximation, pattern association or for the classification of patterns. A set of 
input and output data pairs are used to train the network and during the training process, 
weights and biases are adjusted iteratively to minimise the network performance function, 
viz., SSE or MSE (Mean Square Errors). The manner in which the network performance 
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function is minimised is dependent on the training algorithm used to train the network. The 
Levenberg-Marquardt back-propagation algorithm was chosen to determine the adjustment 
of weights during training of the network. The Levenberg-Marquardt algorithm is often 
selected for use, despite the fact that it is computer-memory intensive, since it operates 
rapidly. 
The percent SBS released at different stages of in vitro dissolution testing of formulations 
that were manufactured for the central composite design studies (Chapter 6) (n = 6) were 
used as the input and target data for the purposes oftraining the ANN. There were 180 (30 X 
6) input-target data pairs that were used to train, test and validate the neural network. 
Although there are no rules as to the distribution of training, testing and validation data sets, 
it has been proposed that 65% of a data set should be used for training, 25% for testing and 
10% for validation purposes [223). For the purposes of this study, the data was split into three 
categories, viz., the training, test and validation data sets, where 67% of the data set was used 
for training and 33% as the test data. The validation set was selected from the test data and 
constituted 67% the test data set. 
The input and target data from in vitro dissolution testing was initially randomised to allow 
for efficient training of the network. Prior to training, the mapminmax function was used to 
scale the inputs and targets so that the values for these fell within a range of -1 to + 1 based on 
the highest and lowest values in the data sets. Scaling the factors to this range is useful for 
efficient training of the network since it prevents bias in training if some of the values are 
significantly bigger or smaller than the other values in the training data set. Ifmapminmax is 
used to scale the target value, then the output of the network will be trained to produce 
outputs in the range -1 to + 1 and these must then be converted back to original values by 
using the reverse of this function. 
A neural network composed of an input and output layer with one hidden layer was chosen 
for the purposes of this study and a 1 og s i g function was used as the transfer function to the 
hidden layer and a pure lin function was used for the output layer. The Levenberg-
Marquardt algorithm for back-propagation with a gradient descent and momentum weight 
and bias learning function, was used to train the network. The MSE was used as the 
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performance function and training was terminated after either 200 validation failures or 800 
epochs or iterations of the network, whichever came first. 
Several training sessions with different numbers of nodes (3- 1 0) in the hidden layer were 
conducted in order to determine the optimal ANN structure and each of these models were 
evaluated as described in § 7.3.3. 
7.3.3 Artificial Neural Network Model Evaluation 
Activation of the neural network was determined by simulating the neural network using 
normalised training data. A post-process activation on the predicted data set was then 
required to convert it back to the original input range. In the final step, the predicted data was 
then compared with the original data set by plotting the predicted vs. original values and 
computing the correlation coefficient for each of the responses in the output layer. These 
results were then compared and the closer the value was to 1 then the better the predictive 
capability of the model. ANN models with different numbers of nodes in the hidden layer 
were compared in this way and the optimal network architecture was then selected for further 
application. This final model was then retrained with the entire data set to obtain a network 
model that can be used for formulation optimisation and further simulations. 
7.3.4 Formulation Optimisation using Artificial Neural Networks 
Formulation optimisation was conducted using the [2 similarity factor [197] for the 
comparison of dissolution profiles. Functions for formulation optimisation using simulation 
of the trained ANN and the [2 similarity factor were written in the Matlab® editor 
(Mathworks Inc., Natick, MA, USA). All possible permutations of the formulation variables, 
viz., Methocel® KlOOM, xanthan gum, Carbopol® 974P and Surelease®, within the 
experimental domain were generated using a brute force method and were then simulated 
using the trained ANN. The resultant simulated profiles were compared with the dissolution 
profiles of the reference formulation, Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, 
India). The function was used to determine the formulation that had the highest value for 
similarity. This formulation was subsequently manufactured and assessed as described in § 
7.3.5. 
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7.3.5 Manufacture and Assessment of Optimised Formulation 
An optimised hydrophilic matrix formulation of SBS was manufactured usmg the wet 
granulation method that was described in § 6.3.3. The tablet formulations were assessed and 
analysed as previously described in § 6.3.4 and § 6.3.5, respectively. 
7.4 RESULTS AND DISCUSSION 
7.4.1 Training and Testing the Neural Network Model 
The number of nodes in the hidden layer that are required to produce a good predictive 
network depends on the complexity of the problem to be solved, the number of nodes in both 
the input and output layers, and the size of the training data set. Furthermore, the amount of 
noise in the target data, network architecture, the required accuracy of the prediction and the 
training algorithm that is used are also important factors that determine the number of nodes 
that are required in the hidden layer [207]. The number of nodes in the hidden layer is of 
paramount importance when constructing an ANN model: having too few hidden nodes 
decreases the learning ability of a network, and too many hidden nodes results in over-fitting 
or memorisation of the training data set and a reduced ability of a network to generalise and 
predict accurately [207]. 
Although several approaches, including Kolmogorov's theorem [224] and Carpenter and 
Hoffman's Equation [225], have been proposed as suitable to determine the number of nodes 
to be included in a hidden layer of an ANN, a trial and error approach is often selected 
[207,226]. The trial and error approach was used to determine the optimal number of nodes 
for inclusion in the network, and the situation that produced the highest range of R2 values 
for each of the response factors was selected as the optimal architecture to use. 
The impact of changing the number of nodes in the hidden layer of an ANN is depicted in 
Figure 7.3. Inspection of this diagram reveals that the efficiency of the network is dependent 
on the number of nodes in that network. It is clearly evident that the optimal number of nodes 
in the hidden layer for this system is nine since this architecture produces the highest value of 
R 2 for all stages of the dissolution test data. As the number of nodes is increased above 9 it is 
also apparent that there is a decrease in the efficiency of the network which is likely due to 
overtraining of the network. 
Page 1151 
1.10 
1.05 
1.00 
0.95 
c 0.90 0 
:0 
"' 0.85 ~
-
-
0 0.80 u 
0.75 
0.70 
0.65 
3 4 5 
%Release after 1 hr 
%Release after 2 hr 
%Release after 4 hr 
%Release after 6 hr 
%Release after 8 hr 
%Release after 12 hr 
6 7 
Chapter 7. Artificial Neural Networks 
8 9 10 
Number of nodes in the hidden layer 
Figure 7.3 The impact of the number of nodes in the hidden layer on the correlation coefficient at different 
stages of the dissolution test 
The training, validation and test error during training of a network that has nine nodes in the 
hidden layer is shown in Figure 7.4. 
--Validation 
-- Test 
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Figure 7.4 Plot of changes in training, validation and test error observed while training the network 
The training error rapidly decreases during the first few epochs, after which it continues to 
decrease during the rest of the training phase (Figure 7.4 ). The validation and test error were 
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more variable and later decreased until a m1mmum was reached. The lowest or best 
validation error was observed at epoch 317 and was equivalent to 0.024861. The low error 
indicates that the model may be used to accurately predict the relationship between input and 
target data pairs and may therefore be used for prediction of outputs given a set of inputs. 
The correlation data for each of the different data points are summarised in Table 8.1. 
Table 7.1 Correlation of output factors 
Output factor 
% Release after 1 hr 
% Release after 2 hr 
% Release after 4 hr 
% Release after 6 hr 
% Release after 8 hr 
% Release after 12 hr 
0.9366 
0.9501 
0.9366 
0.9508 
0.9181 
0.8323 
The results from the prediction of test data generated by the ANN vs. the experimentally 
determined or observed values in the test data set are shown in Figure 7.5. 
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Figure 7.5 Comparison of correlation coefficients for predicted vs. observed data 
These results show that an ANN that has nine nodes in the hidden layer has good predictive 
capabilities and could therefore be used for formulation optimisation and simulation of the 
impact of formulation variables on the dissolution rate of SBS from hydrophilic matrix 
formulations. The network was therefore trained with all data and was used for a formulation 
optimisation exercise as explained in§ 7.3.4. 
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7.4.2 Formulation Optimisation 
The brute force method and program were used to predict the composition of a hydrophilic 
matrix formulation with the desirable release characteristics similar to the reference 
formulation, Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, India). Table 7.2 lists a 
summary of the proposed formulation composition, including the predicted in vitro release 
data and the [2 similarity factor for that hypothetical formulation. 
Table 7.2 Optimisation fonnulation 
Formulation Predicted dissolution profile 
Methocel KlOOM 45 mg Y1h 38.38% 
Xanthan gum 30mg Yzh 49.95% 
Carbopol® 974P 5 mg Y4h 65.87% 
Surelease® JO% w/w Y6h 80.00% 
Avice!® 105.1 mg Yah 87.00% 
Colloidal silica 0.5%w/w Y1Zh 95.00% 
Magnesium stearate l% w/w / 2 factor 90.5 
The physical characteristics of the manufactured formulation were evaluated and are 
summarised in Table 7.3. It is apparent that the tablets that were produced had satisfactory 
performance qualities and attributes and were deemed suitable for their intended use. 
Table 7.3 Physical properties of the optimised fonnulation following manufacture 
Granule characteristics Physical characteristics 
Bulk density 0.437 g/cm Tablet weight 
Tap density 0.442 g/cm3 Tablet thickness 
Carr' s Index 6.98% Tablet diameter 
Angle of repose 37.9° Tablet crushing strength 
Assay 
221.53 ± 1.36 mg 
4.54 ± 0.04 mm 
8.83 ± 0.03 mm 
60.83 ± 6.0 I N 
9.61 ± 0.05 mg 
The in vitro dissolution profile generated for the optimised formulation following 
manufacture is shown in comparison with the predicted and reference formulations in Figure 
7.6. 
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Astbalin® 8 ER 
Predicted formulation 
Manufactured formulation 
10 12 14 
In vitro release profile of the optimised formulation compared with the reference formulation, 
Asthalin"Bl 8 ER 
It is evident that there is a high degree of similarity between the manufactured formulation 
and that of Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, India) tablets. The f 2 similarity 
factor was calculated to be 86.0. The relationship between the manufactured formulation 
derived from the optimisation procedure using ANN and that for the predicted formulation is 
shown in Figure 7.7. The results show that the relationship between the predicted and 
observed formulations was nearly linear showing excellent predictability for the optimisation 
by use of ANN. 
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7.5 CONCLUSIONS 
ANN simulate the learning behaviour of the human brain by modelling data and recognising 
patterns for complicated multi-dimensional relationships between sets of input and output 
data pairs. ANN may be used to predict the output for a specific system given a set of input 
patterns once they have been trained. ANN may also be used for the optimisation of 
pharmaceutical processes and systems. 
The primary advantage of ANN is that they may be used to map relationships between causal 
and response factors without prior information from input data sets and once a network has 
been trained, simulations may be generated from the model. Although ANN are simple to use 
once they have been developed, they are not useful for extrapolation of data that is not within 
the bounds of the training data set that was used. 
Matlab® R2008a (Mathworks Inc., Natick, MA, USA) was used to write code for the training 
and evaluation of a neural network. Formulation variables and in vitro dissolution profiles 
from a central composite study were used for training, testing and validating the network 
models that were developed. 
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The efficiency of the network is dependent on the number of nodes in the hidden layer and 
the numbers of nodes were tested by means of a trial and error approach using between three 
and ten neurons. The optimal number of nodes that produced a good predictive model was 
nine. Once this was established, the data was once again used to train a network that was then 
applied to the optimisation of a SR matrix formulation for SBS. 
The / 2 similarity factor was used to determine whether formulation optimisation had been 
successful by comparing ANN predicted dissolution profiles to that generated from the 
reference formulation, Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, India). A brute 
force method was applied to generate permutations for simulation into the model and the 
combination of formulation variables that resulted in the highest / 2 value was selected. The 
resultant model formulation was then manufactured using the wet granulation procedure 
described in Chapter 6. The resultant formulation was found to perform satisfactorily and an 
/ 2 value of 86.0 was calculated for the comparison, clearly indicating that the dissolution 
profiles were similar. 
These results demonstrate the potential utility of ANN models for formulation development 
and optimisation. Defining CQA from the outset is vitally important in developing a model 
formulation with the desired physical and quality characteristics. 
The ANN model that was developed will be investigated for use in the development of a 
design space for the production of a high quality SR matrix tablet of SBS as described in 
Chapter 8 vide infra. 
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CHAPTERS 
DEVELOPMENT AND ESTABLISHMENT OF A DESIGN SPACE 
8.1 DESIGN SPACES 
8.1.1 Introduction 
According to the ICH Q8 (R2) Pharmaceutical Development guideline [1] a design space is 
"the multidimensional combination and interaction of input variables (e.g. material attributes) 
and process parameters that have been demonstrated to provide an assurance of quality". The 
premise of establishing a design space for formulation development is to define formulation 
and processing variables within which the quality of a product can be maintained with an 
associated reduction in the statistical variation of quality [227]. 
The establishment of a design space is an important driver of efficiency since an operational 
adjustment within an approved design space is not considered by Regulatory Agencies as a 
change that requires post-approval supplementary filing [228]. Furthermore operating within 
a design space allows for the continual improvement of pharmaceutical products during the 
product lifecycle [229]. 
The establishment of a design space commences with the defmition of a target product profile 
that identifies the desired performance characteristics of a product, including dissolution 
profile, quality attributes such as crushing strength, friability ·and other physical 
characteristics. The attributes that are likely to impact product quality, i.e. CQA are identified 
during the initial stages of formulation development experiments, during which multivariate 
experiments and modelling are often used to study complex relationships that exist between 
variables and CQA which must be subsequently linked to a design space [230]. 
One of the key challenges in developing a design space in product development is that the 
concept of a design space in a pharmaceutical context is fairly new and therefore not well 
understood. Consequently, the interpretation of this concept and how best to present usable 
and relevant information that relates to a design space has not yet been standardised. 
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There are many scientifically justifiable approaches that can be used to develop a design 
space and the approach used is dependent on the combination of tools available, technologies 
to be investigated and internal corporate experience [231]. Although the use of formal 
experimental design has been proposed as a means of generating design spaces [1,230] there 
is a dearth of information with respect to the manner of presentation of the actual design 
spaces, although graphical, interaction, response surface and contour plots have been 
proposed as useful techniques for depicting such spaces [ 1,231]. 
The purpose of this research is to identify and present perspectives on the presentation of 
design spaces by focusing on the application of RSM and ANN for this purpose. A 
hydrophilic SR matrix formulation of SBS was used to evaluate these methods on a 
comparative basis. The in vitro dissolution perfonnance of a reference formulation, 
Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, India) was used as a CQA to define 
appropriate dosage form performance. 
8.1.2 Related Concepts 
There are two vital concepts that are intimately related to a design space, viz., knowledge and 
control spaces. A conceptual visualisation of the relationship and interaction between the 
knowledge, design and control spaces that need to be identified and managed when 
developing and optimising formulations is depicted in Figure 8.1. 
Yz 
Knowledge 
space 
Design space 
Yt 
Figure 8.1 The interrelationship between knowledge, design and control spaces with respect to CQA, 
redrawn and adapted from [227] 
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The knowledge space is a summation of all information about the impact of formulation and 
process variables on measured CQA and the design space is a subset of the knowledge space. 
A design space must be defined in terms of product CQA, y1 and y2 and represents a 
multidimensional combination of the variables within which the CQA are acceptable. In other 
words product quality, in terms of safety and efficacy, is assured [227]. 
Although product quality is assured within a design space, most pharmaceutical companies 
operate within control spaces that are located within a specified design space. Control spaces 
are defined in the CQA space as ±3CT limits about the target, where the variance CT2 is based 
on the common cause or inherent variability of a manufacturing process [227]. 
8.1.3 Approaches to the Development of Design Spaces 
Although the concept of design spaces in the pharmaceutical industry is relatively new there 
have been several approaches reported for establishing a design space. A design space may 
be developed from mechanistic models if the scientific principles relating to a process are 
well known. For example, if the thermodynamic and rate phenomena associated with 
chemical processes are well known, a design space can be defined relatively easily. However, 
complex pharmaceutical formulations are not easily defined by simple models and therefore 
may not easily be described using mechanistic models and for that reason empirical research 
and models such as RSM must be used to map any relationships that exist between input 
variables and resultant responses [231]. 
Traditionally, design spaces for raw materials were defmed by setting specifications for 
individual materials separately and identifying the limits within which each material attribute 
(e.g. physical and chemical properties, NMR spectra, etc.) must fall. However the application 
of this approach can be limiting and may lead to the establishment of a poorly defined design 
space for those raw materials [232]. Alternatively a design space for a raw material may be 
defined using Principal Component Analysis (PCA). PCA is used to extract dominant 
patterns in a data matrix using a complementary set of score and loading plots [233]. To 
demonstrate the utility of PCA, the measurable properties of raw materials for manufacturing 
polymer films were defined in a study undertaken by Duchesne and MacGregor [232]. Prior 
to the commencement of the studies, ten properties of raw materials were identified with the 
objective of specifying a design space for each attribute that would result in the production of 
polymer films of acceptable quality. A model that defined the regions, which result in 
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polymer films with acceptable properties by identifying statistically significant terms for the 
production of the films was constructed using PCA. The advantage of using PCA for this 
application is that the method results in the development of a design space that can be 
effectively used to consistently produce quality films [232]. 
Statistical Process Control (SPC) concepts have also been suggested as a means of defining 
pharmaceutical control spaces [227]. The use of this methodology permits the establishment 
of design spaces for a manufacturing process and raw material variables simultaneously, so as 
to ensure the manufacture of pharmaceutical products that satisfy predetermined objectives 
with minimal variability [227]. 
Cogdill et a! [228] used a risk-based strategy for the quality assessment of pharmaceutical 
products that applies a model-based simulation approach to link variations in drug product 
parameters with clinical performance. Taguchi's concept of quality loss, pharmaceutical 
quality and risk, in conjunction with a simulation framework for assessing pharmaceutical 
quality based on probabilistic risk assessment, was used to investigate the concept of QbD 
[228]. One of the key advantages of using risk-spaces to define product quality in 
implementing QbD is that drug product parameters such as API content may be linked to in 
vitro dosage form performance and the possible risk of failing to meet therapeutic objectives 
for that product [228]. 
RSM specifically the use of a Box- Behnken design has been implemented as a strategy for 
understanding formulation variables that impact the quality of a self-nanoemulsified drug 
delivery system [234]. Although the impact of formulation components on the measured 
responses was evaluated using a response surfaces approach, no explicit description of what 
constitutes a design space for this product was reported. 
Takayama eta! [235,236] proposed the use of computer-aided design for establishing design 
spaces for drug products. More specifically, a central composite design with multiple linear 
regression was used to develop quadratic relationships that depicted the interaction between 
input and output factors that affected product performance. However a major limitation of 
using predictions from quadratic polynomials is that the result may be a poor estimation of 
product performance. To overcome these limitations a multivariate spline interpolation was 
investigated to generate smooth response surfaces. In addition a bootstrap re-sampling 
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technique and Kohonen's self-organising map were used to evaluate the reliability of the 
optimal solution to a formulation design that was established using these approaches 
[235,236]. Furthermore, the use of a leave-one-factor-out approach to understand factors that 
significantly affect optimal formulation performance and therefore to establish a region 
within which product quality can be assured, was proposed [236]. 
A multivariate statistical approach that used a simplex lattice design in combination with a 
non-linear response surface method incorporating thin-plate spline interpolation was used as 
a tool for establishing a design space for a SR formulation of diltiazem hydrochloride [23 7]. 
Other multivariate methods that combine the use of experimental design approaches and 
RSM with PCA and Partial Least Squares (PLS) analysis to develop a powerful means to 
elucidate complex multivariate relationships between input factors and outputs have also 
been suggested as possible means of establishing design spaces [238). Furthermore, concepts 
using Bayesian models [239], multivariate chemometrics, engineering process control, design 
of experiments and SPC [227] have been used to establish design spaces. 
8.1.4 Presentation of Design Spaces 
Although there is no set way to represent a proposed pharmaceutical design space, the ICH 
Pharmaceutical Development guideline [1] recommends the use of interaction, contour and 
response surface plots for presenting the design space. 
Interaction plots that were generated from a Box- Behnken experimental design were used to 
highlight the relationship between input factors and the measured responses for a self-
nanoemulsified drug delivery system of cyclosporine A [234]. Alternatively, surface plots 
[240] and design space trajectories [241], a combination of interaction and contour plots 
[242], PCA plots [243] or even a multivariate combinations of interaction profiles and 
response surfaces from formal experimental designs, Partial Least Squares (PLS) and PCA 
plots [238] may be used to fully characterise and understand a specific design space. 
The limitation of using response surface and contour plots for visualising response surfaces is 
that they cannot be used to display the effect of more than two variables on a measured 
response simultaneously. Yamashita et al [244] proposed the use of a novel visualisation 
technique referred to as Hyper-Dimensionality Embedded Cuboids which are useful for 
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understanding design space variables comprehensively. Data from experimental design 
approaches including polynomial models may be used as the input parameters for this data 
visualisation tool. Hyper-Dimensionality Embedded Cuboids are used to map N-dimensional 
data on a two-dimensional rectangular region defined by a recursive slice and dice 
subdivision of the x - y plane. However the use of this technique is limited since the 
computer code to display the resultant data must be written in the Java programming 
language, although there is a graphical user interface which can be used to make the software 
user friendly. 
8.2 METHODS 
8.2.1 Response Surface Methodology 
The Calibration Generation tool in the Model-Based Calibration Toolbox in Matlab® R2008a 
(Mathworks Inc. Natick, MA, USA) was used for the formulation optimisation described in 
Chapter 6 vide infra. The in vitro dissolution profile of Asthalin®8 ER (Cipla Ltd., Mumbai, 
Maharashtra, India) was used as the constraints to determine the levels of polymers which 
would result in the manufacture of similar and acceptable formulations. The impact of the 
levels of Methocel® KlOOM, xanthan gum, Carbopol® 974P and Surelease® on the extent of 
drug release at all stages of dissolution testing was determined from the resultant constraint 
plots. 
8.2.2 Artificial Neural Network Simulation 
The optimisation procedure described in Chapter 7, vide infra revealed that an optimal 
composition with the desired in vitro release characteristics can be manufactured. The impact 
of varying formulation composition within the limits of± 5 mg for solid polymers and ± 5% 
w/w for the composition of the liquid dispersion used to granulate the formulation compared 
with the optimised formulation is summarised in Table 8 .1. 
Table 8.1 ANN limits related to the optimised formulation 
Methocel~ Kl OOM 
Xanthan gum 
Carbopoltt 974P 
Surelease® 
Lower limit Optimised formulation 
40mg 45mg 
25 mg 30 mg 
0 mg 5 mg 
5%w/w 10%w/w 
Upper limit 
50mg 
35 mg 
lOmg 
15 %w/w 
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A function for simulating the in vitro release profile for hypothetical formulations within the 
constraints listed in Table 8.1, using the ANN model described in Chapter 7, was written in 
Matlab® code (Mathworks Inc., Natick, MA, USA) and used to simulate different in vitro 
release profiles. 
The in vitro dissolution profiles that were generated using the simulation function were then 
plotted and compared, using the f2 similarity factor, to those generated for the reference 
formulation [ 197], and these data were used to study the design space for a SR formulation of 
SBS. 
8.3 ESTABLISHMENT OF A DESIGN SPACE 
8.3.1 Response Surface Methodology 
Constraint plots were used to determine the regions of the experimental domain which 
correspond to limits of the dissolution profile of the reference formulation Asthalin®8 ER 
(Cipla Ltd., Mumbai, Maharashtra, India). The impact of each of the formulation variables 
that were investigated and described in Chapter 6 on the different stages of the dissolution 
test are shown in Figures 8.2-8.7. The blue curve in these figures is an indication of the 
change in the extent of drug release at each stage of dissolution test and the red curves 
represent the constraints within which the quality of the product will be maintained. 
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Figure 8.3 Constraint plots for percent SBS released after 2 hr dissolution testing 
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Figure 8.6 Constraint plots for percent SBS released after 8 hr of dissolution testing 
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A summary of the formulation constraints for the optimised formulation that was developed 
from assessment of Figures 8.2-8.7 is listed in Table 8.2. The impact of the different 
formulation variables of the rate and extent of drug release has been described and discussed 
in Chapter 6, vide infra. It is apparent that the limits for each tested formulation change as the 
dissolution test progresses. However it is apparent that there is a region in which the impact 
of formulation variables on SBS release at different stages of the dissolution test, overlap. 
Consequently formulation limits can only be maintained within certain ranges of excipient 
composition in the formulation design. 
Table 8.2 Design space limits obtained from RSM evaluation 
Metbocel® KlOOM Xantban gum Carbopol~ 974P Surelease® 
(mg) (mg) (mg) (% w/w) 
Lower Upper Lower Upper Lower Upper Lower Upper 
limit limit limit limit limit limit limit limit 
Y1hr 28.5 47.0 34.0 45.5 4.5 10.5 10.0 20.0 
Yzhr 17.5 34.0 28.5 37.5 7.5 20.0 6.0 20.0 
Y4hr 16.0 30.0 26.0 36.0 8.0 10.0 7.0 20.0 
Y6hr 28.5 40.0 34.0 47.5 0.0 17.0 18.0 20.0 
Yshr 20.0 40.0 22.0 50.0 5.5 15.5 15.0 20.0 
Y1Zhr 30.0 62.0 35.0 65.0 10.0 20.0 18.5 20.0 
Limits 30.0 30.0 35.0 36.0 10.0 10.0 18.5 20.0 
Although the range of composition for each of the excipients required to satisfy the design 
space criteria are wide in some instances, it is apparent that the limits within which 
formulation performance can be maintained at all stages of the dissolution test are somewhat 
narrow in others. 
The limits that have been identified can therefore be considered to be the design space for the 
SR hydrophilic matrix formulation of SBS that was manufactured in this study. These limits 
can therefore be considered to satisfy the design space for the model formulation. 
8.3.2 Simulation Using Artificial Neural Networks 
ANN simulations can also be used to establish the impact of changing or altering formulation 
variables on CQA and therefore to evaluate if changes in formulation composition produce 
dissolution profiles that differ for hypothetical formulations. 
The formulation compositions described in Table 8.1 were selected and used to assess the 
feasibility of using ANN simulations for developing and monitoring a design space for 
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pharmaceutical formulations. The design space permutations that were investigated are 
shown in Table 8.3. 
Table 8.3 Simulated compositions for hypothetical formulations 
Formulation Methocel® KlOOM Xanthan gum Carbopol® 974P 
40 25 0 
2 40 25 0 
3 40 25 0 
4 
5 
6 
7 
8 
9 
10 
11. 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
45 
25 
25 
25 
25 
25 
25 
30 
30 
30 
30 
30 
30 
30 
30 
30 
35 
35 
35 
35 
35 
35 
35 
35 
35 
25 
25 
25 
25 
25 
25 
25 
25 
25 
30 
30 
30 
30 
30 
30 
30 
30 
30 
35 
35 
5 
5 
5 
10 
10 
10 
0 
0 
0 
5 
5 
5 
10 
10 
10 
0 
0 
0 
5 
5 
5 
10 
10 
10 
0 
0 
0 
5 
5 
5 
10 
10 
10 
0 
0 
0 
5 
5 
5 
10 
10 
10 
0 
0 
Surelease~ 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
15 
5 
10 
f 2 fit factor 
31.6012 
31.6525 
33.6231 
56.2400 
40.3193 
40.6134 
48.6557 
48.1637 
47.2785 
36.5141 
32.5460 
33.8473 
59.4408 
48.6317 
39.3311 
49.3272 
53.0141 
51.8354 
45.5320 
35.1357 
34.6290 
58.4069 
58.0327 
42.2794 
48.9379 
58.5845 
48.4519 
32.0438 
31.3923 
33.4131 
60.2388 
43.4958 
41.9055 
46.7753 
47.5839 
47.4910 
38.1946 
32.5949 
32.5948 
62.0819 
54.0798 
41.5888 
48.8460 
54 1409 
52.2857 
47.5462 
35.9310 
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Formulation Methoccll§ KlOOM Xanthan gum Carbopolilii 974P Surelease® f 2 fit factor 
48 45 35 0 15 34.6761 
49 45 35 5 5 60.2652 
50 45 35 5 10 60.6438 
51 45 35 5 15 46.0947 
52 45 35 10 5 50.3023 
53 45 35 10 10 62 4939 
54 45 35 10 15 49.0600 
55 50 25 0 5 32.7315 
56 50 25 0 10 32.7315 
57 50 25 0 15 33.1909 
58 50 25 5 5 63 .9643 
59 50 25 5 10 47.6710 
60 50 25 5 15 43 .5129 
61 50 25 10 5 49.7792 
62 50 25 10 10 49.1474 
63 so 25 10 15 49.6309 
64 50 30 0 5 40.2822 
65 so 30 0 10 32.7639 
66 50 30 0 15 33.5742 
67 50 30 5 5 64.4999 
68 50 30 5 10 60.3595 
69 50 30 5 15 44.3797 
70 50 30 10 5 51.6535 
7 1 50 30 10 10 58.3930 
72 50 30 10 15 53.2213 
73 50 35 0 5 48.6955 
74 50 35 0 10 37.0437 
75 50 35 0 15 34.7775 
76 50 35 5 5 60.8569 
77 50 35 5 10 61 4447 
78 50 35 5 15 51 .2066 
79 50 35 10 5 54.7737 
RO 50 35 10 10 69.1416 
81 50 35 10 15 69.1415 
* shaded areas represent formulation compositions that produced f2 values >50 
The simulated in vitro dissolution profiles for hypothetical formulations that were generated 
using ANN and that were compared with the in vitro dissolution profile of the reference 
formulation and the manufactured formulation are depicted in Figures 8.8-8.17. 
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Figure 8.8 Dissolution profile simulation for hypothetical formulations 1- 9 compared with the reference 
and manufactured formulations 
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Figure 8.9 Dissolution profile simulation of hypothetical formulations 10-18 compared with the reference 
and manufactured formulations 
Page 1174 
120 
100 
..-.. 
~ 80 
'-' 
<U 
"' c:s
~ 
~ 
!. 
.... 
= <U 
~ 
!. 
~ 
~ 
60 
40 
2 4 6 
Time (hr) 
Chapter 8. Establishment of a Design Space 
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Figure 8.10 Dissolution profile simulation of hypothetical formulations 19- 27 compared with the reference 
and manufactured formulations 
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Figure 8.11 Dissolution profile simulation of hypothetical formulations 28- 36 compared with the reference 
and manufactured formulations 
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Figure 8.12 Dissolution profile simulation of hypothetical formulations 37-45 compared with the reference 
and manufactured formulations 
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Figure 8.13 Dissolution profile simulation of hypothetical formulations 46-54 compared with the reference 
and manufactured formulations 
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Figure 8.14 Dissolution profile simulation of hypothetical formulations 55- 63 compared with the reference 
and manufactured formulations 
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Figure 8.15 Dissolution profile simulation of hypothetical fommlations 64-72 compared with the reference 
and manufactured formulations 
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Figure 8.16 Dissolution profile simulation of hypothetical formulations 73- 81 compared with the reference 
and manufactured formulations 
It is apparent from the data summarised in Table 8.3 and investigation of the f 2 factor values 
that dissolution profile simulation of formulations that contain no Carbopol® 974P resulted in 
release profiles that are not similar to that of the reference formulation. It can therefore be 
concluded that the inclusion of Carbopol® 974P in the formulations is essential for the 
production of hydrophilic matrix formulations that will release SBS at a rate and extent that is 
equivalent to that of the reference formulation. 
Furthermore, it is apparent that formulations that contain low levels of Methocel® KlOOM 
and xanthan gum, i.e. 40 and 25 mg respectively, are generally dissimilar to the target 
formulation. However, formulations that contain either 45/50 mg and 30/35 mg of Methocel® 
KlOOM and xanthan gum, respectively, result in the production of formulations that have 
dissolution profiles that are similar to that of the reference formulation, provided that the 
concentrations of Carbopol® 974P and Surelease® that are used in the formulation are also 
optimised. 
The simulated dissolution profiles for all hypothetical formulations that may result in dosage 
form performance similar to that of the reference formulation are depicted in Figure 8.17. 
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8 10 12 
Figure 8.17 Dissolution profile simulations for formulations that are similar to the reference (red line) and 
manufactured (green line) formulations 
8.3.3 Response Surface Methodology vs. Artificial Neural Network Methodology for 
Establishing a Design Space for Hydrophilic Matrix SR Formulations of SBS 
The studies were conducted to demonstrate whether RSM and ANN could be used to explore 
and establish a design space for pharmaceutical product development. Although both 
approaches have specific advantages that make each methodology potentially useful for 
establishing a design space, the challenges with respect to using these techniques require 
further investigation. 
The use of experimental design methodologies allows for the generation of mathematical 
equations that are then used to depict graphical relationships between input factors and output 
responses that can be used to describe the performance of a specific formulation. This 
approach provides a mechanistic understanding of relationships between input variables and 
output responses that may not be identifiable initially, thereby enhancing the understanding 
of the underlying pharmaceutical principles that impact on formulation performance. This 
approach has the advantage of allowing a formulation scientist to predict the impact of 
changes in formulation performance from a sound scientific basis. 
However, a major limitation of using an experimental design approach to establish a design 
space is that, as more information is added to the knowledge base through augmentation 
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studies, mathematical relationships may shift significantly as the design space becomes more 
complicated and complex. Clearly this approach has the potential to produce a dynamic 
design space as the response surface evolves and will in all likelihood necessitate changes to 
the research strategy as the experimental domain broadens. The use of experimental design is 
further limited by the fact that realistically the technique is only suitable for studying the 
impact of no more than five factors at any one time. This is because as the domain expands, 
mathematical relationships and interactions become more complex, and the information 
generated becomes more difficult to manage effectively. 
The quality attributes of a pharmaceutical product are also determined by processmg 
conditions that are linked, in part, to the levels of formulation composition and the excipients 
that are used. It is also desirable that the impact of processing conditions on product quality 
are studied and that a design space which includes the manufacturing process be established. 
When a RSM is used to establish a design space, it is imperative that at least two separate 
studies are conducted if both the formulation and manufacturing variables are to be fully 
understood. However, this may not be possible since the number of variables to be studied 
increases and therefore the number of experiments to be conducted would increase. 
Consequently it is difficult to rely solely on a tool such as RSM to explore an extensive 
design space for pharmaceutical products. 
The application of ANN overcomes some of the limitations that may be encountered when 
using RSM for establishing and exploring a design space for a pharmaceutical product. An 
advantage of using ANN is that this strategy is an active means of investigating the impact of 
changing variables on a measured outcome for a product. For instance in the RSM study 
described in this Chapter, the impact of changing formulation variables within the 
experimental domain was studied, and it was possible to generate a realistic visual display 
for the impact of formulation compositions on the ultimate in vitro dissolution profiles. 
Furthermore, as information is generated through additional studies during the iifecycle of a 
product, data can be added to the information pool to improve the predictive capability of 
ANN network models. This does not necessarily result in changes in the visual outcome for 
the models compared with those generated when RSM is used but will permit a formulation 
scientist to consider the nature and impact of a specific outcome of a proposed change to a 
formulation as and when they are made. 
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Due to the manner in which ANN deal with the information presented to the network, and 
because ANN can achieve pattern recognition, the impact of process factors and formulation 
variables on CQA can be studied simultaneously, without information being discarded or 
becoming unmanageable. This is also due to ANN's ability to deal with a large number of 
input factors at any one time in order to ensure that accurate predictions are achieved. 
Furthermore, additional information can be added to an ANN following initial model 
parameter allocation; meaningful conclusions can be drawn from the additional data studied, 
which is an important advantage of using ANN models to evaluate data during product 
lifecycle management. 
However, the use of ANN methodology does not permit a mechanistic understanding of the 
scientific principles of a specific formulation composition to be elucidated for a formulation 
scientist. This disadvantage means that there are likely to be instances where a mechanistic 
understanding of formulations and intuition are important for the effective optimisation of a 
dosage form. Furthermore, no clear relationships can be drawn between input variables and 
output factors when using ANN, thereby limiting their use for formulation and manufacturing 
process definition. 
Another limitation of using ANN is that the networks do not necessarily produce a graphical 
output which permits visual mapping of a design space, and therefore it is conceptually 
difficult to visualise a design space without the use of ANN software. Therefore human 
resource training in the use of ANN methodologies and software use is essential when 
attempting to use these approaches for the purposes of establishing a design space for 
formulation optimisation strategies. 
8.4 CONCLUSIONS 
One of the key challenges to developing appropriate design space(s) is that this concept is 
relatively new and is not well understood, and therefore there is wide scope for interpretation 
of the data generated using these concepts. 
Several methods, including an experimental design approach such as central composite 
design and the Box- Behnken strategy, and multivariate methods such as SPC, PLS and PCA, 
have been explored for their utility in identifying and defining a design space for 
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pharmaceutical formulations. Design spaces have been presented as interactive contour and 
response surface plots in the past. 
In this study, RSM methodology and constraint plots generated from statistical optimisation 
processes were used to establish the design space limits for formulation variables that were 
investigated. In addition, the use of ANN simulations was investigated to establish the 
potential for this technique to establish a design space for a pharmaceutical formulation. 
The results reveal that both methods can be used to define a design space and that the use of 
RSM methodologies is also able to produce graphical outcomes. However, simulations using 
ANN produce an outcome that represents the overall effect of all variables on the simulated 
dissolution profiles. Recommendations for establishing design spaces are discussed in 
Chapter 8 vide infra. 
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CHAPTER9 
CONCLUSIONS AND RECOMMENDATIONS 
9.1 CONCLUSIONS 
QbD is a systematic approach for the development of quality pharmaceutical dosage forms 
that begins with predefined objectives based on the premise that quality must be built into a 
product and not tested into it. With respect to formulations, quality products are products that 
ensure consistent dosage form performance and that are designed to achieve specific 
therapeutic outcomes with a low risk of failure in patients. 
The ICH [ 1] has recommended the use of multivariate experiments such as RSM to 
understand the impact of formulation and process variables on product quality and for the 
optimisation of pharmaceutical formulations. An important aspect of QbD is the 
establishment of a design space which is a multidimensional combination and interaction of 
input variables and process parameters that have been demonstrated to provide an assurance 
of quality for a specific dosage form. The overall objective of this research was to investigate 
the feasibility of using RSM and ANN for the optimisation of a SR hydrophilic matrix 
formulation of SBS that had desirable dissolution test characteristics and for the 
establishment of a design space for that formulation. 
SBS is a short-acting {12 agonist that is used for the alleviation of bronchoconstriction and 
bronchospasm in patients with reversible obstructive airway disease and COPD. The use of 
SR formulations of SBS may result in clinical benefits compared with the administration of 
SBS in conventional and/or immediate release dosage forms. SR formulations of SBS have 
been manufactured using lipidic and hydrophilic matrices, acrylic acid based resins and novel 
delivery systems including the use of osmotic pumps and microcapsules. 
A sensitive, accurate, and precise HPLC method for the quantitation of SBS in 
pharmaceutical dosage forms and for assessing in vitro release was developed and validated 
according to ICH guideline Q2 (Rl) (120]. The HPLC method was found to be linear over 
the concentration range 0-50 J..l.g/ml and precise with % RSD values that were <5%. The 
Page 1183 
Chapter 9. Conclusions and Recommendations 
method was also found to be accurate with a% Bias that was determined to be <5% in the 
range that was studied. 
Hydrophilic monolithic matrix devices are commonly used as SR dosage forms due to their 
ease of manufacture and the nature of this well understood technology. HPMC is one of the 
most commonly used hydrophilic matrix forming polymers for SR formulations as it is non-
toxic and has wide regulatory acceptance. There is a wealth of information on the 
characterisation ofHPMC as a SR matrix material, and it was therefore chosen as the primary 
matrix polymer for developing an optimised dosage form and for investigating the concept of 
a design space. The addition of polymeric adjuvants to HPMC matrices may be used to 
modulate both the rate and mechanism of drug release and was therefore investigated as a 
potential strategy for formulation development. The results demonstrated the potential use of 
xanthan gum and Carbopol® polymers as matrix polymers and therefore combinations of 
HPMC, Carbopol~ 974P and xanthan gum in varying proportions were thought to be 
potentially useful for the retardation of SBS release. These polymers were therefore used in a 
statistically designed experiment for the optimisation of a formulation with release 
characteristics that would be similar to that of a reference formulation, Asthalin®8 ER (Cipla 
Ltd., Mumbai, Maharashtra, India). 
When conducting statistically designed experiments, external factors, which are not 
necessarily investigated in a study but have the potential to impact the measured outcomes of 
that study, must be controlled. An Ishikawa or Cause and Effect diagram was used to 
determine these factors and to ensure that the manufacturing method and the analysis of 
dosage forms would produce reproducible and reliable results. 
A central composite design was selected to optimise a SBS formulation. The composition of 
Methocel® KlOO, xanthan gum, Carbopol® 974P and Surelease® were selected as variables to 
establish how these may impact tablet crushing strength, in vitro dissolution and both the rate 
and mechanism of drug release from these formulations. Response surface and contour plots 
were used to examine the nature of the relationships between the levels of input factors and 
the measured responses. 
The results revealed that incorporation ofxanthan gum and Carbopol® 974P had an impact on 
tablet crushing strength and that using high levels of xanthan gum in tablet formulations 
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resulted in the production of soft tablets. In general Methocel® KlOOM and xanthan gum had 
the greatest impact on the extent of drug release at all stages of dissolution testing, and 
increasing the content of these polymers in formulations results in retardation of drug release. 
The content of Carbopol® 974P and Surelease® had less of an impact on drug release, 
although interactions between formulation variables were important in controlling the extent 
of SBS release. Similarly Methocel® KlOOM and xanthan gum had the greatest impact on the 
overall mechanism of SBS release from the formulations tested, and the results revealed that 
drug release from the formulations is primarily diffusion controlled. 
The Calibration Generation Browser in Matlab was used to determine the composition of an 
optimised formulation that would have the appropriate physical characteristics and in vitro 
release profile. The f2 similarity factor was used to compare the dissolution profile of the 
predicted formulation to that of the reference formulation, and a value of [2 = 89.7 was 
generated indicating that the predicted in vitro release profile would be similar to that of the 
reference formulation. The f 2 similarity factor of a formulation manufactured according to 
the composition from the optimisation process compared with the reference formulation was 
83.0, thereby indicating that statistical optimisation was successfully applied to the 
development of an optimised delivery system for SBS. 
Matlab® R2008a was used to write code for the training and evaluation of a neural network. 
Formulation variables and in vitro dissolution profiles from the central composite study were 
used for training, testing and validating the network models that were developed. A three 
layer MLP with nine nodes in the hidden layer was found to have the highest predictive 
ability and was therefore deemed suitable for the simulation of dissolution profiles for 
formulation optimisation and establishment of a design space. 
A brute force method was used to generate permutations for simulation using the ANN 
model, and the combination of formulation variables that resulted in the highest f 2 value was 
selected for further evaluation. The predicted formulation resulted in an f2 value of 90.5. The 
manufactured formulation was found to perform satisfactorily and an f 2 value of 86.0 was 
calculated, clearly indicating the dissolution profile was indeed similar to that of the reference 
formulation. 
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The optimisation outputs from RSM and ANN are summarised in Table 9.1. 
Table 9.1 Comparison of optimised formulation compositions derived from RSM and ANN 
Formulation 
Methocel® KlOOM (mg) 
Xanthan gum (mg) 
Carbopol® 974P (mg) 
Sureleaseil. (% w/w) 
RSM ANN 
29.77 45 
35.31 30 
10.01 
18.5 
5 
10 
The results indicate that the two procedures resulted in different compositions for optimised 
formulations and demonstrate that the optimisation procedure that is used when developing 
formulations has the potential to impact the outcome of these experiments. The optimisation 
method that was used was a Normal Boundary Intersection method for multi-objective 
optimisation, whereas randomised weighting procedures through iterations are used for 
pattern recognition when training ANN. The two methods therefore do not result in the 
generation of a similar formulation composition. Although the formulation compositions, 
which are used to produce a formulation with the release characteristics similar to the 
reference product, are different both approaches result in the production of formulations with 
similar dissolution profiles under the conditions used in this research. The resultant 
dissolution profiles are shown in Figure 9 .1. 
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Figure 9.1 Comparison of formulations predicted and manufactured from RSM and ANN 
compared with the reference formulation 
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ANN are particularly useful for studying systems where there is little known information 
about the relationship between causal and response factors whereas such information needs to 
be explicitly expressed when using statistical optimisation techniques [211 ,214]. The RSM 
data was used to train an ANN model that had a good predictive capability for this research. 
It has been reported that ANN give better predictions to solutions than RSM [209], although 
when RSM analysis is used the surface is described by a continuous function, and a visual 
representation of the relationship between the input variables and outputs can be easily 
mapped [209]. When using RSM the relationship between an input variable and the rate of 
change of a response may be easily determined by plotting the first derivative of the response 
as a function of the input variable [209]. The output for ANN is a discrete set of points, and 
extensive simulations are required to visualise the relationship between an input variable and 
output. In addition, in order to evaluate the rate of change of a response with respect to that of 
an input variable for an ANN model, numerical differentiation of the input variables is 
required [209]. 
It has also been reported that the application of ANN models results in the calculation of 
smaller error values between predicted and experimentally observed responses compared 
with those generated when using RSM analysis [209]. However from the data generated in 
this research, RSM and ANN produced satisfactory results. 
ANN have been shown to model non linear relationships better than classical RSM [245] 
since non-linear functions are typically difficult to describe using classic polynomial 
regression equations. This statement is based on the low value for correlation coefficients 
generated when using classical RSM to model non-linear data patterns [245]. However, RSM 
is reported to be more robust than ANN when dealing with outliers and this must be 
considered when developing ANN models [246]. 
It is clearly evident that SR formulations are inherently complex systems for which the 
performance is affected by the type and levels of polymer combinations that are used to 
manufacture the formulations. Although the research did not focus on the impact of 
manufacturing variables of dosage form characteristics, the impact of processing conditions 
of product quality cannot be overlooked. It is therefore clear from these observations that the 
design and development of SR systems and dosage forms is a multivariate optimisation 
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process and is very challenging. The applications of statistical approaches such as RSM that 
is based on polynomial regression can be used to obtain a mechanistic understanding of the 
complex relationships between formulation variables and measurable characteristics of 
dosage form performance. 
The impact of four formulation variables on the in vitro release profile of SBS using a central 
composite design was investigated. However, 30 experiments are required to completely 
study the experimental domain and as the number of variables to be studied increases, the 
number of experiments becomes unmanageable and therefore unrealistic to evaluate all 
factors entirely. In addition, as the number of input variables increases, the number of 
coefficients for the polynomial equation increase and thereby limiting the application of 
polynomial models for multi-objective optimisation that is necessary when developing SR 
formulations. In general, RSM works well for the low dimensionality or for approximating 
simple functions and is only be practically suited to one dependent variable or a low order 
polynomial such as second order polynomials. When conducting multi-objective 
optimisation, an appropriate response surface model for each response variable that is being 
studied needs to be built and a set of independent variables that optimise all the responses or 
keep them in the desired ranges need to be obtained. This makes the application of RSM for 
formulation optimisation very cumbersome. 
The application of ANN for formulation development overcomes these concerns and 
therefore makes them more suitable for multi-objective optimisation. They are particularly 
useful in incidences when the functional relationships or dependence between input and 
output factors is not clear. A well trained ANN model can handle multiple independent and 
dependent variables simultaneously in one model thereby negating the need for multiple 
polynomial models. For instance, in the current study, it was possible to construct an ANN 
model that was useful for predicting the impact of the four studied formulation variables on 
the extent of in vitro release dissolution at all stages of the dissolution test. This is in 
comparison to the RSM model that was developed, where a separate polynomial model was 
required for each response variable. This made the ANN less cumbersome to use in 
comparison to the RSM model although the disadvantage was that it was not possible to infer 
interactions between input factors from the ANN model that was constructed. When ANN 
models are used to depict relationships between input and output factors, it is also not easy to 
obtain a graphical output of the experimental domain without the use of complicated 
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software. A primary advantage of ANN for developing formulations is that ANN can be 
uploaded with new data that will not necessarily affect the model, but will enhance the 
quality of predictions that can be made from ANN models. It is also possible to increase the 
efficiency of ANN models when dealing with multi-dimensional problems because searching 
algorithms such as genetic algorithms may be integrated in the model and augment the 
predictive ability of ANN models. 
It was established that the optimisation of a SR formulation was possible using both RSM 
and ANN and the selection of either method depends on the expertise available to researchers 
and formulators although previous studies have shown better predictive ability of ANN 
compared to RSM. 
RSM and ANN were further used to establish a design space for the formulation that would 
result in a product with desirable in vitro release characteristics that was similar to that of the 
reference formulation. The impact of the levels of Methocel~~~' KlOOM, xanthan gum, 
Carbopof"' 974P and Surelease® on the extent of drug release at all stages of dissolution 
testing was determined from the resultant constraint plots generated from the RSM 
procedures. The results revealed that the target formulation could be obtained within certain 
limits of each formulation variable to ensure the production of a matrix formulation with the 
desired dissolution profile. 
The impact of varying formulation composition within the limits of ± 5 mg for solid 
polymers and ± 5% w/w for the composition of the liquid dispersion used to granulate the 
formulation compared with the optimised formulation was used to simulate resultant 
dissolution profiles using ANN. This is useful for establishing which compositions would 
result in the generation of formulations with similar performance to that of the reference 
formulation. Using this approach it was possible to simulate the impact of varying the 
composition of the formulation on the resultant dissolution profiles. 
The limitations of both these methods have resulted in the recommendation that perhaps these 
methods should be used in combination to explore a design space effectively. However this 
does not appear possible since the compositions that were generated from the optimisation 
procedure were not similar (Table 9.1). 
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9.2 RECOMMENDATIONS 
9.2.1 Overview 
The QbD system integrates product development and process design, with risk assessment 
and control, which are considered to be crucial for the development of quality pharmaceutical 
products. The interrelationship between these elements is summarised in Figure 9 .2. 
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Figure 9.2 Interrelationship between product development and process design with risk assessment and risk 
control, adapted and redrawn from [1 0] 
The ICH Q8 (R2) Pharmaceutical Development [1], ICH Q9 Quality Risk Management [2] 
and ICH QlO Pharmaceutical Quality System [3] guidelines form the ICH Harmonised 
Tripartite Guidelines which direct QbD. The interrelationship between the guidelines and 
bow they ultimately impact product quality is shown in Figure 9.3. 
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Figure 9.3 Relationship between pharmaceutical development, quality risk management and development 
of pharmaceutical quality systems, adapted and redrawn from J. Ramsbotham [160,247) 
The application of Pharmaceutical Development principles and Pharmacy Quality Systems 
may result in a decreased risk to patients that may otherwise occur as consequence of product 
and processing variability and manufacturing site, respectively. 
The Pharmaceutical Development guideline places an emphasis on the application of 
pharmaceutical and manufacturing sciences to facilitate the production of high quality 
pharmaceutical products [ 1]. As such, an extensive understanding of the formulation 
variables and manufacturing processes that impact product quality is essential [8] and may be 
enhanced by use of RSM and ANN models as completed in the current study. However the 
potential impact of the ICH Q9 [2] and the ICH Q 10 [3] guidelines and how this can be used 
with RSM and ANN must also be considered. 
9.2.2 Pharmaceutical Development Guideline 
Preliminary studies are an integral part of formulation development and provide a 
mechanistic understanding of the variables under investigation and a database from which a 
formulator may continually draw in future research. Conducting carefully designed screening 
studies may also identify variables that do not significantly affect measured responses and 
these may be eliminated from future optimisation work, thereby potentially increasing 
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efficiency and saving valuable and costly resources. Screening studies such as two-level 
factorial designs and Plackett-Burman designs [181] may be suitable for preliminary studies 
to establish those factors that have a significant effect on the measured responses and that are 
useful for future optimisation using RSM. 
The RSM approach described in Chapter 6 revealed that there are potential interactions 
between certain formulation variables that may impact physical quality characteristics such as 
tablet crushing strength and affect the in vitro release performance. Tools such as Differential 
Scanning Calorimetry (DSC) and X-ray Diffraction (XRD) would be useful to identify 
potential interactions between excipients and API. 
The quality target profile of an API encompasses physical quality and in vitro and in vivo 
dosage form performance characteristics. Although the current study has only focused on the 
in vitro dissolution profile of a reference product as the primary CQA, other elements 
including tablet crushing strength, friability etc. must also be considered in formulation 
development studies. In order to study the impact of input variables on the CQA, RSM may 
be used to gain a mechanistic understanding of these factors. However, as the number of 
measurable attributes increases, the information may become unmanageable as the number of 
models that are developed increases. It may therefore become difficult to contextualise the 
information in order to understand the impact of variables on measurable responses. The use 
of ANN for expanding the design space may become suitable as more information is 
generated since the output from an appropriately trained ANN is linked to all measured 
responses. 
Formulation development strategies that use tools such as RSM and ANN provide invaluable 
information regarding the complex relationship between formulation and/or process factors 
and how these may impact predetermined CQA. The result of this research demonstrates that 
it is possible to gain a conceptual understanding of the inter-relationships between 
formulation factors and the in vitro dissolution profile. Therefore this information serves a 
platform for controlling those factors that may be deemed to be high-risk factors and ensuring 
that such conditions are always met when developing pharmaceutical formulations. The use 
of ANN as a tool for understanding the impact of formulation changes on dosage form 
performance can be used to perform iterations on the potential impact of the criticality of 
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formulation and/or process factors on dosage form performance. In this way, this research 
serves to provide a potential platform for the QbD process. 
The design space for a pharmaceutical product is best described by three interacting spaces, 
viz., the raw material property space, CPP (Critical Process Parameters) space and CQA 
spaces. It is imperative that the design and control spaces are carefully controlled and 
managed since any changes in at least one of these domains may adversely affect the other 
domain spaces. As such, when there are changes in any one of these spaces, the impact on 
overall product quality must be addressed or managed. Strategies to control operating and/or 
process variables must be established when defining a design space [227]. It is vitally 
important that operating and/or control strategies for pharmaceutical processes are defined 
prior to defining additional design spaces since changes in procedures have the potential to 
dramatically alter and affect ultimate product quality and performance [227]. 
The quality attributes of a pharmaceutical product are also determined by processing 
conditions that are linked, in part, to the levels of formulation composition and the excipients 
that are used. It is also desirable that the impact of processing conditions on product quality 
are studied and that a design space that includes the manufacturing process must be 
established. Although the focus of the research was limited to understanding the impact of 
formulation variables on in vitro release performance, process information may be added at a 
later stage to an ANN model to enhance understanding of the design space. 
The impact of formulation variables on the in vitro dissolution profile, specifically that of the 
1000-tablet batches manufactured were the focus of this work. The ICH Q8 guideline [1] 
recommends that, when describing a design space for a pharmaceutical formulation, the size 
of the scale must be reported in the application for regulatory approval. The relationship 
between a design space at small or pilot scale to that observed at production scale during the 
manufacturing process must be discussed, and potential risk to product quality must be 
appropriately determined. It may often therefore be desirable that the design space should be 
applicable to multiple operational scales. Although the flexibility of the design space with 
respect to scale-up was not assessed, the use of relevant scale-independent parameters may 
alleviate the risks that are usually associated with scale up. This may often be the case with 
manufacturing processes such as wet granulation procedures that are affected by batch sizes, 
and the use of a shear rate and other dimensionless parameters for scale-up may therefore be 
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included in the determination of a design space [1]. In general, semi-empirical approaches, 
based on the application of sound pharmaceutical and manufacturing sciences to determine 
the relationships between operating conditions when different scales or pieces of equipment 
are used, may be necessary when establishing a design space for a pharmaceutical product 
[1 0]. 
To overcome the limitations of RSM and ANN when establishing a design space for a 
pharmaceutical product it may be possible to use the different methods in combination. In 
this manner, the use of RSM will permit the development of a mechanistic understanding of 
the underlying pharmaceutical principles that apply to a specific formulation and will 
generate graphical outcomes that can be used to enhance understanding of the design space 
that is established. ANN can be used to evaluate the impact of formulation changes at the 
limits of the design space using simulation models to evaluate the impact of formulation 
composition and manufacturing conditions on CQA. 
A recommendation is that RSM and ANN be used in combination to develop an effective and 
applicable pharmaceutical design space. However this approach may not be feasible for all 
dosage forms as it is evident from these outcomes that optimisation using the same data set 
generated from a central composite design (Chapter 6) resulted in different sets of outcomes 
when the data was evaluated using RSM and ANN. Therefore the use of the information from 
RSM and ANN must be thoroughly interrogated in order to prevent misinterpretation of the 
resultant data that is generated. 
Recommendations for developing a design space for pharmaceutical product also include 
considering independent variations from the manufacturing process that are likely to impact 
product quality. This would allow set6ng specifications for operating variables to conditions 
that have been demonstrated to provide an assurance of quality. 
9.2.3 Quality Risk Management 
The ICH Q9 guideline [2] provides a systematic approach to pharmaceutical quality risk 
management and facilitates the assessment and control of risk in those areas of 
pharmaceutical development that are likely to impact product quality. Quality risk 
management is based on scientific knowledge with the core objective of protecting the patient 
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by ensuring product performance, safety and efficacy and minimising the level of risk that is 
associated with pharmaceutical formulations or processes [248]. 
Risk assessment tools are an important aspect of optimising pharmaceutical formulations and 
processes. Various tools including FMEA, FTA, HACCP (Failure Mode Effects Analysis, 
Fault Tree Analysis, Hazard Analysis and Critical Control Points) and Cause and Effect 
(Ishikawa) diagrams may be used for this purpose. Understanding the scope of information 
that can be generated from these tools may be important in assessing wlllch method will 
result in usable information. In this way, potential sources of risk are fully understood, 
managed or eliminated as sources of variability that may impact product quality. 
A recommendation for the Quality Risk Management process is that risk assessment tools 
must be used to identify and rank the variables and control parameters that are related to both 
manufacturing and formulation variables and how these are likely to impact product quality. 
These variables and control parameters must therefore be monitored and controlled when 
developing and optimising pharmaceutical dosage forms. The use of experimental design and 
ANN may be used for evaluating these aspects of control and used to enhance understanding 
of the criticality of these factors and therefore useful to ensure the production of safe and 
effective dosage forms. The risk assessment process must also be linked to the established 
design space to ensure that process and formulations variables will ensure that the design 
space is always maintained. Another potential area for consideration when establishing a 
design space is the impact of different sources of excipients on product quality, which is an 
important variable when working with polymers. 
9.2.4 Product Lifecycle 
The ICH Q 10 guideline [3] describes the development of a model that assures product quality 
throughout the lifecycle of that product and promotes continual improvement in product and 
manufacturing processes that assure that there is minimal risk on product quality [ 13]. This 
allows for the development of quality control strategies that are useful in monitoring and 
controlling quality [248]. Moreover this guideline complements and facilitates the 
implementation of the Pharmaceutical Development [1] and Quality Risk Management [2] 
guidelines. 
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As information is generated through additional studies during the lifecycle of a product, data 
can be added to the information pool to improve the predictive capability of an ANN network 
model, thereby increasing both the experimental domain and the understanding of the design 
space. 
This research has demonstrated the potential utility of RSM and ANN as tools for developing 
quality pharmaceutical formulations and that the establishment and presentation of a design 
space may be conducted using a combination of both these methods. 
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SAMPLE BATCH MANUFACTURING RECORD 
Only one of each direct compression and one wet granulation batch manufacturing record 
templates, indicating the quantities of polymers that were used, procedures that were 
followed and information that was recorded, are included in the thesis. The records for all 
formulation batches that were manufactured are available on request. 
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~hades Univ.: r!'·ty 
Faculty cf Pharmac:, 
Departmen~ of Phamwreut:rs 
Grat>omstO'.~ n 61..+0 
BATCH MANUFACTURING RECORD DIRECT COMPRESSION 
Date of manufacture 
Temperature and humidity 
Formulator Faith Chaibva 
~ 
IUIOO L (; 
Product 
Batch number 
9.6 mg salbutamol sulphate matrix tablets 
SBS-01 
Batch Size 1000 tablets 
Target weight 140mg 
MANUFACTURING DIRECTIONS 
Step 
2 
3 
4 
Procedure 
Separately screen the following 
materials through a 20 mesh screen 
Salbutamol sulphate 
Methocel,. Kl OOM 
Avice!® PHlOl 
PLace the weighed powders in the 
Sara!® Rapid mixer and granulator 
and blend at 100 rpm for 15 min 
Separately screen the following 
materials using a 44 mesh screen 
Colloidal silicone dioxide 
Magnesium stearate 
Add the above to the blend and mix 
for a further 3 min at the same speed 
5 Compress the powder blend using a 
Manestyv F3 single punch tablet 
press to produce tablets of the desired 
weight 
Formula 
9.6 g 
70 g 
58.3 g 
0.7 g 
1.4 g 
OBSERVATIONS 
Weight Time Done Check 
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Rhod~s ;Jni\'e f'Sit y 
Faw lty of Pharmacy 
D:?partment o: Pharmaceut;!::s 
Grol-amstovm 6.i40 
BATCH MANUFACTURING RECORD WET GRANULATION 
Date of manufacture 
Temperature and humidity 
Formulator Faith Chaibva 
Product 
Batch number 
9.6 mg salbutamol sulphate SR matrix tablets 
SALOOlCCD 
Batch Size 
Target weight 
Granulating fluid 
Step Procedure 
1000 tablets 
220mg 
12% Surelease® 
MANUFACTURING DIRECTIONS 
1 Separately screen the following materials through a 20 mesh screen 
Formula Weight Time Done Check 
Salbutamol sulphate 9.6 g 
Methocel® Kl OOM 120 g 
Xanthan gum 50 g 
Carbopol® 974P NF 10 g 
Avice!® PHIOl 12.7 g 
2 Place them in the Saral® Rapid mixer and granulator and blend at l 00 rpm for 15 min 
3 Set the blade to 120 rpm and chopper to 1000 rpm and add 120 g of granulating fluid 
4 Weight of container before 
Weight of container after 
Amount of granulating fluid added 
Time taken to add fluid 
Current measured Impeller 
Chopper 
5 Continue to mix granules for a further 5 min 
6 Remove granules from the mixer and weigh them before drying 
Weight of wet granules 
7 Dry the granules at room temperature for 24 hr 
8 Weight of dried granules 
9 Weight of granules used 
10 Separately screen the following materials using a 44 mesh screen and add to the blend and mix 
for a further 3 min at 1 00 rpm 
Cab-0-Sil® MS (0.5% w/w) 
Magnesium stearate (1% w/w) 
11 Compress the granules blend using a Manesty® B3B rotary tablet press to produce tablets of 
the desired weight 
OBSERVATIONS 
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SAMPLE BATCH RECORDS SUMMARY 
Only one of each direct compressiOn and one wet granulation batch record summary, 
indicating the quantities of polymers that were used, physical tests that were conducted and 
any other information that was recorded are included in the thesis. The records for all 
formulation batches that were manufactured are available on request. 
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Date of manufacture 
Formulator 
Product 
Batch number 
Batch Size 
Target weight 
Salbutamol sulphate 
Methocel® KlOOM 
Colloidal silica 
Magnesium stearate 
Avice)® PH101 qs 
Assay (mg) 
Weight (mg) 
Crushing strength (N) 
Thickness (mm) 
Diameter (mm) 
100 
80 
,..... 
~ 0 
........ 
., 60 
"' 
"' "' .... 
.. 
= 40 ., ... 
.. 
., 
1:1.. 
20 
O• 
0 
Appendix 2. Batch Record Summary Samples 
Rhodes University 
Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 ~ RHODES 
BATCH RECORD SUMMARY 
Formula 
9.6mg 
50% w/w 
0.5% w/w 
1.0% w/w 
100% w/w 
1 May 2008 
Faith Chaibva 
9.6 mg SBS SR matrix tablets 
SBS-01 
1000 tablets 
140 mg 
FORMULATION 
Working formula 
9.6 g 
70 g 
0.7 g 
1.4 g 
140 g 
Rhodes batch number 
RMOOOI88 
RM000062 
X052098 
X052015 
RM000087 
PHYSICAL ASSESSMENT 
2 
Mean±SD 
9.64 ± 0.09 
141.01 ± 2.53 
81.82 ± 4.41 
2.99 ± 0.06 
7.16 ± 0.01 
IN VITRO RELEASE 
4 6 8 10 12 14 
Time (hr) 
Figure 10.1 In vitro release profile ofSBS-01 over a 12 hr period 
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Date of manufacture 
Formulator 
Product 
Batch number 
Batch Size 
Target weight 
Granulating fluid 
Salbutamol sulphate 
Methocel® KlOOM 
Xanthan i um 
Carbopol 974P 
Avicel® PHlOl qs 
Colloidal silica 
Magnesium stearate 
Granule characteristics 
Bulk density (g/cm3) 
Tap density (g/cm3) 
Carr's Index(%) 
Angle of repose (0 ) 
Tablet characteristics 
Assay (mg) 
Weight (mg) 
Crushing strength (N) 
Thickness (mm) 
Diameter (mrn) 
Appendix 2. Batch Record Summary Samples 
Rnodes Ur ·v.: -s ±~· 
Focu:~· cf Pharma:}' 
Department o.f Phorrr;aceu:.::s 
Graflamstowr 6 -l9 
BATCH RECORD SUMMARY 
5 November 2008 
Faith Chaibva 
9.6 mg SBS SR matrix tablets 
SALOOlCCD 
1000 tablets 
220mg 
12% w/w Surelease(E' 
FORMULATION 
Formula 
9.6 g 
120 g 
50 g 
10 g 
12.7 g 
0.5%w/w 
1.0% w/w 
GRANULE ASSESSMENT 
Mean±SD 
9.34 ± 0.36 
221.25 ± 1.07 
33.27 ± 2.13 
4.93 ± 0.08 
PHYSICAL ASSESSMENT 
Mean±SD 
9.34 ± 0.36 
221.25 ± 1.07 
33.27 ± 2.13 
4.93 ± 0.08 
8.73 ± 0.20 
Rhodes batch number 
RM000188 
RM000062 
RM000063 
RM000121 
RM000087 
X052098 
X052015 
~ 
11 0 0( :0 
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IN VITRO RELEASE 
100 
80 
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c 
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"' 
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Figure 10.2 In vitro release profile of SALOO 1 over a 12 hr period 
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RESPONSE SURFACE METHODOLOGY STATISTICS 
11.1 TABLET CRUSHING STRENGTH 
Table 11.1 Model fit comparison for tablet crushing strength 
Model PRESS 
Linear 8.8513 
Quadratic 7.6350 
RMSE 
8.2691 
6.6676 
Table 11.2 Stepwise regression results quadratic model for tablet crushing strength 
Coefficient Value Standard t 
Intercept 27.47 
x 1 - Methocel® KlOOM -3.3236 
Xz - Xanthan gum -23.26 
x3 - Carbopol~ 974P -4.5514 
x 4 - Surelease -2.8431 
X~ -2.9547 
XtXz -9.0125 
XtXJ 5.1625 
XtX4 4.2792 
X~ 15.87 
XzXJ 16.77 
XzX4 5.4708 
X~ 3.5328 
X3X4 -2.3042 
X~ -0.05781 
Table 11.3 ANOV A summary table 
Source 
Regression 
Error 
Total 
ss 
4105.189 
1111.41 
5216.598 
deviation 
1.571 
2.6940 
2.7220 
2.7220 
2.7169 
5.0680 
6.5517 
6.7230 
6.7488 
4.9697 
6.6676 
6.7128 
5.05526 
6.7888 
5.1038 
df 
4 
25 
29 
17.48 
-1.2337 
-8.5445 
-1.6721 
-1.0464 
-0.5830 
-1.3756 
0.7679 
0.6341 
3.1941 
2.5153 
0.8150 
0.6992 
-0.3394 
-0.01133 
MS 
Significance 
Significant 
Not significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Not significant 
Not significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Not significant 
1026.297 
44.456 
0 
YH = 27.5- 23.3x2 - 4.55x3 + 15.9xi + 16.8x2x3 Equation 11.1 
80 . 
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Figure 11.1 Predicted vs. observed 
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Figure 11.2 Studentised residuals vs. observed 
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11.2 PERCENT RELEASE AFTER 1 HR 
Table 11.4 
Model 
Linear 
Quadratic 
Model fit comparison for percent drug released after I hr 
PRESS 
4.8646 
4.0944 
Appendix 3. ANOV A Summary Tables 
RMSE 
4.4295 
3.0088 
Table 11.5 Stepwise regression results quadratic model for percent release after I hr 
Coefficient Value Standard T Significance 
Intercept 30.50 
x 1 - Methocel® K100M -7.6720 
Xz - Xanthan gum -8.4306 
x3 - Carbopol® 974P 0.1926 
x4 - Surelease -1.2723 
X~ 2.5455 
XtXz 9.5520 
XtX3 -3.2283 
XtX4 -0.3566 
X~ 9.7755 
XzX3 -5.6587 
XzX4 -0.7667 
X~ -2.8861 
x3x4 2.2365 
X~ 0.4233 
Table 11.6 ANOV A summary table 
Source 
Regression 
Error 
Total 
ss 
1101.156 
208.21 
1309.366 
deviation 
0.8686 
1.2283 
1.2283 
1.2553 
1.2263 
2.2613 
3.0088 
2.9984 
3.0754 
2.2566 
3.0088 
3.0720 
2.2566 
3.0392 
2.3238 
df 
6 
23 
29 
32.11 
-6.2459 
-6.8635 
0.1535 
-1.0375 
1.1257 
3.1747 
-1.0767 
-0.1160 
4.3320 
-1.8807 
0.2496 
-1.2790 
0.7359 
0.1822 
MS 
Significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Significant 
Not significant 
Not significant 
Significant 
Significant 
Not significant 
Significant 
Not significant 
Not significant 
183.526 
9.053 
0 
Ylh = 30.5- 7.67x1 - 8.43x2 + 9.55x1x2 + 9.78xi- 5.66x2x3 - 2.88x~ Equation 11.2 
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11.3 PERCENT RELEASE AFTER 2 HR 
Table 11.7 Model fit comparison for percent drug released after 2 hr 
Model PRESS 
Linear 5.5492 
Quadratic 5.1703 
Appendix 3. ANOV A Summary Tables 
RMSE 
5.0172 
3.6146 
Table 11.8 Stepwise regression results quadratic model for percent release after 2 hr 
Coefficient Value Standard t Significance 
Intercept 
x 1 - Methocel® KlOOM 
x2 - Xanthan i um 
x3 - Carbopol 974P 
x4 - Surelease 
X~ 
XtXz 
XtX3 
XtX4-
X~ 
XzX3 
XzX4 
X~ 
x3x4 
xz 4 
41.83 
-8.5218 
-10.20 
-0.6528 
-2.2459 
3.3200 
9.4949 
-2.2304 
0.09924 
11.00 
-4.6734 
-l.l203 
-3.1663 
1.9065 
-0.1796 
Table 11.9 ANOV A summary table 
Source SS 
Regression 1451.833 
Error 287.442 
Total 1739.275 
deviation 
1.0435 
1.4757 
1.4757 
1.5037 
1.4757 
2.7012 
3.6146 
3.6675 
3.6996 
2.7110 
3.6146 
3.6916 
2.7110 
3.6762 
2.7964 
df 
7 
22 
29 
40.09 
-5.7749 
6.9102 
-0.4342 
-1.5220 
1.2291 
2.6268 
-0.6082 
0.02682 
4.0952 
-1.2929 
-0.3035 
-1.1680 
0.5186 
-0.06421 
MS 
Significant 
Significant 
Significant 
Not significant 
Significant 
Not significant 
Significant 
Not significant 
Not significant 
Significant 
Significant 
Not significant 
Significant 
Not significant 
Not significant 
207.405 
13.066 
0 
Yzh = 41.8- 8.52x1 - 10.2x2 - 2.25x4 + 9.49x1x2 + ll.Ox?- 4.67x2x3 - 3.17xj 
Equation 11.3 
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Appendix 3. ANOVA Summary Tables 
11.4 PERCENT RELEASE AFTER 4 HR 
Table 11.10 
Model 
Linear 
Quadratic 
Model fit comparison for percent drug released after 4 hr 
PRESS RMSE 
5.4987 4.9461 
5.1843 4.7248 
Table 11.11 Stepwise regression results quadratic model for percent release after 4 hr 
Coefficient Value Standard T Significance 
Intercept 60.26 
x1 - Methocel® KIOOM -10.15 
x 2 - Xanthan gum -9.4504 
x 3 - Carbopol® 974P -2.8128 
x 4 - Surelease -3.4614 
xi 3.4738 
XtXz 7.4074 
XtX3 -0.4601 
XtX4 0.3270 
X~ 8.9463 
XzXJ -2.355 
XzX4 -2.6437 
X~ -4.9034 
X3X4 2.0110 
xi -1.2617 
Table 11.12 ANOV A summary table 
Source 
Regression 
Error 
Total 
ss 
1371.271 
513.447 
1884.7171 
deviation 
1.1136 
1.9389 
1.9389 
1.9389 
1.9389 
3.5467 
4.7248 
4.8300 
4.8305 
3.0806 
4.8048 
4.7980 
3.5217 
4.8119 
3.6132 
df 
6 
23 
29 
54.11 
-5.2611 
-4.8994 
-1.4583 
-1.7945 
0.9794 
1.5678 
-0.09525 
0.06770 
2.9041 
-0.4902 
-0.5510 
-1.3923 
0.4179 
-0.3492 
MS 
Significant 
Significant 
Significant 
Significant 
Significant 
Not significant 
Significant 
Not significant 
Not significant 
Not significant 
Not significant 
Not significant 
Significant 
Not significant 
Not significant 
228.545 
22.324 
0 
y4h = 60.3- 10.2x1 - 9.45x2 - 2.81x3 - 3.46x4 - 7.41x1x2 - 4.90x~ Equation 11.4 
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11.5 PERCENT RELEASE AFTER 6 HR 
Table 11.13 Model fit comparison for percent drug released after 6 hr 
Model PRESS 
Linear 
Quadratic 
5.9872 
5.1152 
Appendix 3. ANOV A Summary Tables 
RMSE 
5.3826 
4.4342 
Table 11.14 Stepwise regression results quadratic model for percent release after 6 hr 
Coefficient Value Standard t Significance 
deviation 
Intercept 72.07 
x1 - Methocel® KlOOM -13.49 
x2 - Xantban gum -8.0773 
x 3 - Carbopol® 974P -4.0048 
x 4 - Surelease -4.4294 
xz 1 10.39 
XtXz 4.9922 
X1X3 0.09546 
XtX4 0.2184 
X~ 5.6356 
XzXJ 0.3365 
XzX4 -4.2177 
X~ -5.2877 
X3X4 2.1363 
X~ -1.8580 
Table 11.15 ANOV A summary table 
Source SS 
Regression 
Error 
Total 
1989.514 
432.567 
2422.081 
1.2800 
1.8103 
1.8103 
1.8103 
1.8103 
3.3257 
4.4342 
4.5385 
4.5383 
3.2028 
4.5380 
4.4443 
3.3257 
4.5145 
3.4068 
df 
7 
22 
29 
56.30 
-7.4537 
-4.4620 
-2.2123 
-2.4469 
3.1267 
1.1258 
0.02103 
0.04813 
1.7595 
0.07414 
-0.9490 
1-5900 
0.4732 
-0.5454 
MS 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Not significant 
Not significant 
Significant 
Not significant 
Not significant 
284.216 
19.662 
0 
y6h = 72.1- 13.5x1 - 8.08x2 - 4.01x3 - 4.43x4 + 10.4xf + 4.49x1x2 - 5.29xj 
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11.6 PERCENT RELEASE AFTER 8 HR 
Table 11.16 Model fit comparison for percent drug released after 8 hr 
Model PRESS 
Linear 5.0768 
Quadratic 4.7586 
Appendix 3. ANOV A Summary Tables 
RMSE 
4.6084 
4.2015 
Table 11.17 Stepwise regression results quadratic model for percent release after 8 hr 
Coefficient Value Standard t Significance 
deviation 
Intercept 82.66 
x 1 - Methocel~ KIOOM -11.95 
Xz - Xanthan gum -7.0601 
x3 - Carbopol® 974P -4.2601 
x 4 - Surelease -4.9151 
xz 1 6.3764 
XtXz 3.1545 
XtX3 0.7125 
XtX4 -0.1416 
X~ 3.4475 
XzXJ 2.0969 
XzX4 -4.4066 
X~ 4.6993 
X3X4 1.9661 
xi -0.8054 
Table 11.18 ANOVA summary table 
Source SS 
Regression 1534.91 
Error 
Total 
406.018 
1940.928 
1.2129 
1.7153 
1.7153 
1.7153 
1.7153 
3.1512 
4.2430 
4.2933 
4.2959 
3.1632 
4.2726 
4.1920 
3.1512 
4.2755 
3.2429 
df 
6 
23 
29 
68.15 
-6.9679 
-4.1160 
-2.4836 
-2.8655 
2.0235 
0.7435 
0.1659 
-0.03296 
1.0899 
0.4908 
-1.051 
-1.4913 
0.4599 
-0.2484 
MS 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Not significant 
Not significant 
Not significant 
Significant 
Not significant 
Not significant 
255.818 
17.653 
0 
Yah= 82.7- 12.0x1 - 7.06x2 - 4.26x3 - 4.91x4 + 6.37xf + 4.70xj Equation 11.6 
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Appendix 3. ANOV A Summary Tables 
11.7 PERCENT RELEASE AFTER 12 HR 
Table 11.19 Model fit comparison for percent drug released after I 2 hr 
Model PRESS 
Linear 
Quadratic 
4.9752 
4.9752 
RMSE 
4.5572 
4.5572 
Table 11.20 Stepwise regression results quadratic model for percent release after 12 hr 
Coefficient Value Standard t 
Intercept 
x 1 - Methocel® K100M 
x2 - Xanthan gum 
x3 - Carbopol~ 974P 
x4 - Surcleasc 
94.33 
-7.7059 
-6.8699 
-3.2194 
-3.9763 
Table 11.21 ANOV A summary table 
Source SS 
Regression 
Error 
Total 
796.5 19 
519.254 
1315.772 
deviation 
0.8321 
1.8606 
1.8606 
1.8606 
1.8606 
df 
4 
25 
29 
113.4 
-4.1417 
-3.6924 
-1.7304 
-2.1372 
MS 
199. 13 
20.77 
0 
y 12h = 94.3- 7.7lx1 - 6.87x2 - 3.2lx3 - 3.98x4 
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Appendix 3. ANOV A Summary Tables 
11.8 DRUG RELEASE RATE 
Table 11.22 Model fit comparison for percent drug release rate, k 
Model PRESS 
Linear 0.048535 
Quadratic 0.041361 
RMSE 
0.044203 
0.030710 
Table 11.23 Stepwise regression results quadratic model for drug release rate, k 
Coefficient Value Standard T Significance 
deviation 
Intercept 0.3038 0.008865 34.27 Significant 
x1- Methoccl® K100M -0.07637 0.01254 -6.0911 Significant 
x 2 - Xanthan gum -0.08757 0.01254 -6.9844 Significant 
x 3 - Carbopof81 974P 0.001650 0.01281 0.1288 Not significant 
x 4 - Surelease -0.01360 0.01249 -1.0891 Not significant 
xi 0.02824 0.02296 1.2301 Not significant 
xlxz 0.09525 0.03071 3.1016 Significant 
xlx3 -0.03305 0.03060 -1.0801 Not significant 
xlx4 -0.003900 0.03139 -0.1242 Not significant 
X~ 0.09551 0.02303 4.1468 Significant 
XzX3 -0.05545 0.03071 -1.8056 Significant 
XzX4 -0.007200 0.03136 -0.2296 Not significant 
X~ -0.02814 0.02303 -1.2216 Significant 
x3x4 0.02210 0.03105 0. 7119 Not significant 
xl 0.002014 0.02373 0.08487 Not significant 
Table 11.24 ANOV A summary table 
Source ss Df MS 
Regression 0.112 6 0.019 
Error 0.022 23 9.431 X J0-4 
Total 0.134 29 0 
k = 0.304- 0.0764x1 - 0_0876x2 + 0.0953x1x2 + 0.095Sxt- 0.0555x2x3 - 0.0281xj 
Equation 11.8 
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Appendix 3. ANOV A Summary Tables 
11.9 MECHANISM OF RELEASE 
Table 11.25 Model fit comparison for exponent of drug release, n 
Model PRESS 
Linear 
Quadratic 
0.033794 
0.024526 
RMSE 
0.031250 
0.020222 
Table 11.26 Stepwise regression results quadratic model for exponent of drug release, n 
Coefficient Value Standard t Significance 
deviation 
Intercept 0.4761 0.004766 99.89 Significant 
x1 - Methocel® K100M 0.04396 0.008256 5.3247 Significant 
x 2 - Xanthao gum 0.05594 0.008256 6.7763 Significant 
x 3 - Carbopol® 974P 0.01751 0.008256 -2.1208 Significant 
x4 - Surelease -0.001858 0.008440 -0.2202 Not significant 
xi -0.02197 0.01476 -1.4882 Not significant 
XtXz -0.06892 0.02022 -3.4085 Significant 
X1X3 0.02597 0.01991 1.3049 Not significant 
XtX4 -0.007527 0.02063 -0.3647 Not significant 
X~ -0.06168 0.01507 -4.0923 Significant 
XzXJ 0.05167 0.02022 2.5554 Significant 
XzX4 0.03552 0.02022 -1.7568 Significant 
X~ -0.02607 0.01444 1.8046 Not significant 
X3X4 -0.04325 0.02068 -0.2092 Not significant 
xi -0.05378 0.01548 -0.3475 Not significant 
Table 11.27 ANOV A summary table 
Source ss Df MS 
Regression 0.048 7 6.82 X 10· 
Error 8.996 X !0'3 22 4.089 X 10'4 
Total 0.057 29 0 
n = 0.476 + 0.0440x1 + 0.0599x2 - 0.0175x3 - 0.06689x1x2 - 0.0617xi 
+ 0.0517x2x3 - 0.0355x2x4 
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